in the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
after 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
after 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
after 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	false
after 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
after 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	false
after 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	effect
these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	effect
these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
these behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
the 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining a5 and a7 noradrenaline cell groups.	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	effect
in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	false
in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	false
in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/a5/a7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	false	effect
our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	false	effect
effect of ketoconazole-mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat (lbh589), an orally active histone deacetylase inhibitor.	ketoconazole	panobinostat	false	false
effect of ketoconazole-mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat (lbh589), an orally active histone deacetylase inhibitor.	ketoconazole	lbh589	false	false
effect of ketoconazole-mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat (lbh589), an orally active histone deacetylase inhibitor.	ketoconazole	histone deacetylase inhibitor	false	false
effect of ketoconazole-mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat (lbh589), an orally active histone deacetylase inhibitor.	panobinostat	lbh589	false	false
effect of ketoconazole-mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat (lbh589), an orally active histone deacetylase inhibitor.	panobinostat	histone deacetylase inhibitor	false	false
effect of ketoconazole-mediated cyp3a4 inhibition on clinical pharmacokinetics of panobinostat (lbh589), an orally active histone deacetylase inhibitor.	lbh589	histone deacetylase inhibitor	false	false
this study evaluated the effect of a potent cyp3a inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.	ketoconazole	panobinostat	false	false
on day 8, a single panobinostat dose was co-administered with ketoconazole.	panobinostat	ketoconazole	false	false
in the presence of ketoconazole, there was 1.6- and 1.8-fold increase in c (max) and auc of panobinostat, respectively.	ketoconazole	panobinostat	false	mechanism
co-administration of panobinostat with cyp3a inhibitors is feasible as the observed increase in panobinostat pk parameters was not considered clinically relevant.	panobinostat	panobinostat	false	false
considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with cyp3a inhibitors, close monitoring of panobinostat-related adverse events is necessary.	panobinostat	panobinostat	false	false
interaction study of moxifloxacin and lomefloxacin with co-administered drugs.	moxifloxacin	lomefloxacin	false	false
moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.	moxifloxacin	lomefloxacin	false	false
moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.	moxifloxacin	fluoroquinolone antibiotics	false	false
moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.	lomefloxacin	fluoroquinolone antibiotics	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	moxifloxacin	fluoroquinolones	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	moxifloxacin	sucralfate	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	moxifloxacin	gelusil	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	moxifloxacin	erythromycin	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	moxifloxacin	multi minerals	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	fluoroquinolones	sucralfate	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	fluoroquinolones	gelusil	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	fluoroquinolones	erythromycin	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	fluoroquinolones	multi minerals	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	sucralfate	gelusil	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	sucralfate	erythromycin	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	sucralfate	multi minerals	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	gelusil	erythromycin	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	gelusil	multi minerals	false	false
being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	erythromycin	multi minerals	false	false
the response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a shimadzu hplc system with pda detector.	moxifloxacin	lomefloxacin	false	false
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	moxifloxacin	lomefloxacin	false	false
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	moxifloxacin	sucralfate	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	moxifloxacin	gelusil	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	moxifloxacin	erythromycin	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	moxifloxacin	multi-minerals	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	lomefloxacin	sucralfate	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	lomefloxacin	gelusil	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	lomefloxacin	erythromycin	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	lomefloxacin	multi-minerals	false	mechanism
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	sucralfate	gelusil	false	false
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	sucralfate	erythromycin	false	false
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	sucralfate	multi-minerals	false	false
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	gelusil	erythromycin	false	false
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	gelusil	multi-minerals	false	false
moxifloxacin and lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	erythromycin	multi-minerals	false	false
exposure to oral s-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.	s-ketamine	itraconazole	false	false
exposure to oral s-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.	s-ketamine	ticlopidine	false	effect
exposure to oral s-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.	itraconazole	ticlopidine	false	false
this study examined drug-drug interactions of oral s-ketamine with the cytochrome p450 (cyp) 2b6 inhibitor ticlopidine and the cyp3a inhibitor itraconazole.	s-ketamine	ticlopidine	false	false
this study examined drug-drug interactions of oral s-ketamine with the cytochrome p450 (cyp) 2b6 inhibitor ticlopidine and the cyp3a inhibitor itraconazole.	s-ketamine	itraconazole	false	false
this study examined drug-drug interactions of oral s-ketamine with the cytochrome p450 (cyp) 2b6 inhibitor ticlopidine and the cyp3a inhibitor itraconazole.	ticlopidine	itraconazole	false	false
in this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg s-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	s-ketamine	ticlopidine	false	false
in this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg s-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	s-ketamine	itraconazole	false	false
in this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg s-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	ticlopidine	itraconazole	false	false
ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (auc(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to s-ketamine.	ticlopidine	ketamine	false	mechanism
ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (auc(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to s-ketamine.	ticlopidine	itraconazole	false	false
ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (auc(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to s-ketamine.	ticlopidine	s-ketamine	false	false
ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (auc(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to s-ketamine.	ketamine	itraconazole	false	false
ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (auc(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to s-ketamine.	ketamine	s-ketamine	false	false
ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (auc(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to s-ketamine.	itraconazole	s-ketamine	false	false
the ratio of norketamine auc(0-   ) to ketamine auc(0-   ) was significantly decreased in the ticlopidine (p &lt; 0.001) and itraconazole phases (p = 0.006) as compared to placebo.	norketamine	ketamine	false	false
the ratio of norketamine auc(0-   ) to ketamine auc(0-   ) was significantly decreased in the ticlopidine (p &lt; 0.001) and itraconazole phases (p = 0.006) as compared to placebo.	norketamine	ticlopidine	false	false
the ratio of norketamine auc(0-   ) to ketamine auc(0-   ) was significantly decreased in the ticlopidine (p &lt; 0.001) and itraconazole phases (p = 0.006) as compared to placebo.	norketamine	itraconazole	false	false
the ratio of norketamine auc(0-   ) to ketamine auc(0-   ) was significantly decreased in the ticlopidine (p &lt; 0.001) and itraconazole phases (p = 0.006) as compared to placebo.	ketamine	ticlopidine	false	false
the ratio of norketamine auc(0-   ) to ketamine auc(0-   ) was significantly decreased in the ticlopidine (p &lt; 0.001) and itraconazole phases (p = 0.006) as compared to placebo.	ketamine	itraconazole	false	false
the ratio of norketamine auc(0-   ) to ketamine auc(0-   ) was significantly decreased in the ticlopidine (p &lt; 0.001) and itraconazole phases (p = 0.006) as compared to placebo.	ticlopidine	itraconazole	false	false
in the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (p < 0.05).	ticlopidine	itraconazole	false	false
the findings suggest that the dosage of s-ketamine should be reduced in patients receiving ticlopidine.	s-ketamine	ticlopidine	false	advise
the 3-deazaneplanocin a (dznep), one of s-adenosylhomocysteine (adohcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.	3-deazaneplanocin a	dznep	false	false
we also found that bcl-2 was overexpressed in dznep insensitive cells, and cotreatment with dznep and abt-737, a bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells.	dznep	dznep	false	false
we also found that bcl-2 was overexpressed in dznep insensitive cells, and cotreatment with dznep and abt-737, a bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells.	dznep	abt-737	false	false
we also found that bcl-2 was overexpressed in dznep insensitive cells, and cotreatment with dznep and abt-737, a bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells.	dznep	dznep	false	false
we also found that bcl-2 was overexpressed in dznep insensitive cells, and cotreatment with dznep and abt-737, a bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells.	dznep	abt-737	false	effect
we also found that bcl-2 was overexpressed in dznep insensitive cells, and cotreatment with dznep and abt-737, a bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells.	dznep	dznep	false	false
we also found that bcl-2 was overexpressed in dznep insensitive cells, and cotreatment with dznep and abt-737, a bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of dznep insensitive mm cells.	abt-737	dznep	false	false
in addition, dznep insensitivity might be associated with overexpression of bcl-2, and the combination of abt-737 and dznep could synergistically induced apoptosis.	dznep	abt-737	false	false
in addition, dznep insensitivity might be associated with overexpression of bcl-2, and the combination of abt-737 and dznep could synergistically induced apoptosis.	dznep	dznep	false	false
in addition, dznep insensitivity might be associated with overexpression of bcl-2, and the combination of abt-737 and dznep could synergistically induced apoptosis.	abt-737	dznep	false	effect
implanon   failure in an hiv-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.	implanon	antiretroviral	false	effect
we present an interesting case of an hiv-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with implanon in place.	antiretroviral	implanon	false	effect
antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.	antidepressant	warfarin	false	false
we sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.	antidepressant	warfarin	false	false
in total, 430,455 warfarin users contributed 407,370 person-years of warfarin use.	warfarin	warfarin	false	false
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	warfarin	citalopram	false	effect
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	warfarin	fluoxetine	false	effect
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	warfarin	paroxetine	false	effect
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	warfarin	amitriptyline	false	effect
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	citalopram	fluoxetine	false	false
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	citalopram	paroxetine	false	false
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	citalopram	amitriptyline	false	false
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	fluoxetine	paroxetine	false	false
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	fluoxetine	amitriptyline	false	false
warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (or   =   1.73 [95% ci, 1.25-2.38]), fluoxetine (or   =   1.63 [95% ci, 1.11-2.38]), paroxetine (or   =   1.64 [95% ci, 1.27-2.12]), amitriptyline (or   =   1.47 [95% ci, 1.02-2.11]).	paroxetine	amitriptyline	false	false
also mirtazapine, which is not believed to interact with warfarin, increased the risk of gi bleeding (or   =   1.75 [95% ci, 1.30-2.35]).	mirtazapine	warfarin	false	effect
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	warfarin	citalopram	false	effect
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	warfarin	fluoxetine	false	effect
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	warfarin	paroxetine	false	effect
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	warfarin	amitriptyline	false	effect
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	warfarin	mirtazapine	false	effect
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	citalopram	fluoxetine	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	citalopram	paroxetine	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	citalopram	amitriptyline	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	citalopram	mirtazapine	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	fluoxetine	paroxetine	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	fluoxetine	amitriptyline	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	fluoxetine	mirtazapine	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	paroxetine	amitriptyline	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	paroxetine	mirtazapine	false	false
warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	amitriptyline	mirtazapine	false	false
the incubations were performed in the absence and presence of the non-specific cyp inhibitor, 1-aminobenzotriazole (abt) and isoform-specific inhibitors.	1-aminobenzotriazole	abt	false	false
abt decreased the toxicity of precocene i, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.	abt	precocene i	false	effect
of the isoform-specific cyp inhibitors tested for an effect on the precocene i metabolite profile, only tranylcypromine was noticeably effective, indicating a role of cyps 2a6, 2c9, 2cl9, and 2e1.	precocene i	tranylcypromine	false	false
with respect to toxicity, the order of cyp inhibitor effectiveness was abt>diethyldithiocarbamate~tranylcypromine>ketoconazole.	abt	diethyldithiocarbamate	false	false
with respect to toxicity, the order of cyp inhibitor effectiveness was abt>diethyldithiocarbamate~tranylcypromine>ketoconazole.	abt	tranylcypromine	false	false
with respect to toxicity, the order of cyp inhibitor effectiveness was abt>diethyldithiocarbamate~tranylcypromine>ketoconazole.	abt	ketoconazole	false	false
with respect to toxicity, the order of cyp inhibitor effectiveness was abt>diethyldithiocarbamate~tranylcypromine>ketoconazole.	diethyldithiocarbamate	tranylcypromine	false	false
with respect to toxicity, the order of cyp inhibitor effectiveness was abt>diethyldithiocarbamate~tranylcypromine>ketoconazole.	diethyldithiocarbamate	ketoconazole	false	false
with respect to toxicity, the order of cyp inhibitor effectiveness was abt>diethyldithiocarbamate~tranylcypromine>ketoconazole.	tranylcypromine	ketoconazole	false	false
furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene i toxicity.	furafylline	sulfaphenazole	false	false
furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene i toxicity.	furafylline	quinidine	false	false
furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene i toxicity.	furafylline	precocene i	false	false
furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene i toxicity.	sulfaphenazole	quinidine	false	false
furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene i toxicity.	sulfaphenazole	precocene i	false	false
furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene i toxicity.	quinidine	precocene i	false	effect
these results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene i and therefore may not be an appropriate model for precocene i metabolism.	precocene i	precocene i	false	false
to determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (aav2).	adeno-associated virus-2	aav2	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	aav2	collagenase	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	aav2	hyaluronan lyase	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	aav2	heparinase iii	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	aav2	chondroitin abc lyase	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	collagenase	hyaluronan lyase	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	collagenase	heparinase iii	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	collagenase	chondroitin abc lyase	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	hyaluronan lyase	heparinase iii	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	hyaluronan lyase	chondroitin abc lyase	false	false
aav2 containing cdna encoding enhanced green fluorescent protein (gfp), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase iii, or chondroitin abc lyase.	heparinase iii	chondroitin abc lyase	false	false
the addition of heparinase iii or chondroitin abc lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.	heparinase iii	chondroitin abc lyase	false	false
hyaluronan lyase had a limited effect and collagenase was ineffective.	hyaluronan lyase	collagenase	false	false
electroretinograms survived with higher concentrations of heparinase iii and chondroitin abc lyase than were required for optimal retinal transduction.	heparinase iii	chondroitin abc lyase	false	false
aav2-mediated retinal transduction is improved by co-injection of heparinase iii or chondroitin abc lyase.	aav2	heparinase iii	false	effect
aav2-mediated retinal transduction is improved by co-injection of heparinase iii or chondroitin abc lyase.	aav2	chondroitin abc lyase	false	effect
aav2-mediated retinal transduction is improved by co-injection of heparinase iii or chondroitin abc lyase.	heparinase iii	chondroitin abc lyase	false	false
prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.	ketamine	propofol	false	false
we retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (tiva) repeatedly for radiation therapy.	ketamine	propofol	false	false
ea signs were observed in all 7 patients in association with propofol tiva but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol.	propofol	ketamine	false	false
ea signs were observed in all 7 patients in association with propofol tiva but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol.	propofol	propofol	false	false
ea signs were observed in all 7 patients in association with propofol tiva but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol.	ketamine	propofol	false	false
based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of ea in children with a history of ea with propofol tiva.	ketamine	propofol	false	effect
based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of ea in children with a history of ea with propofol tiva.	ketamine	propofol	false	false
based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of ea in children with a history of ea with propofol tiva.	propofol	propofol	false	false
tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer.	tamoxifen	estrogen antagonist	false	false
paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.	paroxetine	fluoxetine	false	false
paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.	paroxetine	endoxifen	false	mechanism
paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.	fluoxetine	endoxifen	false	mechanism
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with tamoxifen for breast cancer, especially ssri antidepressants such as paroxetine and fluoxetine.	tamoxifen	ssri antidepressants	false	advise
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with tamoxifen for breast cancer, especially ssri antidepressants such as paroxetine and fluoxetine.	tamoxifen	paroxetine	false	advise
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with tamoxifen for breast cancer, especially ssri antidepressants such as paroxetine and fluoxetine.	tamoxifen	fluoxetine	false	advise
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with tamoxifen for breast cancer, especially ssri antidepressants such as paroxetine and fluoxetine.	ssri antidepressants	paroxetine	false	false
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with tamoxifen for breast cancer, especially ssri antidepressants such as paroxetine and fluoxetine.	ssri antidepressants	fluoxetine	false	false
it is better to avoid prescribing isoenzyme cyp 2d6 inhibitors to women treated with tamoxifen for breast cancer, especially ssri antidepressants such as paroxetine and fluoxetine.	paroxetine	fluoxetine	false	false
depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause.	antidepressant drug	antidepressants	false	false
if in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	tamoxifen	false	advise
if in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	anastrozole	false	false
if in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	tamoxifen	anastrozole	false	false
amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.	amphetamine	quinpirole	false	false
the objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures.	quinpirole	amphetamine	false	false
in female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	quinpirole	amphetamine	false	effect
in female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	quinpirole	quinpirole	false	false
in female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	quinpirole	amphetamine	false	false
in female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	amphetamine	quinpirole	false	false
in female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	amphetamine	amphetamine	false	false
in female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	quinpirole	amphetamine	false	false
male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole.	amphetamine	quinpirole	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	quinpirole	amphetamine	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	quinpirole	quinpirole	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	quinpirole	amphetamine	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	quinpirole	amphetamine	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	amphetamine	quinpirole	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	amphetamine	amphetamine	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	amphetamine	amphetamine	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	quinpirole	amphetamine	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	quinpirole	amphetamine	false	false
rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	amphetamine	amphetamine	false	false
in vivo cyp3a activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.	cyclosporine	tacrolimus	false	false
in vitro studies have identified cyclosporine and tacrolimus as cyp3a inhibitors.	cyclosporine	tacrolimus	false	false
systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, p = 0.022) and 31% (479    190 vs. 688    265  ml/min, p = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).	midazolam	cyclosporine	false	mechanism
systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, p = 0.022) and 31% (479    190 vs. 688    265  ml/min, p = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).	midazolam	tacrolimus	false	false
systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, p = 0.022) and 31% (479    190 vs. 688    265  ml/min, p = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).	cyclosporine	tacrolimus	false	false
the latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).	midazolam	tacrolimus	false	false
the latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).	midazolam	calcineurin inhibitor	false	false
the latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).	tacrolimus	calcineurin inhibitor	false	false
this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to cyp3a inhibition.	cyclosporine	tacrolimus	false	false
this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to cyp3a inhibition.	cyclosporine	cyclosporine	false	false
this implies that in vivo hepatic and first-pass cyp3a activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to cyp3a inhibition.	tacrolimus	cyclosporine	false	false
improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.	cinacalcet	darbepoetin	false	false
uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (epo) resistance.	erythropoietin	epo	false	false
medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (pth) levels, but its effect on darbepoetin dosing is unknown.	cinacalcet	darbepoetin	false	false
the primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy.	darbepoetin	cinacalcet	false	false
reduction of pth by cinacalcet is associated with a decrease in darbepoetin requirement.	cinacalcet	darbepoetin	false	effect
interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.	celecoxib	anti-cancer drugs	false	effect
this study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents.	cyclooxygenase-2 inhibitors	chemotherapeutic agents	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-fu	cisplatin	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-fu	doxorubicin	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-fu	etoposide	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-fu	celecoxib	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	doxorubicin	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	etoposide	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	celecoxib	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	etoposide	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	celecoxib	false	false
the sensitivity, cell cycle, apoptosis and dna damage of five different cancer cell lines (hela, hct116, hepg2, mcf7 and u251) to 5-fu, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	etoposide	celecoxib	false	false
we found antagonism between celecoxib and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in hct116 cells.	celecoxib	celecoxib	false	false
we found antagonism between celecoxib and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in hct116 cells.	celecoxib	doxorubicin	false	false
we found antagonism between celecoxib and the four drugs in the breast cancer cells mcf7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in hct116 cells.	celecoxib	doxorubicin	false	effect
these results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers.	celecoxib	doxorubicin	false	false
[interaction between clopidogrel and proton pump inhibitors].	clopidogrel	proton pump inhibitors	false	false
the drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years.	proton pump inhibitors	clopidogrel	false	false
contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature.	proton pump inhibitors	clopidogrel	false	false
concomitant use of omeprazole and clopidogrel was found to decrease the exposure (auc) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of cyp2c19, a cytochrome p450 (cyp) enzyme.	omeprazole	clopidogrel	false	mechanism
concomitant use of omeprazole and clopidogrel was found to decrease the exposure (auc) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of cyp2c19, a cytochrome p450 (cyp) enzyme.	omeprazole	omeprazole	false	false
concomitant use of omeprazole and clopidogrel was found to decrease the exposure (auc) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of cyp2c19, a cytochrome p450 (cyp) enzyme.	clopidogrel	omeprazole	false	false
pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use.	pantoprazole	clopidogrel	false	mechanism
the influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies.	proton pump inhibitors	clopidogrel	false	false
regulatory agencies state that the combination of clopidogrel and the cyp2c19 inhibitors omeprazole and esomeprazole should be avoided.	clopidogrel	omeprazole	false	advise
regulatory agencies state that the combination of clopidogrel and the cyp2c19 inhibitors omeprazole and esomeprazole should be avoided.	clopidogrel	esomeprazole	false	advise
regulatory agencies state that the combination of clopidogrel and the cyp2c19 inhibitors omeprazole and esomeprazole should be avoided.	omeprazole	esomeprazole	false	false
to date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.	proton pump inhibitors	clopidogrel	false	false
in vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant staphylococcus aureus.	minocycline	fosfomycin	false	false
in vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant staphylococcus aureus.	minocycline	methicillin	false	false
in vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant staphylococcus aureus.	fosfomycin	methicillin	false	false
this study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant staphylococcus aureus (mrsa).	minocycline	fosfomycin	false	false
this study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant staphylococcus aureus (mrsa).	minocycline	methicillin	false	false
this study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant staphylococcus aureus (mrsa).	fosfomycin	methicillin	false	false
the susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria.	minocycline	fosfomycin	false	false
the combination of minocycline and fosfomycin can be synergistic against mrsa.	minocycline	fosfomycin	false	effect
the authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone.	levothyroxine	simeticone	false	int
questioning revealed the child was taking infacol drops before feeds while on levothyroxine.	infacol	levothyroxine	false	false
drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the british national formulary for children.	thyroxine	simeticone	false	false
calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	calcium	nonheme iron	false	false
calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	calcium	heme iron	false	false
calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	nonheme iron	heme iron	false	false
calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.	calcium	nonheme iron	false	mechanism
calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.	calcium	heme iron	false	mechanism
calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.	nonheme iron	heme iron	false	false
however, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.	calcium	iron	false	mechanism
however, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.	calcium	calcium	false	false
however, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.	iron	calcium	false	false
our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal.	calcium	nonheme iron	false	false
our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal.	calcium	heme iron	false	false
our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal.	nonheme iron	heme iron	false	false
we evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate).	calcium	nonheme iron	false	false
we evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate).	calcium	ferrous sulfate	false	false
we evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate).	nonheme iron	ferrous sulfate	false	false
we also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated rbc (crbc)].	calcium	heme iron	false	false
calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach.	calcium	calcium chloride	false	false
calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach.	calcium	minerals	false	false
calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach.	calcium chloride	minerals	false	false
calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.	calcium	nonheme iron	false	mechanism
a calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%.	calcium	heme iron	false	mechanism
in conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as crbc) iron.	calcium	nonheme iron	false	mechanism
in conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as crbc) iron.	calcium	heme iron	false	mechanism
in conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as crbc) iron.	nonheme iron	heme iron	false	false
synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with egfr tkis-resistant mutation.	sunitinib	docetaxel	false	int
this study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in nsclc cell lines that are resistant to egfr tkis.	sunitinib	sunitinib	false	false
this study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in nsclc cell lines that are resistant to egfr tkis.	sunitinib	docetaxel	false	false
this study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in nsclc cell lines that are resistant to egfr tkis.	sunitinib	docetaxel	false	false
nsclc cell lines with egfr t790m mutation and k-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations.	sunitinib	docetaxel	false	false
sunitinib exhibited dose-dependent growth inhibition in nsclc cell lines and arrested cell cycle at g1 phase, whereas docetaxel arrested at s phase.	sunitinib	docetaxel	false	false
although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.	sunitinib	docetaxel	false	effect
when cells were exposed to docetaxel followed by sunitinib, synergism was observed.	docetaxel	sunitinib	false	effect
the molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib.	docetaxel	sunitinib	false	effect
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	sunitinib	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	sunitinib	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	false	effect
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	docetaxel	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	sunitinib	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	false	false
sunitinib as a single agent exhibits anti-proliferative effects in vitro in nsclc cell lines with egfr t790m and k-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	false	false
distinct synergistic action of piperacillin and methylglyoxal against pseudomonas aeruginosa.	piperacillin	methylglyoxal	false	false
results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.	piperacillin	carbenicillin	false	false
results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.	piperacillin	amikacin	false	false
results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.	piperacillin	ciprofloxacin	false	false
results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.	carbenicillin	amikacin	false	false
results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.	carbenicillin	ciprofloxacin	false	false
results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.	amikacin	ciprofloxacin	false	false
distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects.	methylglyoxal	piperacillin	false	effect
synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	carbenicillin	false	effect
synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	amikacin	false	effect
synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	carbenicillin	amikacin	false	false
protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.	acetyl-l-carnitine	alpha lipoic acid	false	false
(ii) acetyl-l-carnitine elicits a significant protective effect on deb induced toxicity, which was potentiated by  alpha-lipoic acid.	acetyl-l-carnitine	alpha-lipoic acid	false	effect
[influence of hemantane and doxycycline on mptp-evoked behavior violations in c57bl/6 mice].	hemantane	doxycycline	false	false
the effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)	anti-parkinsonian drug	hemantane	false	false
the effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)	anti-parkinsonian drug	(2-adamantyl)hexamethylenimine	false	false
the effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)	hemantane	(2-adamantyl)hexamethylenimine	false	false
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (mptp) (4 x 20 mg/kg, i. p.)	antibiotic drug	doxycycline	false	false
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (mptp) (4 x 20 mg/kg, i. p.)	antibiotic drug	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	false	false
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (mptp) (4 x 20 mg/kg, i. p.)	antibiotic drug	mptp	false	false
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (mptp) (4 x 20 mg/kg, i. p.)	doxycycline	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	false	false
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (mptp) (4 x 20 mg/kg, i. p.)	doxycycline	mptp	false	false
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (mptp) (4 x 20 mg/kg, i. p.)	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	mptp	false	false
acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity.	hemantane	doxycycline	false	effect
the role of p27(kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.	dasatinib	paclitaxel	false	effect
the effect of dasatinib, an inhibitor of src and abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and hey xenografts.	dasatinib	paclitaxel	false	false
the roles of p27(kip1), bcl-2, and cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dutp nick-end labeling (tunel) assay, sirna knockdown of gene expression, transfection with bcl-2 and cdk1 expression vectors, and flow cytometry.	dasatinib	paclitaxel	false	false
hey cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone.	dasatinib	paclitaxel	false	effect
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	dasatinib	paclitaxel	false	effect
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	dasatinib	dasatinib	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	dasatinib	paclitaxel	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	dasatinib	paclitaxel	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	paclitaxel	dasatinib	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	paclitaxel	paclitaxel	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	paclitaxel	paclitaxel	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	dasatinib	paclitaxel	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	dasatinib	paclitaxel	false	false
treatment of hey xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [ci] = 0.44 to 0.62 cm3, p = .014);	paclitaxel	paclitaxel	false	false
dasatinib + paclitaxel vs.	dasatinib	paclitaxel	false	false
the sirna knockdown of p27(kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control sirna (sub-g1 fraction, control sirna vs. p27(kip1) sirna: 42.5% vs. 20.1%, difference = 22.4%, 95% ci = 20.1% to 24.7%, p = .017).	dasatinib	paclitaxel	false	false
studies with forced expression and sirna knockdown of bcl-2 and cdk1 suggest that dasatinib-mediated induction of p27(kip1) enhanced paclitaxel-induced apoptosis by negatively regulating bcl-2 and cdk1 expression.	dasatinib	paclitaxel	false	effect
inhibition of src family and abl kinases with either sirnas or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(kip1)-mediated suppression of bcl-2 and cdk1 expression.	dasatinib	paclitaxel	false	effect
phase i trial of lenalidomide and cci-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-cci-779 interaction via p-glycoprotein.	lenalidomide	cci-779	false	false
phase i trial of lenalidomide and cci-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-cci-779 interaction via p-glycoprotein.	lenalidomide	lenalidomide	false	false
phase i trial of lenalidomide and cci-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-cci-779 interaction via p-glycoprotein.	lenalidomide	cci-779	false	false
phase i trial of lenalidomide and cci-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-cci-779 interaction via p-glycoprotein.	cci-779	lenalidomide	false	false
phase i trial of lenalidomide and cci-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-cci-779 interaction via p-glycoprotein.	cci-779	cci-779	false	false
phase i trial of lenalidomide and cci-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-cci-779 interaction via p-glycoprotein.	lenalidomide	cci-779	false	false
the preclinical combination of lenalidomide with the mtor inhibitor cci-779 has displayed synergy in vitro and represents a novel combination in mm.	lenalidomide	cci-779	false	effect
enhancement of humoral immune responses to inactivated newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.	avian influenza vaccines	ginseng stem-and-leaf saponins	false	false
the objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (gsls) on the humoral immune responses of chickens to inactivated nd and ai vaccines.	ginseng stem-and-leaf saponins	gsls	false	false
the objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (gsls) on the humoral immune responses of chickens to inactivated nd and ai vaccines.	ginseng stem-and-leaf saponins	inactivated nd vaccines	false	false
the objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (gsls) on the humoral immune responses of chickens to inactivated nd and ai vaccines.	ginseng stem-and-leaf saponins	inactivated ai vaccines	false	false
the objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (gsls) on the humoral immune responses of chickens to inactivated nd and ai vaccines.	gsls	inactivated nd vaccines	false	false
the objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (gsls) on the humoral immune responses of chickens to inactivated nd and ai vaccines.	gsls	inactivated ai vaccines	false	false
the objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (gsls) on the humoral immune responses of chickens to inactivated nd and ai vaccines.	inactivated nd vaccines	inactivated ai vaccines	false	false
in experiment 1, oral administration of gsls at a dose of 5 mg/kg of bw for 7 d on the immune response in chickens intramuscularly injected with inactivated nd vaccine was evaluated.	gsls	inactivated nd vaccine	false	false
in experiment 2, the same regimen of gsls was administered to chickens inoculated with inactivated ai vaccines, and an enhanced serum antibody response to ai vaccination was also observed.	gsls	inactivated ai vaccines	false	effect
considering the safety of gsls, because no adverse effect was found throughout the experiments, gsls may be a promising oral adjuvant to improve immunization in poultry.	gsls	gsls	false	false
interaction of dacarbazine and imexon, in vitro and in vivo, in human a375 melanoma cells.	dacarbazine	imexon	false	false
we evaluated mechanisms of interaction between the alkyating agent dacarbazine (dtic) and the pro-oxidant, imexon, in the human a375 melanoma cell line.	dacarbazine	dtic	false	false
we evaluated mechanisms of interaction between the alkyating agent dacarbazine (dtic) and the pro-oxidant, imexon, in the human a375 melanoma cell line.	dacarbazine	imexon	false	false
we evaluated mechanisms of interaction between the alkyating agent dacarbazine (dtic) and the pro-oxidant, imexon, in the human a375 melanoma cell line.	dtic	imexon	false	false
the effect of dtic and imexon, alone and in combination, was evaluated for growth inhibition (mtt), radiolabeled drug uptake, cellular thiol content (hplc), and dna strand breaks (comet assay).	dtic	imexon	false	false
there was a >75% reduction in cellular glutathione and cysteine with imexon but not dtic.	imexon	dtic	false	false
imexon and dacarbazine show additive effects in vitro but not in vivo in human a375 melanoma cells.	imexon	dacarbazine	false	effect
lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface her2 expression.	lapatinib	herceptin	false	effect
although it was previously reported that lapatinib combined with herceptin improved the progression-free survival rate compared with lapatinib alone for patients with herceptin-refractory her2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	herceptin	false	effect
although it was previously reported that lapatinib combined with herceptin improved the progression-free survival rate compared with lapatinib alone for patients with herceptin-refractory her2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	lapatinib	false	false
although it was previously reported that lapatinib combined with herceptin improved the progression-free survival rate compared with lapatinib alone for patients with herceptin-refractory her2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	herceptin	false	false
although it was previously reported that lapatinib combined with herceptin improved the progression-free survival rate compared with lapatinib alone for patients with herceptin-refractory her2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	herceptin	lapatinib	false	false
although it was previously reported that lapatinib combined with herceptin improved the progression-free survival rate compared with lapatinib alone for patients with herceptin-refractory her2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	herceptin	herceptin	false	false
although it was previously reported that lapatinib combined with herceptin improved the progression-free survival rate compared with lapatinib alone for patients with herceptin-refractory her2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	herceptin	false	false
we evaluated how lapatinib interacts with herceptin in her2-positive breast cancer, with a particular focus on herceptin-mediated antibody-dependent cellular cytotoxicity (adcc).	lapatinib	herceptin	false	false
we evaluated how lapatinib interacts with herceptin in her2-positive breast cancer, with a particular focus on herceptin-mediated antibody-dependent cellular cytotoxicity (adcc).	lapatinib	herceptin	false	false
we evaluated how lapatinib interacts with herceptin in her2-positive breast cancer, with a particular focus on herceptin-mediated antibody-dependent cellular cytotoxicity (adcc).	herceptin	herceptin	false	false
in an in vitro assay, lapatinib induced her2 expression at the cell surface of her2-positive breast cancer cell lines, leading to the enhancement of herceptin-mediated adcc.	lapatinib	herceptin	false	effect
furthermore, we present a case report in which a second herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in her2-positive breast cancer.	herceptin	lapatinib	false	effect
lapatinib may have the potential to convert herceptin-refractory to herceptin-sensitive tumors in her2-positive breast cancer by up-regulation of the cell surface expression of her2.	lapatinib	herceptin	false	false
lapatinib may have the potential to convert herceptin-refractory to herceptin-sensitive tumors in her2-positive breast cancer by up-regulation of the cell surface expression of her2.	lapatinib	herceptin	false	false
lapatinib may have the potential to convert herceptin-refractory to herceptin-sensitive tumors in her2-positive breast cancer by up-regulation of the cell surface expression of her2.	herceptin	herceptin	false	false
the aim of the present study was to investigate whether hb-egf is a therapeutic target for t-all, and to further elucidate the antitumor effects of a specific inhibitor of hb-egf, cross-reacting material 197 (crm197).	cross-reacting material 197	crm197	false	false
we elucidated the expression of hb-egf in t-all cell lines, and evaluated the effect of crm197 on these cells alone or in combination with anticancer agent.	crm197	anticancer agent	false	false
crm197 induced apoptosis, and furthermore, the combination of crm197 plus doxorubicin enhanced cytotoxicity in a t-all cell line.	crm197	crm197	false	false
crm197 induced apoptosis, and furthermore, the combination of crm197 plus doxorubicin enhanced cytotoxicity in a t-all cell line.	crm197	doxorubicin	false	false
crm197 induced apoptosis, and furthermore, the combination of crm197 plus doxorubicin enhanced cytotoxicity in a t-all cell line.	crm197	doxorubicin	false	effect
ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.	ephedrine	dexmedetomidine	false	effect
the purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.	ephedrine	dexmedetomidine	false	false
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	ephedrine	dexmedetomidine	false	false
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	ephedrine	ephedrine	false	false
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	ephedrine	dexmedetomidine	false	false
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	dexmedetomidine	ephedrine	false	false
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	dexmedetomidine	dexmedetomidine	false	false
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	ephedrine	dexmedetomidine	false	false
in the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.	dexmedetomidine	ephedrine	false	effect
in the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.	dexmedetomidine	dexmedetomidine	false	false
in the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.	ephedrine	dexmedetomidine	false	false
at the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine.	dexmedetomidine	ephedrine	false	effect
we concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	ephedrine	false	effect
we concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	dexmedetomidine	false	false
we concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	false	false
we concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	dexmedetomidine	false	false
we concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	analgesic	false	false
we concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	false	false
[efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]	amlodipine	valsartan	false	false
efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.	amlodipine	valsartan	false	false
all patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43).	amlodipine	valsartan	false	false
rate of achievement of target bp with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%).	amlodipine	valsartan	false	false
but the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured bp, quicker achievement of target bp (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	amlodipine	valsartan	false	effect
but the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured bp, quicker achievement of target bp (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	amlodipine	antihypertensive drugs	false	false
but the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured bp, quicker achievement of target bp (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	valsartan	antihypertensive drugs	false	false
we have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target bp in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	valsartan	false	effect
we have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target bp in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	antihypertensive drugs	false	false
we have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target bp in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	valsartan	antihypertensive drugs	false	false
ticagrelor (brilinta)--better than clopidogrel (plavix)	ticagrelor	brilinta	false	false
ticagrelor (brilinta)--better than clopidogrel (plavix)	ticagrelor	clopidogrel	false	false
ticagrelor (brilinta)--better than clopidogrel (plavix)	ticagrelor	plavix	false	false
ticagrelor (brilinta)--better than clopidogrel (plavix)	brilinta	clopidogrel	false	false
ticagrelor (brilinta)--better than clopidogrel (plavix)	brilinta	plavix	false	false
ticagrelor (brilinta)--better than clopidogrel (plavix)	clopidogrel	plavix	false	false
the fda has approved ticagrelor (brilinta-astrazeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (acs).	ticagrelor	brilinta	false	false
the fda has approved ticagrelor (brilinta-astrazeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (acs).	ticagrelor	antiplatelet drug	false	false
the fda has approved ticagrelor (brilinta-astrazeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (acs).	ticagrelor	aspirin	false	effect
the fda has approved ticagrelor (brilinta-astrazeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (acs).	brilinta	antiplatelet drug	false	false
the fda has approved ticagrelor (brilinta-astrazeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (acs).	brilinta	aspirin	false	effect
the fda has approved ticagrelor (brilinta-astrazeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (acs).	antiplatelet drug	aspirin	false	false
it will compete with clopidogrel (plavix) and prasugrel (effient) for such use.	clopidogrel	plavix	false	false
it will compete with clopidogrel (plavix) and prasugrel (effient) for such use.	clopidogrel	prasugrel	false	false
it will compete with clopidogrel (plavix) and prasugrel (effient) for such use.	clopidogrel	effient	false	false
it will compete with clopidogrel (plavix) and prasugrel (effient) for such use.	plavix	prasugrel	false	false
it will compete with clopidogrel (plavix) and prasugrel (effient) for such use.	plavix	effient	false	false
it will compete with clopidogrel (plavix) and prasugrel (effient) for such use.	prasugrel	effient	false	false
influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.	piperine	ibuprofen	false	false
in the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	piperine	ibuprofen	false	effect
in the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	piperine	acetic acid	false	false
in the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	piperine	ibuprofen	false	false
in the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	ibuprofen	acetic acid	false	false
in the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	ibuprofen	ibuprofen	false	false
in the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	acetic acid	ibuprofen	false	false
ibuprofen plasma concentration was also increased when it was administered with piperine.	ibuprofen	piperine	false	mechanism
the synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen.	ibuprofen	piperine	false	mechanism
the synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen.	ibuprofen	ibuprofen	false	false
the synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen.	piperine	ibuprofen	false	false
from this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.	piperine	ibuprofen	false	effect
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	abacavir	lamivudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	abacavir	zidovudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	abacavir	lamivudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	abacavir	zidovudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	lamivudine	zidovudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	lamivudine	lamivudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	lamivudine	zidovudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	zidovudine	lamivudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	zidovudine	zidovudine	false	false
pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.	lamivudine	zidovudine	false	false
no clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir.	lamivudine	zidovudine	false	false
no clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir.	lamivudine	abacavir	false	false
no clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir.	zidovudine	abacavir	false	false
abacavir has no effect on the pharmacokinetic properties of ethanol.	abacavir	ethanol	false	false
ethanol decreases the elimination of abacavir causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	ethanol	abacavir	false	mechanism
ethanol decreases the elimination of abacavir causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	ethanol	methadone	false	false
ethanol decreases the elimination of abacavir causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	ethanol	abacavir	false	false
ethanol decreases the elimination of abacavir causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	abacavir	methadone	false	false
ethanol decreases the elimination of abacavir causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	abacavir	abacavir	false	false
ethanol decreases the elimination of abacavir causing an increase in overall exposure . the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	methadone	abacavir	false	false
in a study of 11 hiv-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ziagen twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% ci 6% to 42%).	methadone	ziagen	false	mechanism
in a study of 11 hiv-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ziagen twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% ci 6% to 42%).	methadone	methadone	false	false
in a study of 11 hiv-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ziagen twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% ci 6% to 42%).	ziagen	methadone	false	false
cholestyramine: concomitant cholestyramine administration decreased the mean auc of total ezetimibe approximately 55%.	cholestyramine	cholestyramine	false	false
cholestyramine: concomitant cholestyramine administration decreased the mean auc of total ezetimibe approximately 55%.	cholestyramine	ezetimibe	false	false
cholestyramine: concomitant cholestyramine administration decreased the mean auc of total ezetimibe approximately 55%.	cholestyramine	ezetimibe	false	mechanism
the incremental ldl-c reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.	ezetimibe	cholestyramine	false	effect
fibrates: the safety and effectiveness of ezetimibe administered with fibrates have not been established.	fibrates	ezetimibe	false	false
fibrates: the safety and effectiveness of ezetimibe administered with fibrates have not been established.	fibrates	fibrates	false	false
fibrates: the safety and effectiveness of ezetimibe administered with fibrates have not been established.	ezetimibe	fibrates	false	false
co-administration of zetia with fibrates is not recommended until use in patients is studied.	zetia	fibrates	false	advise
fenofibrate: in a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.	fenofibrate	fenofibrate	false	false
fenofibrate: in a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.	fenofibrate	ezetimibe	false	false
fenofibrate: in a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.	fenofibrate	ezetimibe	false	mechanism
gemfibrozil: in a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold.	gemfibrozil	gemfibrozil	false	false
gemfibrozil: in a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold.	gemfibrozil	ezetimibe	false	false
gemfibrozil: in a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold.	gemfibrozil	ezetimibe	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	hmg-coa reductase inhibitors	ezetimibe	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	hmg-coa reductase inhibitors	atorvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	hmg-coa reductase inhibitors	simvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	hmg-coa reductase inhibitors	pravastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	hmg-coa reductase inhibitors	lovastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	hmg-coa reductase inhibitors	fluvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	ezetimibe	atorvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	ezetimibe	simvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	ezetimibe	pravastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	ezetimibe	lovastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	ezetimibe	fluvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	atorvastatin	simvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	atorvastatin	pravastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	atorvastatin	lovastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	atorvastatin	fluvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	simvastatin	pravastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	simvastatin	lovastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	simvastatin	fluvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	pravastatin	lovastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	pravastatin	fluvastatin	false	false
hmg-coa reductase inhibitors: no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	lovastatin	fluvastatin	false	false
cyclosporine: the total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.	cyclosporine	ezetimibe	false	false
cyclosporine: the total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.	cyclosporine	cyclosporine	false	false
cyclosporine: the total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.	ezetimibe	cyclosporine	false	mechanism
patients who take both ezetimibe and cyclosporine should be carefully monitored.	ezetimibe	cyclosporine	false	advise
carcinogenesis, mutagenesis, impairment of fertility a 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on auc0-24hr for total ezetimibe).	ezetimibe	ezetimibe	false	false
a 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on auc0-24hr for total ezetimibe).	ezetimibe	ezetimibe	false	false
in oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on auc0-24hr for total ezetimibe).	ezetimibe	ezetimibe	false	false
in rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on auc0-24hr for total ezetimibe).	ezetimibe	ezetimibe	false	false
multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	ezetimibe	hmg-coa reductase inhibitors	false	false
multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	ezetimibe	statins	false	false
multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	ezetimibe	ezetimibe	false	false
multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	hmg-coa reductase inhibitors	statins	false	false
multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	hmg-coa reductase inhibitors	ezetimibe	false	false
multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	statins	ezetimibe	false	false
when zetia is administered with an hmg-coa reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the hmg-coa reductase inhibitor.	zetia	hmg-coa reductase inhibitor	false	false
when zetia is administered with an hmg-coa reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the hmg-coa reductase inhibitor.	zetia	hmg-coa reductase inhibitor	false	false
when zetia is administered with an hmg-coa reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the hmg-coa reductase inhibitor.	hmg-coa reductase inhibitor	hmg-coa reductase inhibitor	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	coumarin-type anticoagulants	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	phenytoin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	cyclosporine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	rifampin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	theophylline	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	terfenadine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	cisapride	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	phenytoin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	cyclosporine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	rifampin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	theophylline	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	terfenadine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	cisapride	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	coumarin-type anticoagulants	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	cyclosporine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	rifampin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	theophylline	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	terfenadine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	cisapride	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	phenytoin	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	rifampin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	theophylline	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	terfenadine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	cisapride	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cyclosporine	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	theophylline	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	terfenadine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	cisapride	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifampin	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	terfenadine	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	cisapride	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	theophylline	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	cisapride	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	terfenadine	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cisapride	astemizole	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cisapride	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cisapride	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cisapride	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cisapride	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cisapride	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	cisapride	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	astemizole	rifabutin	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	astemizole	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	astemizole	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	astemizole	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	astemizole	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	astemizole	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifabutin	tacrolimus	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifabutin	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifabutin	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifabutin	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	rifabutin	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	tacrolimus	short-acting benzodiazepines	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	tacrolimus	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	tacrolimus	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	tacrolimus	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	short-acting benzodiazepines	hypoglycemics	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	short-acting benzodiazepines	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	short-acting benzodiazepines	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	diflucan	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	hypoglycemics	hypoglycemic agents	false	false
these are described in greater detail below:  oral hypoglycemics, coumarin-type anticoagulants, phenytoin, cyclosporine, rifampin, theophylline, terfenadine, cisapride, astemizole, rifabutin, tacrolimus, short-acting benzodiazepines,  oral hypoglycemics: clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents;	diflucan	hypoglycemic agents	false	effect
one fatality has been reported from hypoglycemia in association with combined diflucan and glyburide use.	diflucan	glyburide	false	effect
diflucan reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.	diflucan	tolbutamide	false	mechanism
diflucan reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.	diflucan	glyburide	false	mechanism
diflucan reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.	diflucan	glipizide	false	mechanism
diflucan reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.	tolbutamide	glyburide	false	false
diflucan reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.	tolbutamide	glipizide	false	false
diflucan reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.	glyburide	glipizide	false	false
when diflucan is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.	diflucan	sulfonylurea oral hypoglycemic agents	false	advise
when diflucan is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.	diflucan	sulfonylurea	false	false
when diflucan is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.	sulfonylurea oral hypoglycemic agents	sulfonylurea	false	false
coumarin-type anticoagulants: prothrombin time may be increased in patients receiving concomitant diflucan and coumarin-type anticoagulants.	coumarin-type anticoagulants	diflucan	false	false
coumarin-type anticoagulants: prothrombin time may be increased in patients receiving concomitant diflucan and coumarin-type anticoagulants.	coumarin-type anticoagulants	coumarin-type anticoagulants	false	false
coumarin-type anticoagulants: prothrombin time may be increased in patients receiving concomitant diflucan and coumarin-type anticoagulants.	diflucan	coumarin-type anticoagulants	false	effect
in post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.	azole antifungals	fluconazole	false	false
in post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.	azole antifungals	warfarin	false	false
in post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.	fluconazole	warfarin	false	effect
careful monitoring of prothrombin time in patients receiving diflucan and coumarin-type anticoagulants is recommended.	diflucan	coumarin-type anticoagulants	false	advise
phenytoin: diflucan increases the plasma concentrations of phenytoin.	phenytoin	diflucan	false	false
phenytoin: diflucan increases the plasma concentrations of phenytoin.	phenytoin	phenytoin	false	false
phenytoin: diflucan increases the plasma concentrations of phenytoin.	diflucan	phenytoin	false	mechanism
careful monitoring of phenytoin concentrations in patients receiving diflucan and phenytoin is recommended.	phenytoin	diflucan	false	false
careful monitoring of phenytoin concentrations in patients receiving diflucan and phenytoin is recommended.	phenytoin	phenytoin	false	false
careful monitoring of phenytoin concentrations in patients receiving diflucan and phenytoin is recommended.	diflucan	phenytoin	false	advise
cyclosporine: diflucan may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.	cyclosporine	diflucan	false	false
cyclosporine: diflucan may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.	cyclosporine	cyclosporine	false	false
cyclosporine: diflucan may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.	diflucan	cyclosporine	false	mechanism
careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving diflucan and cyclosporine.	cyclosporine	diflucan	false	false
careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving diflucan and cyclosporine.	cyclosporine	cyclosporine	false	false
careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving diflucan and cyclosporine.	diflucan	cyclosporine	false	advise
rifampin: rifampin enhances the metabolism of concurrently administered diflucan.	rifampin	rifampin	false	false
rifampin: rifampin enhances the metabolism of concurrently administered diflucan.	rifampin	diflucan	false	false
rifampin: rifampin enhances the metabolism of concurrently administered diflucan.	rifampin	diflucan	false	mechanism
depending on clinical circumstances, consideration should be given to increasing the dose of diflucan when it is administered with rifampin.	diflucan	rifampin	false	advise
theophylline: diflucan increases the serum concentrations of theophylline.	theophylline	diflucan	false	false
theophylline: diflucan increases the serum concentrations of theophylline.	theophylline	theophylline	false	false
theophylline: diflucan increases the serum concentrations of theophylline.	diflucan	theophylline	false	mechanism
careful monitoring of serum theophylline concentrations in patients receiving diflucan and theophylline is recommended.	theophylline	diflucan	false	false
careful monitoring of serum theophylline concentrations in patients receiving diflucan and theophylline is recommended.	theophylline	theophylline	false	false
careful monitoring of serum theophylline concentrations in patients receiving diflucan and theophylline is recommended.	diflucan	theophylline	false	advise
terfenadine: because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.	terfenadine	azole antifungals	false	false
terfenadine: because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.	terfenadine	terfenadine	false	false
terfenadine: because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.	azole antifungals	terfenadine	false	effect
another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that diflucan taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.	fluconazole	diflucan	false	false
another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that diflucan taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.	fluconazole	terfenadine	false	false
another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that diflucan taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.	diflucan	terfenadine	false	mechanism
the combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.	fluconazole	terfenadine	false	advise
the coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.	fluconazole	terfenadine	false	advise
cisapride: there have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.	cisapride	fluconazole	false	false
cisapride: there have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.	cisapride	cisapride	false	false
cisapride: there have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.	fluconazole	cisapride	false	effect
a controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of qtc interval.	fluconazole	cisapride	false	mechanism
a controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of qtc interval.	fluconazole	cisapride	false	false
a controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of qtc interval.	cisapride	cisapride	false	false
the combined use of fluconazole with cisapride is contraindicated.	fluconazole	cisapride	false	advise
astemizole: the use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs.	astemizole	fluconazole	false	false
astemizole: the use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs.	astemizole	astemizole	false	false
astemizole: the use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs.	fluconazole	astemizole	false	mechanism
rifabutin: there have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.	rifabutin	fluconazole	false	false
rifabutin: there have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.	rifabutin	rifabutin	false	false
rifabutin: there have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.	fluconazole	rifabutin	false	effect
patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.	rifabutin	fluconazole	false	advise
tacrolimus: there have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.	tacrolimus	fluconazole	false	false
tacrolimus: there have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.	tacrolimus	tacrolimus	false	false
tacrolimus: there have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.	fluconazole	tacrolimus	false	effect
patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.	tacrolimus	fluconazole	false	advise
short-acting benzodiazepines: following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	short-acting benzodiazepines	midazolam	false	false
short-acting benzodiazepines: following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	short-acting benzodiazepines	fluconazole	false	false
short-acting benzodiazepines: following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	short-acting benzodiazepines	midazolam	false	false
short-acting benzodiazepines: following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	midazolam	fluconazole	false	mechanism
short-acting benzodiazepines: following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	midazolam	midazolam	false	false
short-acting benzodiazepines: following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	fluconazole	midazolam	false	false
this effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.	midazolam	fluconazole	false	effect
this effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.	midazolam	fluconazole	false	false
this effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.	fluconazole	fluconazole	false	false
if short-acting benzodiazepines, which are metabolized by the cytochrome p450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.	short-acting benzodiazepines	fluconazole	false	advise
if short-acting benzodiazepines, which are metabolized by the cytochrome p450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.	short-acting benzodiazepines	benzodiazepine	false	false
if short-acting benzodiazepines, which are metabolized by the cytochrome p450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.	fluconazole	benzodiazepine	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	fluconazole	ethinyl estradiol	false	mechanism
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	fluconazole	levonorgestrel	false	mechanism
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	fluconazole	contraceptives	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	fluconazole	ethinyl estradiol	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	fluconazole	levonorgestrel	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	ethinyl estradiol	levonorgestrel	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	ethinyl estradiol	contraceptives	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	ethinyl estradiol	ethinyl estradiol	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	ethinyl estradiol	levonorgestrel	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	levonorgestrel	contraceptives	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	levonorgestrel	ethinyl estradiol	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	levonorgestrel	levonorgestrel	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	contraceptives	ethinyl estradiol	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	contraceptives	levonorgestrel	false	false
fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	ethinyl estradiol	levonorgestrel	false	false
however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels.	ethinyl estradiol	levonorgestrel	false	false
the data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel auc values with fluconazole treatment are likely the result of random variation.	ethinyl estradiol	levonorgestrel	false	false
the data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel auc values with fluconazole treatment are likely the result of random variation.	ethinyl estradiol	fluconazole	false	false
the data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel auc values with fluconazole treatment are likely the result of random variation.	levonorgestrel	fluconazole	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	fluconazole	ethinyl estradiol	false	mechanism
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	fluconazole	levonorgestrel	false	mechanism
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	fluconazole	fluconazole	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	fluconazole	ethinyl estradiol	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	fluconazole	levonorgestrel	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	ethinyl estradiol	levonorgestrel	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	ethinyl estradiol	fluconazole	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	ethinyl estradiol	ethinyl estradiol	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	ethinyl estradiol	levonorgestrel	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	levonorgestrel	fluconazole	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	levonorgestrel	ethinyl estradiol	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	levonorgestrel	levonorgestrel	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	fluconazole	ethinyl estradiol	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	fluconazole	levonorgestrel	false	false
while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	ethinyl estradiol	levonorgestrel	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	monoamine oxidase inhibitor	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	maoi	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	isocarboxazid	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	marplan	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	tranylcypromine	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	parnate	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	phenelzine	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	mazindol	nardil	false	advise
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	monoamine oxidase inhibitor	maoi	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	monoamine oxidase inhibitor	isocarboxazid	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	monoamine oxidase inhibitor	marplan	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	monoamine oxidase inhibitor	tranylcypromine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	monoamine oxidase inhibitor	parnate	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	monoamine oxidase inhibitor	phenelzine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	monoamine oxidase inhibitor	nardil	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	maoi	isocarboxazid	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	maoi	marplan	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	maoi	tranylcypromine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	maoi	parnate	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	maoi	phenelzine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	maoi	nardil	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	isocarboxazid	marplan	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	isocarboxazid	tranylcypromine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	isocarboxazid	parnate	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	isocarboxazid	phenelzine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	isocarboxazid	nardil	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	marplan	tranylcypromine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	marplan	parnate	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	marplan	phenelzine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	marplan	nardil	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	tranylcypromine	parnate	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	tranylcypromine	phenelzine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	tranylcypromine	nardil	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	parnate	phenelzine	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	parnate	nardil	false	false
you cannot take mazindol if you have taken a monoamine oxidase inhibitor (maoi) such as isocarboxazid (marplan), tranylcypromine (parnate), or phenelzine (nardil) in the last 14 days.	phenelzine	nardil	false	false
changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.	insulin	mazindol	false	advise
mazindol may reduce the effects of guanethidine (ismelin).	mazindol	guanethidine	false	effect
mazindol may reduce the effects of guanethidine (ismelin).	mazindol	ismelin	false	effect
mazindol may reduce the effects of guanethidine (ismelin).	guanethidine	ismelin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	amitriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	elavil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	amoxapine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	asendin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	doxepin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	sinequan	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	nortriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tricyclic antidepressant	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	elavil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	amoxapine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	asendin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	doxepin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	sinequan	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	nortriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amitriptyline	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	amoxapine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	asendin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	doxepin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	sinequan	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	nortriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	elavil	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	asendin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	doxepin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	sinequan	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	nortriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	amoxapine	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	doxepin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	sinequan	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	nortriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	asendin	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	sinequan	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	nortriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	doxepin	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	nortriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	sinequan	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	pamelor	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	nortriptyline	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	imipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	pamelor	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	imipramine	tofranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	imipramine	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	imipramine	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	imipramine	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	imipramine	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	imipramine	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	imipramine	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tofranil	clomipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tofranil	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tofranil	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tofranil	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tofranil	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	tofranil	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	clomipramine	anafranil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	clomipramine	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	clomipramine	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	clomipramine	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	clomipramine	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	anafranil	protriptyline	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	anafranil	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	anafranil	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	anafranil	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	protriptyline	vivactil	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	protriptyline	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	protriptyline	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	vivactil	desipramine	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	vivactil	norpramin	false	false
before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (elavil), amoxapine (asendin), doxepin (sinequan), nortriptyline (pamelor), imipramine (tofranil), clomipramine (anafranil), protriptyline (vivactil), or desipramine (norpramin).	desipramine	norpramin	false	false
preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.	cimetidine	mebendazole	false	mechanism
preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.	cimetidine	mebendazole	false	false
preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.	mebendazole	mebendazole	false	false
patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.	antibiotics	sulfonamides	false	false
patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.	antibiotics	ganglion blockers	false	advise
patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.	sulfonamides	ganglion blockers	false	advise
the action of mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.	mecamylamine	antihypertensive drugs	false	effect
the action of mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.	mecamylamine	alcohol	false	effect
the action of mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.	antihypertensive drugs	alcohol	false	false
aminoglutethimide administered concomitantly with depo-subq provera 104 may significantly decrease the serum concentrations of mpa.	aminoglutethimide	depo-subq provera 104	false	mechanism
aminoglutethimide administered concomitantly with depo-subq provera 104 may significantly decrease the serum concentrations of mpa.	aminoglutethimide	mpa	false	false
aminoglutethimide administered concomitantly with depo-subq provera 104 may significantly decrease the serum concentrations of mpa.	depo-subq provera 104	mpa	false	false
pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs.	zidovudine	rifabutin	false	false
pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs.	zidovudine	megestrol acetate	false	false
pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs.	rifabutin	megestrol acetate	false	false
a pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for cmax and ~28% for auc) of indinavir.	megestrol acetate	indinavir	false	mechanism
a pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for cmax and ~28% for auc) of indinavir.	megestrol acetate	indinavir	false	false
a pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for cmax and ~28% for auc) of indinavir.	indinavir	indinavir	false	false
administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate.	indinavir	megestrol acetate	false	advise
the effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	indinavir	zidovudine	false	false
the effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	indinavir	rifabutin	false	false
the effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	indinavir	megestrol acetate	false	false
the effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	zidovudine	rifabutin	false	false
the effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	zidovudine	megestrol acetate	false	false
the effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	rifabutin	megestrol acetate	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	aspirin	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	nsaids	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluvoxamine	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	beta blockers	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluoxetine	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	int
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	nsaids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	fluvoxamine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	beta blockers	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	fluoxetine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	aspirin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	fluvoxamine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	beta blockers	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	fluoxetine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	nsaids	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluvoxamine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	beta blockers	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluoxetine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	beta blockers	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	fluoxetine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluvoxamine	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	beta blockers	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluoxetine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	fluoxetine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	beta blockers	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	fluoxetine	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	fluoxetine	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	progestin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	progestin	false	effect
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	benzodiazepenes	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	progestin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	benzodiazepenes	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	melatonin	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	effect
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	melatonin	corticosteroids	false	false
melatonin may interact with the following drugs: aspirin and other nsaids (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	corticosteroids	corticosteroids	false	false
ace inhibitors reports suggest that nsaids may diminish the antihypertensive effect of angiotensin-converting enzyme (ace) inhibitors.	ace inhibitors	nsaids	false	false
ace inhibitors reports suggest that nsaids may diminish the antihypertensive effect of angiotensin-converting enzyme (ace) inhibitors.	ace inhibitors	angiotensin-converting enzyme (ace) inhibitors	false	false
ace inhibitors reports suggest that nsaids may diminish the antihypertensive effect of angiotensin-converting enzyme (ace) inhibitors.	nsaids	angiotensin-converting enzyme (ace) inhibitors	false	effect
this interaction should be given consideration in patients taking nsaids concomitantly with ace inhibitors.	nsaids	ace inhibitors	false	advise
aspirin: concomitant administration of aspirin (1000 mg tid) to healthy volunteers tended to increase the auc (10%) and cmax (24%) of meloxicam.	aspirin	aspirin	false	false
aspirin: concomitant administration of aspirin (1000 mg tid) to healthy volunteers tended to increase the auc (10%) and cmax (24%) of meloxicam.	aspirin	meloxicam	false	false
aspirin: concomitant administration of aspirin (1000 mg tid) to healthy volunteers tended to increase the auc (10%) and cmax (24%) of meloxicam.	aspirin	meloxicam	false	mechanism
however, as with other nsaids, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.	nsaids	meloxicam	false	false
however, as with other nsaids, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.	nsaids	aspirin	false	advise
however, as with other nsaids, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.	meloxicam	aspirin	false	advise
concomitant administration of low-dose aspirin with mobic may result in an increased rate of gi ulceration or other complications, compared to use of mobic alone.	aspirin	mobic	false	effect
concomitant administration of low-dose aspirin with mobic may result in an increased rate of gi ulceration or other complications, compared to use of mobic alone.	aspirin	mobic	false	false
concomitant administration of low-dose aspirin with mobic may result in an increased rate of gi ulceration or other complications, compared to use of mobic alone.	mobic	mobic	false	false
mobic is not a substitute for aspirin for cardiovascular prophylaxis.	mobic	aspirin	false	false
cholestyramine: pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.	cholestyramine	cholestyramine	false	false
cholestyramine: pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.	cholestyramine	meloxicam	false	false
cholestyramine: pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.	cholestyramine	meloxicam	false	mechanism
cimetidine: concomitant administration of 200 mg cimetidine qid did not alter the single-dose pharmacokinetics of 30 mg meloxicam.	cimetidine	cimetidine	false	false
cimetidine: concomitant administration of 200 mg cimetidine qid did not alter the single-dose pharmacokinetics of 30 mg meloxicam.	cimetidine	meloxicam	false	false
cimetidine: concomitant administration of 200 mg cimetidine qid did not alter the single-dose pharmacokinetics of 30 mg meloxicam.	cimetidine	meloxicam	false	false
digoxin: meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.	digoxin	meloxicam	false	false
digoxin: meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.	digoxin	digoxin	false	false
digoxin: meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.	meloxicam	digoxin	false	false
in vitro testing found no protein binding drug interaction between digoxin and meloxicam.	digoxin	meloxicam	false	false
furosemide: clinical studies, as well as post-marketing observations, have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	furosemide	nsaids	false	false
furosemide: clinical studies, as well as post-marketing observations, have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	furosemide	furosemide	false	false
furosemide: clinical studies, as well as post-marketing observations, have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	furosemide	thiazide diuretics	false	false
furosemide: clinical studies, as well as post-marketing observations, have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	nsaids	furosemide	false	effect
furosemide: clinical studies, as well as post-marketing observations, have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	nsaids	thiazide diuretics	false	effect
furosemide: clinical studies, as well as post-marketing observations, have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	furosemide	thiazide diuretics	false	false
studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect.	furosemide	meloxicam	false	false
furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam.	furosemide	meloxicam	false	false
nevertheless, during concomitant therapy with furosemide and mobic, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.	furosemide	mobic	false	advise
lithium: in clinical trials, nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	lithium	nsaids	false	false
lithium: in clinical trials, nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	lithium	lithium	false	false
lithium: in clinical trials, nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	lithium	lithium	false	false
lithium: in clinical trials, nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	nsaids	lithium	false	mechanism
lithium: in clinical trials, nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	nsaids	lithium	false	false
lithium: in clinical trials, nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	lithium	lithium	false	false
in a study conducted in healthy subjects, mean pre-dose lithium concentration and auc were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone.	lithium	lithium	false	false
in a study conducted in healthy subjects, mean pre-dose lithium concentration and auc were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone.	lithium	meloxicam	false	false
in a study conducted in healthy subjects, mean pre-dose lithium concentration and auc were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone.	lithium	lithium	false	false
in a study conducted in healthy subjects, mean pre-dose lithium concentration and auc were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone.	lithium	meloxicam	false	mechanism
in a study conducted in healthy subjects, mean pre-dose lithium concentration and auc were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone.	lithium	lithium	false	false
in a study conducted in healthy subjects, mean pre-dose lithium concentration and auc were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone.	meloxicam	lithium	false	false
patients on lithium treatment should be closely monitored when mobic is introduced or withdrawn.	lithium	mobic	false	advise
methotrexate: a study in 13 rheumatoid arthritis (ra) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly.	methotrexate	meloxicam	false	false
methotrexate: a study in 13 rheumatoid arthritis (ra) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly.	methotrexate	methotrexate	false	false
methotrexate: a study in 13 rheumatoid arthritis (ra) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly.	meloxicam	methotrexate	false	false
meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate.	meloxicam	methotrexate	false	false
in vitro, methotrexate did not displace meloxicam from its human serum binding sites.	methotrexate	meloxicam	false	false
warfarin: anticoagulant activity should be monitored, particularly in the first few days after initiating or changing mobic therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.	warfarin	mobic	false	false
warfarin: anticoagulant activity should be monitored, particularly in the first few days after initiating or changing mobic therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.	warfarin	warfarin	false	false
warfarin: anticoagulant activity should be monitored, particularly in the first few days after initiating or changing mobic therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.	mobic	warfarin	false	advise
the effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an inr (international normalized ratio) between 1.2 and 1.8.	meloxicam	warfarin	false	false
the effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an inr (international normalized ratio) between 1.2 and 1.8.	meloxicam	warfarin	false	false
the effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an inr (international normalized ratio) between 1.2 and 1.8.	warfarin	warfarin	false	false
in these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.	meloxicam	warfarin	false	false
in these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.	meloxicam	warfarin	false	false
in these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.	warfarin	warfarin	false	false
caution should be used when administering mobic with warfarin since patients on warfarin may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced.	mobic	warfarin	false	advise
caution should be used when administering mobic with warfarin since patients on warfarin may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced.	mobic	warfarin	false	false
caution should be used when administering mobic with warfarin since patients on warfarin may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced.	warfarin	warfarin	false	false
drug interactions  there are no known drug/drug interactions with oral alkeran  vaccinations with live organism vaccines are not recommended in immunocompromised individuals  nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	alkeran	live organism vaccines	false	false
drug interactions  there are no known drug/drug interactions with oral alkeran  vaccinations with live organism vaccines are not recommended in immunocompromised individuals  nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	alkeran	nalidixic acid	false	false
drug interactions  there are no known drug/drug interactions with oral alkeran  vaccinations with live organism vaccines are not recommended in immunocompromised individuals  nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	alkeran	melphalan	false	false
drug interactions  there are no known drug/drug interactions with oral alkeran  vaccinations with live organism vaccines are not recommended in immunocompromised individuals  nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	live organism vaccines	nalidixic acid	false	false
drug interactions  there are no known drug/drug interactions with oral alkeran  vaccinations with live organism vaccines are not recommended in immunocompromised individuals  nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	live organism vaccines	melphalan	false	false
drug interactions  there are no known drug/drug interactions with oral alkeran  vaccinations with live organism vaccines are not recommended in immunocompromised individuals  nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	nalidixic acid	melphalan	false	effect
impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease	melphalan	cyclosporin	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	amantadine	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	antiarrhythmic agents of class i	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	quinidine	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	antihistamines	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	antipsychotic agents	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	phenothiazines	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	benzodiazepines	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	mao inhibitors	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	narcotic analgesics	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	meperidine	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	nitrates	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	nitrites	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	sympathomimetic agents	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	anticholinergic drugs	tricyclic antidepressants	false	effect
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	antiarrhythmic agents of class i	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	quinidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	antihistamines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	antipsychotic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	phenothiazines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	benzodiazepines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	mao inhibitors	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	amantadine	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	quinidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	antihistamines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	antipsychotic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	phenothiazines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	benzodiazepines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	mao inhibitors	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antiarrhythmic agents of class i	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	antihistamines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	antipsychotic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	phenothiazines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	benzodiazepines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	mao inhibitors	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	quinidine	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	antipsychotic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	phenothiazines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	benzodiazepines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	mao inhibitors	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antihistamines	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	phenothiazines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	benzodiazepines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	mao inhibitors	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	antipsychotic agents	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	benzodiazepines	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	mao inhibitors	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	phenothiazines	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	benzodiazepines	mao inhibitors	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	benzodiazepines	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	benzodiazepines	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	benzodiazepines	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	benzodiazepines	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	benzodiazepines	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	benzodiazepines	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	mao inhibitors	narcotic analgesics	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	mao inhibitors	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	mao inhibitors	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	mao inhibitors	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	mao inhibitors	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	mao inhibitors	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	narcotic analgesics	meperidine	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	narcotic analgesics	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	narcotic analgesics	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	narcotic analgesics	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	narcotic analgesics	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	meperidine	nitrates	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	meperidine	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	meperidine	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	meperidine	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	nitrates	nitrites	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	nitrates	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	nitrates	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	nitrites	sympathomimetic agents	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	nitrites	tricyclic antidepressants	false	false
the following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class i (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, mao inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	sympathomimetic agents	tricyclic antidepressants	false	false
anticholinergics antagonize the effects of antiglaucoma agents.	anticholinergics	antiglaucoma agents	false	effect
anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.	anticholinergic drugs	corticosteroids	false	effect
anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;	anticholinergic agents	digoxin	false	mechanism
anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.	anticholinergic drugs	metoclopramide	false	effect
because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.	antacids	anticholinergic agents	false	mechanism
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	meperidine	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	narcotic analgesics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	anesthetics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	phenothiazines	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	tranquilizers	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	sedative-hypnotics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	barbiturates	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	tricyclic antidepressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	central nervous system depressants	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	narcotic analgesics	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	anesthetics	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	phenothiazines	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	tranquilizers	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	sedative-hypnotics	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	barbiturates	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	tricyclic antidepressants	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	cns depressants	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	meperidine	alcohol	false	advise
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	anesthetics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	phenothiazines	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	tranquilizers	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	sedative-hypnotics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	barbiturates	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	tricyclic antidepressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	narcotic analgesics	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	anesthetics	phenothiazines	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	anesthetics	tranquilizers	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	anesthetics	sedative-hypnotics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	anesthetics	barbiturates	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	anesthetics	tricyclic antidepressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	anesthetics	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	anesthetics	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	phenothiazines	tranquilizers	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	phenothiazines	sedative-hypnotics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	phenothiazines	barbiturates	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	phenothiazines	tricyclic antidepressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	phenothiazines	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	phenothiazines	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	tranquilizers	sedative-hypnotics	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	tranquilizers	barbiturates	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	tranquilizers	tricyclic antidepressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	tranquilizers	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	tranquilizers	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	sedative-hypnotics	barbiturates	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	sedative-hypnotics	tricyclic antidepressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	sedative-hypnotics	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	sedative-hypnotics	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	barbiturates	tricyclic antidepressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	barbiturates	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	barbiturates	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	tricyclic antidepressants	cns depressants	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	tricyclic antidepressants	alcohol	false	false
interaction with other central nervous system depressants: meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics (including barbiturates), tricyclic antidepressants and other cns depressants (including alcohol).	cns depressants	alcohol	false	false
some anticonvulsants may interact with mephenytoin.	anticonvulsants	mephenytoin	false	int
those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.	anticonvulsants	divalproex sodium	false	false
those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.	anticonvulsants	valproic acid	false	false
those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.	anticonvulsants	phenobarbital	false	false
those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.	divalproex sodium	valproic acid	false	false
those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.	divalproex sodium	phenobarbital	false	false
those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.	valproic acid	phenobarbital	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	mephenytoin	steroid medications	false	effect
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	mephenytoin	warfarin	false	effect
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	mephenytoin	anti-infective medicines	false	effect
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	mephenytoin	furosemide	false	effect
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	mephenytoin	theophylline	false	effect
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	mephenytoin	mephenytoin	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	steroid medications	warfarin	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	steroid medications	anti-infective medicines	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	steroid medications	furosemide	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	steroid medications	theophylline	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	steroid medications	mephenytoin	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	warfarin	anti-infective medicines	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	warfarin	furosemide	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	warfarin	theophylline	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	warfarin	mephenytoin	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	anti-infective medicines	furosemide	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	anti-infective medicines	theophylline	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	anti-infective medicines	mephenytoin	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	furosemide	theophylline	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	furosemide	mephenytoin	false	false
mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here.	theophylline	mephenytoin	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	mequitazine	cns depressant	false	int
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	mequitazine	antichlolinergic	false	int
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	mequitazine	tca	false	int
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	mequitazine	maois	false	int
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	mequitazine	alcohol	false	int
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	cns depressant	antichlolinergic	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	cns depressant	tca	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	cns depressant	maois	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	cns depressant	alcohol	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	antichlolinergic	tca	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	antichlolinergic	maois	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	antichlolinergic	alcohol	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	tca	maois	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	tca	alcohol	false	false
mequitazine can interact with cns depressant, antichlolinergic, tca, maois, and alcohol.	maois	alcohol	false	false
probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.	probenecid	meropenem	false	mechanism
probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.	probenecid	meropenem	false	false
probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.	meropenem	meropenem	false	false
therefore, the coadministration of probenecid with meropenem is not recommended.	probenecid	meropenem	false	advise
there is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/ml total valproate).	meropenem	valproic acid	false	mechanism
there is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/ml total valproate).	meropenem	valproate	false	false
there is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/ml total valproate).	valproic acid	valproate	false	false
aramine should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.	aramine	digitalis	false	false
aramine should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.	aramine	sympathomimetic amines	false	false
aramine should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.	digitalis	sympathomimetic amines	false	effect
monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.	monoamine oxidase inhibitors	tricyclic antidepressants	false	false
monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.	monoamine oxidase inhibitors	sympathomimetic amines	false	effect
monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.	tricyclic antidepressants	sympathomimetic amines	false	effect
skelaxin may enhance the effects of alcohol, barbiturates and other cns depressants.	skelaxin	alcohol	false	effect
skelaxin may enhance the effects of alcohol, barbiturates and other cns depressants.	skelaxin	barbiturates	false	effect
skelaxin may enhance the effects of alcohol, barbiturates and other cns depressants.	skelaxin	cns depressants	false	effect
skelaxin may enhance the effects of alcohol, barbiturates and other cns depressants.	alcohol	barbiturates	false	false
skelaxin may enhance the effects of alcohol, barbiturates and other cns depressants.	alcohol	cns depressants	false	false
skelaxin may enhance the effects of alcohol, barbiturates and other cns depressants.	barbiturates	cns depressants	false	false
caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	methazolamide	false	advise
caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	aspirin	false	false
caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	carbonic anhydrase inhibitors	false	false
caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	methazolamide	aspirin	false	false
caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	methazolamide	carbonic anhydrase inhibitors	false	false
caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	aspirin	carbonic anhydrase inhibitors	false	effect
anticoagulants (oral): the activity of oral anticoagulants may be potentiated by anti-vitamin-k activity attributed to methimazole.	anticoagulants	anticoagulants	false	false
anticoagulants (oral): the activity of oral anticoagulants may be potentiated by anti-vitamin-k activity attributed to methimazole.	anticoagulants	methimazole	false	false
anticoagulants (oral): the activity of oral anticoagulants may be potentiated by anti-vitamin-k activity attributed to methimazole.	anticoagulants	methimazole	false	effect
digitalis glycosides: serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid;	digitalis glycosides	digitalis glycoside	false	false
theophylline: theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid;	theophylline	theophylline	false	false
theophylline: theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid;	theophylline	theophylline	false	false
theophylline: theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid;	theophylline	theophylline	false	false
dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.	opioids	levomepromazine	false	effect
dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.	opioids	opioids	false	false
dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.	levomepromazine	opioids	false	effect
combination with tramadol (ultram) is associated with increased risk of seizures.	tramadol	ultram	false	false
additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.	levomepromazine	benzodiazepines	false	effect
additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.	levomepromazine	barbiturates	false	effect
additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.	benzodiazepines	barbiturates	false	false
exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	levomepromazine	anticholinergic drugs	false	advise
exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	levomepromazine	tricyclic antidepressants	false	advise
exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	levomepromazine	antiparkinsonian-agents	false	advise
exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	anticholinergic drugs	tricyclic antidepressants	false	false
exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	anticholinergic drugs	antiparkinsonian-agents	false	false
exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	tricyclic antidepressants	antiparkinsonian-agents	false	false
caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.	caffeine	ephedrine	false	false
caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.	caffeine	amphetamine	false	false
caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.	caffeine	levomepromazine	false	effect
caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.	ephedrine	amphetamine	false	false
caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.	ephedrine	levomepromazine	false	effect
caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.	amphetamine	levomepromazine	false	effect
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	celontin	methsuximide	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	celontin	antiepileptic drugs	false	advise
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	celontin	methsuximide	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	celontin	phenytoin	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	celontin	phenobarbital	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	antiepileptic drugs	false	advise
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	methsuximide	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenytoin	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenobarbital	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	antiepileptic drugs	methsuximide	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	antiepileptic drugs	phenytoin	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	antiepileptic drugs	phenobarbital	false	false
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenytoin	false	mechanism
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	methsuximide	phenobarbital	false	mechanism
since celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	phenytoin	phenobarbital	false	false
hypokalemia may develop during concomitant use of steroids or acth.	steroids	acth	false	false
thiazides may decrease arterial responsiveness to norepinephrine.	thiazides	norepinephrine	false	effect
thiazide drugs may increase the responsiveness of tubocurarine.	thiazide drugs	tubocurarine	false	effect
lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.	lithium	thiazides	false	mechanism
lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.	lithium	lithium	false	false
lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.	thiazides	lithium	false	false
thiazides may add to or potentiate the action of other antihypertensive drugs.	thiazides	antihypertensive drugs	false	effect
potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.	ganglionic adrenergic blocking drugs	peripheral adrenergic blocking drugs	false	false
when methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur.	methyldopa	antihypertensive drugs	false	effect
patients may require reduced doses of anesthetics when on methyldopa.	anesthetics	methyldopa	false	advise
when methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.	methyldopa	lithium	false	advise
when methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.	methyldopa	lithium	false	false
when methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.	lithium	lithium	false	false
several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.	methyldopa	ferrous sulfate	false	mechanism
several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.	methyldopa	ferrous gluconate	false	mechanism
several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.	ferrous sulfate	ferrous gluconate	false	false
coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.	methyldopa	ferrous sulfate	false	advise
coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.	methyldopa	ferrous gluconate	false	advise
coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.	ferrous sulfate	ferrous gluconate	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	methyldopa	vma	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	methyldopa	vanillylmandelic acid	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	methyldopa	vma	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	methyldopa	vanillin	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	vma	vanillylmandelic acid	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	vma	vma	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	vma	vanillin	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	vanillylmandelic acid	vma	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	vanillylmandelic acid	vanillin	false	false
methyldopa does not interfere with measurement of vma (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert vma to vanillin.	vma	vanillin	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	macrolide antibiotics	protease inhibitors	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	macrolide antibiotics	ergot alkaloid drugs	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	macrolide antibiotics	dihydroergotamine	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	macrolide antibiotics	ergotamine	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	protease inhibitors	ergot alkaloid drugs	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	protease inhibitors	dihydroergotamine	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	protease inhibitors	ergotamine	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	ergot alkaloid drugs	dihydroergotamine	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	ergot alkaloid drugs	ergotamine	false	false
cyp 3a4 inhibitors (e.g. macrolide antibiotics and protease inhibitors) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent cyp 3a4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	dihydroergotamine	ergotamine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	erythromycin	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	troleandomycin	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	clarithromycin	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	hiv protease inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	reverse transcriptase inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	ritonavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	indinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	macrolide antibiotics	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	troleandomycin	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	clarithromycin	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	hiv protease inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	reverse transcriptase inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	ritonavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	indinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	erythromycin	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	clarithromycin	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	hiv protease inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	reverse transcriptase inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	ritonavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	indinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	troleandomycin	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	hiv protease inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	reverse transcriptase inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	ritonavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	indinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	clarithromycin	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	reverse transcriptase inhibitors	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	ritonavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	indinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	hiv protease inhibitors	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	ritonavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	indinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	reverse transcriptase inhibitors	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ritonavir	indinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ritonavir	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ritonavir	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ritonavir	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ritonavir	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ritonavir	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ritonavir	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	indinavir	nelfinavir	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	indinavir	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	indinavir	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	indinavir	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	indinavir	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	indinavir	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	nelfinavir	delavirdine	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	nelfinavir	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	nelfinavir	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	nelfinavir	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	nelfinavir	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	delavirdine	azole antifungals	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	delavirdine	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	delavirdine	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	delavirdine	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	azole antifungals	ketoconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	azole antifungals	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	azole antifungals	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ketoconazole	itraconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	ketoconazole	voriconazole	false	false
examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), hiv protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	itraconazole	voriconazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	saquinavir	nefazodone	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	saquinavir	fluconazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	saquinavir	fluoxetine	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	saquinavir	fluvoxamine	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	saquinavir	zileuton	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	saquinavir	clotrimazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	nefazodone	fluconazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	nefazodone	fluoxetine	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	nefazodone	fluvoxamine	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	nefazodone	zileuton	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	nefazodone	clotrimazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluconazole	fluoxetine	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluconazole	fluvoxamine	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluconazole	zileuton	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluconazole	clotrimazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluoxetine	fluvoxamine	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluoxetine	zileuton	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluoxetine	clotrimazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluvoxamine	zileuton	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	fluvoxamine	clotrimazole	false	false
less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	zileuton	clotrimazole	false	false
caution should be exercised when methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	methergine	methylergonovine maleate	false	false
caution should be exercised when methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	methergine	vasoconstrictors	false	advise
caution should be exercised when methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	methergine	ergot alkaloids	false	advise
caution should be exercised when methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	methylergonovine maleate	vasoconstrictors	false	advise
caution should be exercised when methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	methylergonovine maleate	ergot alkaloids	false	false
caution should be exercised when methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.	vasoconstrictors	ergot alkaloids	false	false
ritalin may decrease the hypotensive effect of guanethidine.	ritalin	guanethidine	false	effect
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	coumarin anticoagulants	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	anticonvulsants	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	phenobarbital	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	diphenylhydantoin	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	primidone	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	phenylbutazone	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	tricyclic drugs	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	imipramine	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	clomipramine	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	ritalin	desipramine	false	mechanism
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	anticonvulsants	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	phenobarbital	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	diphenylhydantoin	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	primidone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	phenylbutazone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	tricyclic drugs	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	imipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	coumarin anticoagulants	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	phenobarbital	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	diphenylhydantoin	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	primidone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	phenylbutazone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	tricyclic drugs	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	imipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	anticonvulsants	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenobarbital	diphenylhydantoin	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenobarbital	primidone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenobarbital	phenylbutazone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenobarbital	tricyclic drugs	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenobarbital	imipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenobarbital	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenobarbital	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	diphenylhydantoin	primidone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	diphenylhydantoin	phenylbutazone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	diphenylhydantoin	tricyclic drugs	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	diphenylhydantoin	imipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	diphenylhydantoin	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	diphenylhydantoin	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	primidone	phenylbutazone	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	primidone	tricyclic drugs	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	primidone	imipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	primidone	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	primidone	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenylbutazone	tricyclic drugs	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenylbutazone	imipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenylbutazone	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	phenylbutazone	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	tricyclic drugs	imipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	tricyclic drugs	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	tricyclic drugs	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	imipramine	clomipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	imipramine	desipramine	false	false
human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	clomipramine	desipramine	false	false
the safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.	methylphenidate	clonidine	false	false
the safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.	methylphenidate	alpha-2 agonists	false	false
the safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.	clonidine	alpha-2 agonists	false	false
mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone;	cyclosporin	methylprednisolone	false	mechanism
convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.	methylprednisolone	cyclosporin	false	effect
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	phenobarbital	phenytoin	false	false
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	phenobarbital	rifampin	false	false
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	phenobarbital	methylprednisolone	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	phenobarbital	methylprednisolone	false	advise
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	phenytoin	rifampin	false	false
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	phenytoin	methylprednisolone	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	phenytoin	methylprednisolone	false	advise
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	rifampin	methylprednisolone	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	rifampin	methylprednisolone	false	advise
drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	methylprednisolone	methylprednisolone	false	false
drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.	troleandomycin	ketoconazole	false	false
drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.	troleandomycin	methylprednisolone	false	mechanism
drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.	ketoconazole	methylprednisolone	false	mechanism
methylprednisolone may increase the clearance of chronic high dose aspirin.	methylprednisolone	aspirin	false	mechanism
this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.	salicylate	salicylate	false	false
this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.	salicylate	methylprednisolone	false	false
this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.	salicylate	methylprednisolone	false	effect
aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.	aspirin	corticosteroids	false	advise
the effect of methylprednisolone on oral anticoagulants is variable.	methylprednisolone	anticoagulants	false	false
there are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids.	anticoagulant	corticosteroids	false	effect
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	antidepressants	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	tricyclic	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	mao inhibitors	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	phenelzine	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	linezolid	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	tranylcypromine	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	isocarboxazid	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	selegiline	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	furazolidone	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	quinidine	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	amantadine	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	antihistamines	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	diphenhydramine	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	anticholinergics	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	potassium chloride	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	antacids	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	absorbent-type anti-diarrhea medicines	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	kaolin	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	pectin	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	phenothiazines	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	chlorpromazine	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	methscopolamine	promethazine	false	int
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	tricyclic	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	mao inhibitors	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	phenelzine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	linezolid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	tranylcypromine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	isocarboxazid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	selegiline	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antidepressants	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	mao inhibitors	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	phenelzine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	linezolid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	tranylcypromine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	isocarboxazid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	selegiline	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tricyclic	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	phenelzine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	linezolid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	tranylcypromine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	isocarboxazid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	selegiline	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	mao inhibitors	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	linezolid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	tranylcypromine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	isocarboxazid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	selegiline	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenelzine	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	tranylcypromine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	isocarboxazid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	selegiline	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	linezolid	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	isocarboxazid	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	selegiline	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	tranylcypromine	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	selegiline	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	isocarboxazid	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	furazolidone	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	selegiline	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	quinidine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	furazolidone	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	amantadine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	quinidine	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	antihistamines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	amantadine	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	diphenhydramine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antihistamines	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	anticholinergics	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	diphenhydramine	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	potassium chloride	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	anticholinergics	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	antacids	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	potassium chloride	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	absorbent-type anti-diarrhea medicines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	antacids	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	kaolin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	absorbent-type anti-diarrhea medicines	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	pectin	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	kaolin	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	pectin	phenothiazines	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	pectin	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	pectin	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenothiazines	chlorpromazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	phenothiazines	promethazine	false	false
methscopolamine may interact with antidepressants (tricyclic type), mao inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	chlorpromazine	promethazine	false	false
concurrent use of alcohol and other cns depression-producing drugs may increase the cns depressant effects of methyprylon or these other medications.	alcohol	cns depression-producing drugs	false	false
concurrent use of alcohol and other cns depression-producing drugs may increase the cns depressant effects of methyprylon or these other medications.	alcohol	methyprylon	false	effect
concurrent use of alcohol and other cns depression-producing drugs may increase the cns depressant effects of methyprylon or these other medications.	cns depression-producing drugs	methyprylon	false	effect
methysergide may reverse the analgesic activity of narcotic analgesics.	methysergide	narcotic analgesics	false	effect
concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	vasoconstrictor agents	ergot alkaloids	false	false
concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	vasoconstrictor agents	sumatriptan	false	false
concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	vasoconstrictor agents	nicotine	false	false
concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	ergot alkaloids	sumatriptan	false	false
concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	ergot alkaloids	nicotine	false	false
concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	sumatriptan	nicotine	false	false
the effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.	metoclopramide	anticholinergic drugs	false	effect
the effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.	metoclopramide	narcotic analgesics	false	effect
the effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.	anticholinergic drugs	narcotic analgesics	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	metoclopramide	alcohol	false	effect
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	metoclopramide	sedatives	false	effect
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	metoclopramide	hypnotics	false	effect
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	metoclopramide	narcotics	false	effect
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	metoclopramide	tranquilizers	false	effect
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	alcohol	sedatives	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	alcohol	hypnotics	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	alcohol	narcotics	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	alcohol	tranquilizers	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	sedatives	hypnotics	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	sedatives	narcotics	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	sedatives	tranquilizers	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	hypnotics	narcotics	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	hypnotics	tranquilizers	false	false
additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.	narcotics	tranquilizers	false	false
the finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.	metoclopramide	monoamine oxi-dase inhibitors	false	advise
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	digoxin	metoclopramide	false	mechanism
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	digoxin	acetaminophen	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	digoxin	tetracycline	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	digoxin	levodopa	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	digoxin	ethanol	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	digoxin	cyclosporine	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	metoclopramide	acetaminophen	false	mechanism
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	metoclopramide	tetracycline	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	metoclopramide	levodopa	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	metoclopramide	ethanol	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	metoclopramide	cyclosporine	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	acetaminophen	tetracycline	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	acetaminophen	levodopa	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	acetaminophen	ethanol	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	acetaminophen	cyclosporine	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	tetracycline	levodopa	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	tetracycline	ethanol	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	tetracycline	cyclosporine	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	levodopa	ethanol	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	levodopa	cyclosporine	false	false
absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	ethanol	cyclosporine	false	false
because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.	metoclopramide	insulin	false	advise
diuretics: furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	diuretics	furosemide	false	false
diuretics: furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	diuretics	loop diuretics	false	false
diuretics: furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	diuretics	metolazone	false	false
diuretics: furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	furosemide	loop diuretics	false	false
diuretics: furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	furosemide	metolazone	false	effect
diuretics: furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	loop diuretics	metolazone	false	effect
other antihypertensives: when mykrox tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.	antihypertensives	mykrox	false	false
other antihypertensives: when mykrox tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.	antihypertensives	antihypertensive drugs	false	false
other antihypertensives: when mykrox tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.	mykrox	antihypertensive drugs	false	advise
alcohol, barbiturates, and narcotics: the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	alcohol	barbiturates	false	false
alcohol, barbiturates, and narcotics: the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	alcohol	narcotics	false	false
alcohol, barbiturates, and narcotics: the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	alcohol	metolazone	false	false
alcohol, barbiturates, and narcotics: the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	barbiturates	narcotics	false	false
alcohol, barbiturates, and narcotics: the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	barbiturates	metolazone	false	false
alcohol, barbiturates, and narcotics: the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	narcotics	metolazone	false	false
digitalis glycosides: diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.	digitalis glycosides	diuretic	false	false
digitalis glycosides: diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.	digitalis glycosides	digitalis	false	false
digitalis glycosides: diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.	diuretic	digitalis	false	effect
corticosteroids or acth: may increase the risk of hypokalemia and increase salt and water retention.	corticosteroids	acth	false	false
lithium: serum lithium levels may increase.	lithium	lithium	false	false
curariform drugs: diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	curariform drugs	diuretic	false	false
curariform drugs: diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	curariform drugs	curariform drugs	false	false
curariform drugs: diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	curariform drugs	tubocurarine	false	false
curariform drugs: diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	diuretic	curariform drugs	false	effect
curariform drugs: diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	diuretic	tubocurarine	false	effect
curariform drugs: diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	curariform drugs	tubocurarine	false	false
salicylates and other non-steroidal anti-inflammatory drugs: may decrease the antihypertensive effects of mykrox tablets.	salicylates	non-steroidal anti-inflammatory drugs	false	false
salicylates and other non-steroidal anti-inflammatory drugs: may decrease the antihypertensive effects of mykrox tablets.	salicylates	mykrox	false	effect
salicylates and other non-steroidal anti-inflammatory drugs: may decrease the antihypertensive effects of mykrox tablets.	non-steroidal anti-inflammatory drugs	mykrox	false	effect
sympathomimetics: metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	sympathomimetics	metolazone	false	false
sympathomimetics: metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	sympathomimetics	norepinephrine	false	false
sympathomimetics: metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	metolazone	norepinephrine	false	effect
methenamine: efficacy may be decreased due to urinary alkalizing effect of metolazone.	methenamine	metolazone	false	effect
anticoagulants: metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	anticoagulants	metolazone	false	false
anticoagulants: metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	anticoagulants	thiazide-like diuretics	false	false
anticoagulants: metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	anticoagulants	anticoagulants	false	false
anticoagulants: metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	metolazone	thiazide-like diuretics	false	false
anticoagulants: metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	metolazone	anticoagulants	false	effect
anticoagulants: metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	thiazide-like diuretics	anticoagulants	false	false
catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.	reserpine	beta-blocking agents	false	effect
oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.	metronidazole	coumarin	false	effect
oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.	metronidazole	warfarin	false	effect
oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.	coumarin	warfarin	false	false
drug interactions should be kept in mind when metrogel (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.	metrogel	metronidazole	false	false
drug interactions should be kept in mind when metrogel (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.	metrogel	metronidazole	false	false
drug interactions should be kept in mind when metrogel (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.	metronidazole	metronidazole	false	false
the metabolism of metopirone is accelerated by phenytoin;	metopirone	phenytoin	false	mechanism
metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.	metopirone	acetaminophen	false	mechanism
metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.	metopirone	acetaminophen	false	effect
metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.	acetaminophen	acetaminophen	false	false
caution should be observed in administering demser to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	demser	phenothiazines	false	advise
caution should be observed in administering demser to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	demser	haloperidol	false	advise
caution should be observed in administering demser to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	phenothiazines	haloperidol	false	false
concurrent use of demser with alcohol or other cns depressants can increase their sedative effects.	demser	alcohol	false	effect
concurrent use of demser with alcohol or other cns depressants can increase their sedative effects.	demser	cns depressants	false	effect
concurrent use of demser with alcohol or other cns depressants can increase their sedative effects.	alcohol	cns depressants	false	false
since mexitil is a substrate for the metabolic pathways involving cyp2d6 and cyp1a2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.	mexitil	mexiletine	false	false
in a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of cyp1a2.	mexiletine	fluvoxamine	false	mechanism
in another formal study (n = 8 extensive and n = 7 poor metabolizers of cyp2d6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor cyp2d6 metabolizer group.	propafenone	mexiletine	false	false
in this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.	propafenone	mexiletine	false	false
addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of qrs, qtc, rr, and pr intervals than propafenone alone.	mexiletine	propafenone	false	false
addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of qrs, qtc, rr, and pr intervals than propafenone alone.	mexiletine	propafenone	false	false
addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of qrs, qtc, rr, and pr intervals than propafenone alone.	propafenone	propafenone	false	false
when concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect.	mexiletine	mexiletine	false	false
in a large compassionate use program mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions.	mexitil	antihypertensive	false	false
in a large compassionate use program mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions.	mexitil	anticoagulant drugs	false	false
in a large compassionate use program mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions.	antihypertensive	anticoagulant drugs	false	false
a variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy.	antiarrhythmics	quinidine	false	false
a variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy.	antiarrhythmics	propranolol	false	false
a variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy.	quinidine	propranolol	false	false
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	phenytoin	rifampin	false	false
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	phenytoin	phenobarbital	false	false
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	phenytoin	mexitil	false	mechanism
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	phenytoin	mexitil	false	false
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	rifampin	phenobarbital	false	false
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	rifampin	mexitil	false	mechanism
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	rifampin	mexitil	false	false
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	phenobarbital	mexitil	false	mechanism
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	phenobarbital	mexitil	false	false
when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil   , lowered mexitil    plasma levels have been reported.	mexitil	mexitil	false	false
in a formal study, benzodiazepines were shown not to affect mexitil    plasma concentrations.	benzodiazepines	mexitil	false	false
ecg intervals (pr, qrs, and qt) were not affected by concurrent mexitil    and digoxin, diuretics, or propranolol.	mexitil	digoxin	false	false
ecg intervals (pr, qrs, and qt) were not affected by concurrent mexitil    and digoxin, diuretics, or propranolol.	mexitil	diuretics	false	false
ecg intervals (pr, qrs, and qt) were not affected by concurrent mexitil    and digoxin, diuretics, or propranolol.	mexitil	propranolol	false	false
ecg intervals (pr, qrs, and qt) were not affected by concurrent mexitil    and digoxin, diuretics, or propranolol.	digoxin	diuretics	false	false
ecg intervals (pr, qrs, and qt) were not affected by concurrent mexitil    and digoxin, diuretics, or propranolol.	digoxin	propranolol	false	false
ecg intervals (pr, qrs, and qt) were not affected by concurrent mexitil    and digoxin, diuretics, or propranolol.	diuretics	propranolol	false	false
concurrent administration of cimetidine and mexitil    has been reported to increase, decrease, or leave unchanged mexitil    plasma levels;	cimetidine	mexitil	false	mechanism
concurrent administration of cimetidine and mexitil    has been reported to increase, decrease, or leave unchanged mexitil    plasma levels;	cimetidine	mexitil	false	false
concurrent administration of cimetidine and mexitil    has been reported to increase, decrease, or leave unchanged mexitil    plasma levels;	mexitil	mexitil	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	mexitil	digoxin	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	mexitil	magnesium-aluminum hydroxide	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	mexitil	mexitil	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	mexitil	digoxin	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	digoxin	magnesium-aluminum hydroxide	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	digoxin	mexitil	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	digoxin	digoxin	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	magnesium-aluminum hydroxide	mexitil	false	false
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	magnesium-aluminum hydroxide	digoxin	false	mechanism
mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexitil   , has been reported to lower serum digoxin levels.	mexitil	digoxin	false	false
concurrent use of mexitil    and theophylline may lead to increased plasma theophylline levels.	mexitil	theophylline	false	mechanism
concurrent use of mexitil    and theophylline may lead to increased plasma theophylline levels.	mexitil	theophylline	false	false
concurrent use of mexitil    and theophylline may lead to increased plasma theophylline levels.	theophylline	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	mexitil	false	mechanism
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	advise
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	mexitil	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	theophylline	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	mexitil	false	false
this increase was observed at the first test point which was the second day after starting mexitil   . theophylline plasma levels returned to pre-mexitil    values within 48 hours after discontinuing mexitil   . if mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the mexitil    dose is changed.	theophylline	mexitil	false	false
additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of mexitil   .	caffeine	mexitil	false	mechanism
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	posicor	terfenadine	false	mechanism
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	posicor	astemizole	false	mechanism
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	posicor	cisapride	false	mechanism
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	posicor	cyclosporine	false	mechanism
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	posicor	tricyclic antidepressants	false	mechanism
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	terfenadine	astemizole	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	terfenadine	cisapride	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	terfenadine	cyclosporine	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	terfenadine	tricyclic antidepressants	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	astemizole	cisapride	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	astemizole	cyclosporine	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	astemizole	tricyclic antidepressants	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	cisapride	cyclosporine	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	cisapride	tricyclic antidepressants	false	false
posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	cyclosporine	tricyclic antidepressants	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	mycophenolate mofetil	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	cyclosporine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	tacrolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	prednisolone	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	sirolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	nifedipine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	fluconazole	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycamine	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	cyclosporine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	tacrolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	prednisolone	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	sirolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	nifedipine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	fluconazole	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	mycophenolate mofetil	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	cyclosporine	tacrolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	cyclosporine	prednisolone	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	cyclosporine	sirolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	cyclosporine	nifedipine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	cyclosporine	fluconazole	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	cyclosporine	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	cyclosporine	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	tacrolimus	prednisolone	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	tacrolimus	sirolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	tacrolimus	nifedipine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	tacrolimus	fluconazole	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	tacrolimus	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	tacrolimus	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	prednisolone	sirolimus	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	prednisolone	nifedipine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	prednisolone	fluconazole	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	prednisolone	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	prednisolone	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	sirolimus	nifedipine	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	sirolimus	fluconazole	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	sirolimus	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	sirolimus	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	nifedipine	fluconazole	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	nifedipine	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	nifedipine	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	fluconazole	ritonavir	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	fluconazole	rifampin	false	false
a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	ritonavir	rifampin	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycamine	mycophenolate mofetil	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycamine	cyclosporine	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycamine	tacrolimus	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycamine	prednisolone	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycamine	fluconazole	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycophenolate mofetil	cyclosporine	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycophenolate mofetil	tacrolimus	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycophenolate mofetil	prednisolone	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	mycophenolate mofetil	fluconazole	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	cyclosporine	tacrolimus	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	cyclosporine	prednisolone	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	cyclosporine	fluconazole	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	tacrolimus	prednisolone	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	tacrolimus	fluconazole	false	false
there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	prednisolone	fluconazole	false	false
sirolimus auc was increased by 21% with no effect on cmax in the presence of steady-state mycamine compared with sirolimus alone.	sirolimus	mycamine	false	mechanism
sirolimus auc was increased by 21% with no effect on cmax in the presence of steady-state mycamine compared with sirolimus alone.	sirolimus	sirolimus	false	false
sirolimus auc was increased by 21% with no effect on cmax in the presence of steady-state mycamine compared with sirolimus alone.	mycamine	sirolimus	false	false
nifedipine auc and cmax were increased by 18% and 42%, respectively, in the presence of steady-state mycamine compared with nifedipine alone.	nifedipine	mycamine	false	mechanism
nifedipine auc and cmax were increased by 18% and 42%, respectively, in the presence of steady-state mycamine compared with nifedipine alone.	nifedipine	nifedipine	false	false
nifedipine auc and cmax were increased by 18% and 42%, respectively, in the presence of steady-state mycamine compared with nifedipine alone.	mycamine	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	mycamine	false	advise
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	nifedipine	mycamine	false	advise
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	nifedipine	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	nifedipine	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	nifedipine	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	nifedipine	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	mycamine	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	mycamine	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	mycamine	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	mycamine	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	nifedipine	sirolimus	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	nifedipine	nifedipine	false	false
patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	sirolimus	nifedipine	false	false
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	midazolam	azole antimycotics	false	advise
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	midazolam	protease inhibitors	false	advise
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	midazolam	calcium channel antagonists	false	advise
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	midazolam	macrolide antibiotics	false	advise
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	azole antimycotics	protease inhibitors	false	false
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	azole antimycotics	calcium channel antagonists	false	false
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	azole antimycotics	macrolide antibiotics	false	false
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	protease inhibitors	calcium channel antagonists	false	false
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	protease inhibitors	macrolide antibiotics	false	false
drug interactions: inhibitors of cyp3a4 isozymes: caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	calcium channel antagonists	macrolide antibiotics	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	erythromycin	diltiazem	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	erythromycin	verapamil	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	erythromycin	ketoconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	erythromycin	fluconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	erythromycin	itraconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	erythromycin	midazolam	false	mechanism
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	diltiazem	verapamil	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	diltiazem	ketoconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	diltiazem	fluconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	diltiazem	itraconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	diltiazem	midazolam	false	mechanism
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	verapamil	ketoconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	verapamil	fluconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	verapamil	itraconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	verapamil	midazolam	false	mechanism
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	ketoconazole	fluconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	ketoconazole	itraconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	ketoconazole	midazolam	false	mechanism
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	fluconazole	itraconazole	false	false
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	fluconazole	midazolam	false	mechanism
drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam.	itraconazole	midazolam	false	mechanism
although not studied, the potent cytochrome p450 3a4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.	ritonavir	nelfinavir	false	false
although not studied, the potent cytochrome p450 3a4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.	ritonavir	midazolam	false	mechanism
although not studied, the potent cytochrome p450 3a4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.	nelfinavir	midazolam	false	mechanism
inducers of cyp3a4 isozymes: cytochrome p450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies.	rifampin	carbamazepine	false	false
inducers of cyp3a4 isozymes: cytochrome p450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies.	rifampin	phenytoin	false	false
inducers of cyp3a4 isozymes: cytochrome p450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies.	rifampin	midazolam	false	mechanism
inducers of cyp3a4 isozymes: cytochrome p450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies.	carbamazepine	phenytoin	false	false
inducers of cyp3a4 isozymes: cytochrome p450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies.	carbamazepine	midazolam	false	mechanism
inducers of cyp3a4 isozymes: cytochrome p450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies.	phenytoin	midazolam	false	mechanism
the difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate.	sedatives	methylphenidate	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	narcotics	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	morphine	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	meperidine	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	fentanyl	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	propofol	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	ketamine	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	nitrous oxide	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	secobarbital	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	versed syrup	droperidol	false	effect
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	morphine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	meperidine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	fentanyl	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	propofol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	ketamine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	nitrous oxide	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	secobarbital	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	narcotics	droperidol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	morphine	meperidine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	morphine	fentanyl	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	morphine	propofol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	morphine	ketamine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	morphine	nitrous oxide	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	morphine	secobarbital	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	morphine	droperidol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	meperidine	fentanyl	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	meperidine	propofol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	meperidine	ketamine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	meperidine	nitrous oxide	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	meperidine	secobarbital	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	meperidine	droperidol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	fentanyl	propofol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	fentanyl	ketamine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	fentanyl	nitrous oxide	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	fentanyl	secobarbital	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	fentanyl	droperidol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	propofol	ketamine	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	propofol	nitrous oxide	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	propofol	secobarbital	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	propofol	droperidol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	ketamine	nitrous oxide	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	ketamine	secobarbital	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	ketamine	droperidol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	nitrous oxide	secobarbital	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	nitrous oxide	droperidol	false	false
the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	secobarbital	droperidol	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	scopolamine	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	glycopyrrolate	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	diazepam	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	hydroxyzine	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	muscle relaxants	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	atropine	anesthetics	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	glycopyrrolate	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	diazepam	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	hydroxyzine	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	muscle relaxants	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	scopolamine	anesthetics	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	diazepam	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	hydroxyzine	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	muscle relaxants	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	glycopyrrolate	anesthetics	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	diazepam	hydroxyzine	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	diazepam	muscle relaxants	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	diazepam	anesthetics	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	hydroxyzine	muscle relaxants	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	hydroxyzine	anesthetics	false	false
no significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	muscle relaxants	anesthetics	false	false
when administered concomitantly with proamatine   , cardiac glycosides may enhance or precipitate bradycardia, a.v.	proamatine	cardiac glycosides	false	effect
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylephrine	pseudoephedrine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylephrine	ephedrine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylephrine	phenylpropanolamine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylephrine	dihydroergotamine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylephrine	proamatine	false	effect
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylephrine	proamatine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	pseudoephedrine	ephedrine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	pseudoephedrine	phenylpropanolamine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	pseudoephedrine	dihydroergotamine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	pseudoephedrine	proamatine	false	effect
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	pseudoephedrine	proamatine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	ephedrine	phenylpropanolamine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	ephedrine	dihydroergotamine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	ephedrine	proamatine	false	effect
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	ephedrine	proamatine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylpropanolamine	dihydroergotamine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylpropanolamine	proamatine	false	effect
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	phenylpropanolamine	proamatine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	dihydroergotamine	proamatine	false	effect
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	dihydroergotamine	proamatine	false	false
the use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of proamatine   . therefore, caution should be used when proamatine    is administered concomitantly with agents that cause vasoconstriction.	proamatine	proamatine	false	false
proamatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation.	proamatine	fludrocortisone acetate	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	alpha-adrenergic blocking agents	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	prazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	terazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	doxazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	proamatine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	desglymidodrine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	metformin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	cimetidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	prazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	terazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	doxazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	proamatine	false	effect
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	desglymidodrine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	metformin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	cimetidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	alpha-adrenergic blocking agents	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	terazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	doxazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	proamatine	false	effect
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	desglymidodrine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	metformin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	cimetidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	prazosin	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	doxazosin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	proamatine	false	effect
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	desglymidodrine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	metformin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	cimetidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	terazosin	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	proamatine	false	effect
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	desglymidodrine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	metformin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	cimetidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	doxazosin	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	desglymidodrine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	metformin	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	cimetidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	proamatine	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	desglymidodrine	metformin	false	mechanism
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	desglymidodrine	cimetidine	false	mechanism
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	desglymidodrine	ranitidine	false	mechanism
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	desglymidodrine	procainamide	false	mechanism
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	desglymidodrine	triamterene	false	mechanism
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	desglymidodrine	flecainide	false	mechanism
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	desglymidodrine	quinidine	false	mechanism
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	metformin	cimetidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	metformin	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	metformin	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	metformin	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	metformin	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	metformin	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	cimetidine	ranitidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	cimetidine	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	cimetidine	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	cimetidine	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	cimetidine	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	ranitidine	procainamide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	ranitidine	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	ranitidine	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	ranitidine	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	procainamide	triamterene	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	procainamide	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	procainamide	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	triamterene	flecainide	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	triamterene	quinidine	false	false
proamatine. alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of proamatine. potential for drug interactions: it appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	flecainide	quinidine	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	mifepristone	ketoconazole	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	mifepristone	itraconazole	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	mifepristone	erythromycin	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	mifepristone	mifepristone	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	ketoconazole	itraconazole	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	ketoconazole	erythromycin	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	ketoconazole	mifepristone	false	mechanism
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	itraconazole	erythromycin	false	false
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	itraconazole	mifepristone	false	mechanism
although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by cyp 3a4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	erythromycin	mifepristone	false	mechanism
furthermore, rifampin, dexamethasone, st.	rifampin	dexamethasone	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	anticonvulsants	phenytoin	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	anticonvulsants	phenobarbital	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	anticonvulsants	carbamazepine	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	anticonvulsants	mifepristone	false	mechanism
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	anticonvulsants	mifepristone	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	phenytoin	phenobarbital	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	phenytoin	carbamazepine	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	phenytoin	mifepristone	false	mechanism
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	phenytoin	mifepristone	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	phenobarbital	carbamazepine	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	phenobarbital	mifepristone	false	mechanism
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	phenobarbital	mifepristone	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	carbamazepine	mifepristone	false	mechanism
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	carbamazepine	mifepristone	false	false
john   s wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	mifepristone	mifepristone	false	false
while co-administration of zavesca    appeared to increase the clearance of cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of cerezyme.	zavesca	cerezyme	false	mechanism
while co-administration of zavesca    appeared to increase the clearance of cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of cerezyme.	zavesca	cerezyme	false	false
while co-administration of zavesca    appeared to increase the clearance of cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of cerezyme.	cerezyme	cerezyme	false	false
combination therapy with cerezyme    (imiglucerase) and zavesca    is not indicated.	cerezyme	imiglucerase	false	false
combination therapy with cerezyme    (imiglucerase) and zavesca    is not indicated.	cerezyme	zavesca	false	advise
combination therapy with cerezyme    (imiglucerase) and zavesca    is not indicated.	imiglucerase	zavesca	false	advise
because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.	tetracyclines	anticoagulant	false	advise
because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.	tetracyclines	anticoagulant	false	false
because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.	anticoagulant	anticoagulant	false	false
since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.	penicillin	tetracycline class drugs	false	false
since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.	penicillin	penicillin	false	false
since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.	tetracycline class drugs	penicillin	false	advise
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	tetracyclines	antacids	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	tetracyclines	aluminum	false	mechanism
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	tetracyclines	calcium	false	mechanism
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	tetracyclines	magnesium	false	mechanism
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	tetracyclines	iron	false	mechanism
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	antacids	aluminum	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	antacids	calcium	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	antacids	magnesium	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	antacids	iron	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	aluminum	calcium	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	aluminum	magnesium	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	aluminum	iron	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	calcium	magnesium	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	calcium	iron	false	false
absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.	magnesium	iron	false	false
the concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.	tetracycline	methoxyflurane	false	effect
concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.	tetracyclines	contraceptives	false	effect
concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.	tetracyclines	contraceptives	false	false
concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.	contraceptives	contraceptives	false	false
interaction with guanethidine: although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.	guanethidine	minoxidil	false	false
interaction with guanethidine: although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.	guanethidine	guanethidine	false	false
interaction with guanethidine: although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.	minoxidil	guanethidine	false	effect
if at all possible guanethidine should be discontinued well before minoxidil is begun.	guanethidine	minoxidil	false	advise
drugs affecting hepatic metabolism the metabolism and pharmacokinetics of remeron soltab    (mirtazapine) orally disintegrating tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.	remeron soltab	mirtazapine	false	false
while in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes, the concomitant use of remeron soltab with most other drugs metabolized by these enzymes has not been formally studied.	mirtazapine	mirtazapine	false	false
while in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes, the concomitant use of remeron soltab with most other drugs metabolized by these enzymes has not been formally studied.	mirtazapine	remeron soltab	false	false
while in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes, the concomitant use of remeron soltab with most other drugs metabolized by these enzymes has not been formally studied.	mirtazapine	remeron soltab	false	false
alcohol: concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.	alcohol	alcohol	false	false
alcohol: concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.	alcohol	mirtazapine	false	false
alcohol: concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.	alcohol	mirtazapine	false	mechanism
however, the impairment of cognitive and motor skills produced by remeron    were shown to be additive with those produced by alcohol.	remeron	alcohol	false	effect
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	alcohol	remeron soltab	false	advise
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	alcohol	diazepam	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	alcohol	diazepam	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	alcohol	mirtazapine	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	remeron soltab	diazepam	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	remeron soltab	diazepam	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	remeron soltab	mirtazapine	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	diazepam	diazepam	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	diazepam	mirtazapine	false	false
accordingly, patients should be advised to avoid alcohol while taking remeron soltab. diazepam: concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	diazepam	mirtazapine	false	mechanism
however, the impairment of motor skills produced by remeron has been shown to be additive with those caused by diazepam.	remeron	diazepam	false	effect
accordingly, patients should be advised to avoid diazepam and other similar drugs while taking remeron soltab.	diazepam	remeron soltab	false	advise
mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.	mitotane	warfarin	false	mechanism
mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.	mitotane	warfarin	false	false
mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.	warfarin	warfarin	false	false
therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering mitotane to patients on coumarin-type anticoagulants.	anticoagulant	mitotane	false	false
therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering mitotane to patients on coumarin-type anticoagulants.	anticoagulant	coumarin-type anticoagulants	false	false
therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering mitotane to patients on coumarin-type anticoagulants.	mitotane	coumarin-type anticoagulants	false	advise
although mivacron (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between mivacron and succinylcholine has not been systematically studied.	mivacron	mivacron	false	false
although mivacron (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between mivacron and succinylcholine has not been systematically studied.	mivacron	succinylcholine	false	false
although mivacron (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between mivacron and succinylcholine has not been systematically studied.	mivacron	succinylcholine	false	false
prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents.	succinylcholine	nondepolarizing agents	false	effect
evidence of spontaneous recovery from succinylcholine should be observed before the administration of mivacron.	succinylcholine	mivacron	false	advise
the use of mivacron before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.	mivacron	succinylcholine	false	false
the use of mivacron before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.	mivacron	succinylcholine	false	false
the use of mivacron before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.	succinylcholine	succinylcholine	false	false
there are no clinical data on the use of mivacron with other nondepolarizing neuromuscular blocking agents.	mivacron	nondepolarizing neuromuscular blocking agents	false	false
isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 m.c.	isoflurane	enflurane	false	false
isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 m.c.	isoflurane	nitrous oxide	false	false
isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 m.c.	isoflurane	oxygen	false	false
isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 m.c.	enflurane	nitrous oxide	false	false
isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 m.c.	enflurane	oxygen	false	false
isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 m.c.	nitrous oxide	oxygen	false	false
a greater potentiation of the neuromuscular blocking effects of mivacron may be expected with higher concentrations of enflurane or isoflurane.	mivacron	enflurane	false	false
a greater potentiation of the neuromuscular blocking effects of mivacron may be expected with higher concentrations of enflurane or isoflurane.	mivacron	isoflurane	false	false
a greater potentiation of the neuromuscular blocking effects of mivacron may be expected with higher concentrations of enflurane or isoflurane.	enflurane	isoflurane	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	mivacron	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	antibiotics	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	aminoglycosides	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	tetracyclines	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	bacitracin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	polymyxins	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	lincomycin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	clindamycin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	colistin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	sodium colistimethate	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	magnesium	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	lithium	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	anesthetics	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	procainamide	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	nondepolarizing agents	quinidine	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	antibiotics	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	aminoglycosides	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	tetracyclines	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	bacitracin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	polymyxins	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	lincomycin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	clindamycin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	colistin	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	sodium colistimethate	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	magnesium	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	lithium	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	anesthetics	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	procainamide	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	mivacron	quinidine	false	int
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	aminoglycosides	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	tetracyclines	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	bacitracin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	polymyxins	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	lincomycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	clindamycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	colistin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	antibiotics	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	tetracyclines	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	bacitracin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	polymyxins	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	lincomycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	clindamycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	colistin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	aminoglycosides	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	bacitracin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	polymyxins	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	lincomycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	clindamycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	colistin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	tetracyclines	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	polymyxins	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	lincomycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	clindamycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	colistin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	bacitracin	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	lincomycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	clindamycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	colistin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	polymyxins	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	clindamycin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	colistin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lincomycin	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	clindamycin	colistin	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	clindamycin	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	clindamycin	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	clindamycin	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	clindamycin	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	clindamycin	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	clindamycin	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	colistin	sodium colistimethate	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	colistin	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	colistin	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	colistin	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	colistin	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	colistin	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	sodium colistimethate	magnesium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	sodium colistimethate	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	sodium colistimethate	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	sodium colistimethate	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	sodium colistimethate	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	magnesium	lithium	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	magnesium	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	magnesium	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	magnesium	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lithium	anesthetics	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lithium	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	lithium	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	anesthetics	procainamide	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	anesthetics	quinidine	false	false
other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	procainamide	quinidine	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	mivacron	contraceptives	false	effect
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	mivacron	glucocorticoids	false	effect
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	mivacron	monoamine oxidase inhibitors	false	effect
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	mivacron	neuromuscular blocking agents	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	mivacron	phenytoin	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	mivacron	carbamazepine	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	contraceptives	glucocorticoids	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	contraceptives	monoamine oxidase inhibitors	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	contraceptives	neuromuscular blocking agents	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	contraceptives	phenytoin	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	contraceptives	carbamazepine	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	glucocorticoids	monoamine oxidase inhibitors	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	glucocorticoids	neuromuscular blocking agents	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	glucocorticoids	phenytoin	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	glucocorticoids	carbamazepine	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	monoamine oxidase inhibitors	neuromuscular blocking agents	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	monoamine oxidase inhibitors	phenytoin	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	monoamine oxidase inhibitors	carbamazepine	false	false
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	neuromuscular blocking agents	phenytoin	false	effect
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	neuromuscular blocking agents	carbamazepine	false	effect
the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	phenytoin	carbamazepine	false	false
while the effects of chronic phenytoin or carbamazepine therapy on the action of mivacron are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	phenytoin	carbamazepine	false	false
while the effects of chronic phenytoin or carbamazepine therapy on the action of mivacron are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	phenytoin	mivacron	false	effect
while the effects of chronic phenytoin or carbamazepine therapy on the action of mivacron are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	carbamazepine	mivacron	false	effect
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	phenytoin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	carbamazepine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	antibiotics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	cisplatin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	edrophonium	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	neostigmine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	polymyxin b	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	corticosteroids	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	carbamazepine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	antibiotics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	cisplatin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	edrophonium	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	neostigmine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	polymyxin b	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	phenytoin	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	antibiotics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	cisplatin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	edrophonium	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	neostigmine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	polymyxin b	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	carbamazepine	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	cisplatin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	edrophonium	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	neostigmine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	polymyxin b	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	antibiotics	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	edrophonium	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	neostigmine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	polymyxin b	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	cisplatin	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	neostigmine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	polymyxin b	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	edrophonium	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	polymyxin b	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	neostigmine	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin b	bacitracin	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin b	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin b	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin b	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin b	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	polymyxin b	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	bacitracin	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	procaine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	procaine	anesthetics	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	procaine	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	procaine	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	succinylcholine	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	anesthetics	muscle relaxants	false	false
some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	succinylcholine	muscle relaxants	false	false
diuretics: excessive reductions in blood pressure may occur in patients on diuretic therapy when ace inhibitors are started.	diuretics	ace inhibitors	false	false
the possibility of hypotensive effects with univasc    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with univasc   . if this is not possible, the starting dose of moexpril should be reduced..	univasc	univasc	false	false
the possibility of hypotensive effects with univasc    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with univasc   . if this is not possible, the starting dose of moexpril should be reduced..	univasc	moexpril	false	false
the possibility of hypotensive effects with univasc    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with univasc   . if this is not possible, the starting dose of moexpril should be reduced..	univasc	moexpril	false	false
potassium supplements and potassium-sparing diuretics: univasc    can increase serum potassium because it decreases aldosterone secretion.	potassium	potassium-sparing diuretics	false	false
potassium supplements and potassium-sparing diuretics: univasc    can increase serum potassium because it decreases aldosterone secretion.	potassium	univasc	false	false
potassium supplements and potassium-sparing diuretics: univasc    can increase serum potassium because it decreases aldosterone secretion.	potassium-sparing diuretics	univasc	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	potassium-sparing diuretics	spironolactone	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	potassium-sparing diuretics	triamterene	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	potassium-sparing diuretics	amiloride	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	potassium-sparing diuretics	potassium	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	potassium-sparing diuretics	ace inhibitors	false	effect
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	spironolactone	triamterene	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	spironolactone	amiloride	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	spironolactone	potassium	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	spironolactone	ace inhibitors	false	effect
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	triamterene	amiloride	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	triamterene	potassium	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	triamterene	ace inhibitors	false	effect
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	amiloride	potassium	false	false
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	amiloride	ace inhibitors	false	effect
use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia.	potassium	ace inhibitors	false	effect
oral anticoagulants: interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.	anticoagulants	warfarin	false	false
oral anticoagulants: interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.	anticoagulants	anticoagulant	false	false
oral anticoagulants: interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.	warfarin	anticoagulant	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	lithium	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	lithium	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	ace inhibitors	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	lithium	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	lithium	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	ace inhibitors	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	lithium	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	ace inhibitors	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	lithium	lithium	false	false
lithium: increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium.	ace inhibitors	lithium	false	effect
if a diuretic is also used, the risk of lithium toxicity may be increased.	diuretic	lithium	false	effect
other agents: no clinically important pharmacokinetic interactions occurred when univasc    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.	univasc	hydrochlorothiazide	false	false
other agents: no clinically important pharmacokinetic interactions occurred when univasc    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.	univasc	digoxin	false	false
other agents: no clinically important pharmacokinetic interactions occurred when univasc    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.	univasc	cimetidine	false	false
other agents: no clinically important pharmacokinetic interactions occurred when univasc    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.	hydrochlorothiazide	digoxin	false	false
other agents: no clinically important pharmacokinetic interactions occurred when univasc    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.	hydrochlorothiazide	cimetidine	false	false
other agents: no clinically important pharmacokinetic interactions occurred when univasc    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.	digoxin	cimetidine	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	univasc	calcium-channel-blocking agents	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	univasc	diuretics	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	univasc	h2 blockers	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	univasc	digoxin	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	univasc	hypoglycemic agents	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	calcium-channel-blocking agents	diuretics	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	calcium-channel-blocking agents	h2 blockers	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	calcium-channel-blocking agents	digoxin	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	calcium-channel-blocking agents	hypoglycemic agents	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	diuretics	h2 blockers	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	diuretics	digoxin	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	diuretics	hypoglycemic agents	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	h2 blockers	digoxin	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	h2 blockers	hypoglycemic agents	false	false
univasc    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, h2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	digoxin	hypoglycemic agents	false	false
however, ketoconazole, a potent inhibitor of cytochrome p450 3a4, may increase plasma levels of mometasone furoate during concomitant dosing.	ketoconazole	mometasone furoate	false	mechanism
montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome p450 1a2 substrate).	montelukast	theophylline	false	false
- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes p450 2a6 and 2c9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the inr (international normalized ratio).	warfarin	warfarin	false	false
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome p450 3a4) or fexofenadine, its carboxylated metabolite, and did not prolong the qtc interval following co-administration with terfenadine 60 mg twice daily.	terfenadine	fexofenadine	false	false
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome p450 3a4) or fexofenadine, its carboxylated metabolite, and did not prolong the qtc interval following co-administration with terfenadine 60 mg twice daily.	terfenadine	terfenadine	false	false
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome p450 3a4) or fexofenadine, its carboxylated metabolite, and did not prolong the qtc interval following co-administration with terfenadine 60 mg twice daily.	fexofenadine	terfenadine	false	false
montelukast at doses of    100 mg daily dosed to pharmacokinetic steady state:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	montelukast	contraceptive	false	false
montelukast at doses of    100 mg daily dosed to pharmacokinetic steady state:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	montelukast	norethindrone	false	false
montelukast at doses of    100 mg daily dosed to pharmacokinetic steady state:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	montelukast	estradiol	false	false
montelukast at doses of    100 mg daily dosed to pharmacokinetic steady state:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	contraceptive	norethindrone	false	false
montelukast at doses of    100 mg daily dosed to pharmacokinetic steady state:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	contraceptive	estradiol	false	false
montelukast at doses of    100 mg daily dosed to pharmacokinetic steady state:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	norethindrone	estradiol	false	false
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.	prednisone	prednisolone	false	false
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.	prednisone	prednisone	false	false
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.	prednisone	prednisolone	false	false
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.	prednisolone	prednisone	false	false
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.	prednisolone	prednisolone	false	false
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.	prednisone	prednisolone	false	false
phenobarbital, which induces hepatic metabolism, decreased the auc of montelukast approximately 40% following a single 10-mg dose of montelukast.	phenobarbital	montelukast	false	false
phenobarbital, which induces hepatic metabolism, decreased the auc of montelukast approximately 40% following a single 10-mg dose of montelukast.	phenobarbital	montelukast	false	false
phenobarbital, which induces hepatic metabolism, decreased the auc of montelukast approximately 40% following a single 10-mg dose of montelukast.	montelukast	montelukast	false	false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	phenobarbital	rifampin	false	false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	phenobarbital	montelukast	false	advise
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	rifampin	montelukast	false	advise
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	theophylline	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	prednisone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	prednisolone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	contraceptives	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	norethindrone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	ethinyl estradiol	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	terfenadine	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	montelukast	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	prednisone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	prednisolone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	contraceptives	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	norethindrone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	ethinyl estradiol	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	terfenadine	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	theophylline	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisone	prednisolone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisone	contraceptives	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisone	norethindrone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisone	ethinyl estradiol	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisone	terfenadine	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisone	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisone	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisolone	contraceptives	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisolone	norethindrone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisolone	ethinyl estradiol	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisolone	terfenadine	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisolone	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	prednisolone	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	contraceptives	norethindrone	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	contraceptives	ethinyl estradiol	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	contraceptives	terfenadine	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	contraceptives	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	contraceptives	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	norethindrone	ethinyl estradiol	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	norethindrone	terfenadine	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	norethindrone	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	norethindrone	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	ethinyl estradiol	terfenadine	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	ethinyl estradiol	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	ethinyl estradiol	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	terfenadine	digoxin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	terfenadine	warfarin	false	false
in drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	digoxin	warfarin	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	thyroid hormones	sedative hypnotics	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	thyroid hormones	non-steroidal anti-inflammatory agents	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	thyroid hormones	benzodiazepines	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	thyroid hormones	decongestants	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	sedative hypnotics	non-steroidal anti-inflammatory agents	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	sedative hypnotics	benzodiazepines	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	sedative hypnotics	decongestants	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	non-steroidal anti-inflammatory agents	benzodiazepines	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	non-steroidal anti-inflammatory agents	decongestants	false	false
these medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	benzodiazepines	decongestants	false	false
phenobarbital, which induces hepatic metabolism, decreased the auc of montelukast approximately 40% following a single 10-mg dose of montelukast.	phenobarbital	montelukast	false	false
phenobarbital, which induces hepatic metabolism, decreased the auc of montelukast approximately 40% following a single 10-mg dose of montelukast.	phenobarbital	montelukast	false	false
phenobarbital, which induces hepatic metabolism, decreased the auc of montelukast approximately 40% following a single 10-mg dose of montelukast.	montelukast	montelukast	false	false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	phenobarbital	rifampin	false	false
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	phenobarbital	montelukast	false	advise
it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.	rifampin	montelukast	false	advise
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	central nervous system depressants	morphine	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	central nervous system depressants	cns depressants	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	central nervous system depressants	alcohol	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	central nervous system depressants	sedatives	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	central nervous system depressants	antihistaminics	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	central nervous system depressants	psychotropic drugs	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	morphine	cns depressants	false	effect
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	morphine	alcohol	false	effect
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	morphine	sedatives	false	effect
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	morphine	antihistaminics	false	effect
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	morphine	psychotropic drugs	false	effect
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	cns depressants	alcohol	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	cns depressants	sedatives	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	cns depressants	antihistaminics	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	cns depressants	psychotropic drugs	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	alcohol	sedatives	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	alcohol	antihistaminics	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	alcohol	psychotropic drugs	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	sedatives	antihistaminics	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	sedatives	psychotropic drugs	false	false
use with other central nervous system depressants: the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	antihistaminics	psychotropic drugs	false	false
use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.	neuroleptics	morphine	false	effect
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	mixed agonist/antagonist opioid analgesics	agonist/antagonist analgesics	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	mixed agonist/antagonist opioid analgesics	pentazocine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	mixed agonist/antagonist opioid analgesics	nalbuphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	mixed agonist/antagonist opioid analgesics	butorphanol	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	mixed agonist/antagonist opioid analgesics	buprenorphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	mixed agonist/antagonist opioid analgesics	opioid agonist analgesic	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	agonist/antagonist analgesics	pentazocine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	agonist/antagonist analgesics	nalbuphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	agonist/antagonist analgesics	butorphanol	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	agonist/antagonist analgesics	buprenorphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	agonist/antagonist analgesics	opioid agonist analgesic	false	advise
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	pentazocine	nalbuphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	pentazocine	butorphanol	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	pentazocine	buprenorphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	pentazocine	opioid agonist analgesic	false	advise
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	nalbuphine	butorphanol	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	nalbuphine	buprenorphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	nalbuphine	opioid agonist analgesic	false	advise
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	butorphanol	buprenorphine	false	false
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	butorphanol	opioid agonist analgesic	false	advise
interaction with mixed agonist/antagonist opioid analgesics: agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	buprenorphine	opioid agonist analgesic	false	advise
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	antacids	myfortic	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	antacids	magnesium	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	antacids	aluminum	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	antacids	antacids	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	antacids	myfortic	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	myfortic	magnesium	false	mechanism
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	myfortic	aluminum	false	mechanism
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	myfortic	antacids	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	myfortic	myfortic	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	magnesium	aluminum	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	magnesium	antacids	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	magnesium	myfortic	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	aluminum	antacids	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	aluminum	myfortic	false	false
antacids: absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 ml): the mean cmax and auc(0-t) values for mpa were 25% and 37% lower, respectively, than when myfortic was administered alone under fasting conditions.	antacids	myfortic	false	false
it is recommended that myfortic and antacids not be administered simultaneously.	myfortic	antacids	false	advise
cyclosporine: when studied in stable renal transplant patients, cyclosporine, usp (modified) pharmacokinetics were unaffected by steady state dosing of myfortic.	cyclosporine	cyclosporine	false	false
cyclosporine: when studied in stable renal transplant patients, cyclosporine, usp (modified) pharmacokinetics were unaffected by steady state dosing of myfortic.	cyclosporine	myfortic	false	false
cyclosporine: when studied in stable renal transplant patients, cyclosporine, usp (modified) pharmacokinetics were unaffected by steady state dosing of myfortic.	cyclosporine	myfortic	false	false
acyclovir/ganciclovir: may be taken with myfortic;	acyclovir	ganciclovir	false	false
acyclovir/ganciclovir: may be taken with myfortic;	acyclovir	myfortic	false	false
acyclovir/ganciclovir: may be taken with myfortic;	ganciclovir	myfortic	false	false
both acyclovir/ganciclovir and mpag concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	acyclovir	ganciclovir	false	false
both acyclovir/ganciclovir and mpag concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	acyclovir	mpag	false	false
both acyclovir/ganciclovir and mpag concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	ganciclovir	mpag	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	azathioprine	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	myfortic	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	azathioprine	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	azathioprine	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	myfortic	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	azathioprine	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	myfortic	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	azathioprine	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	myfortic	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	azathioprine	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	mycophenolate mofetil	mycophenolate mofetil	false	false
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	myfortic	azathioprine	false	advise
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	myfortic	mycophenolate mofetil	false	advise
azathioprine/mycophenolate mofetil: given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	azathioprine	mycophenolate mofetil	false	false
cholestyramine and drugs that bind bile acids: these drugs interrupt enterohepatic recirculation and reduce mpa exposure when coadministered with mycophenolate mofetil.	cholestyramine	mpa	false	false
cholestyramine and drugs that bind bile acids: these drugs interrupt enterohepatic recirculation and reduce mpa exposure when coadministered with mycophenolate mofetil.	cholestyramine	mycophenolate mofetil	false	false
cholestyramine and drugs that bind bile acids: these drugs interrupt enterohepatic recirculation and reduce mpa exposure when coadministered with mycophenolate mofetil.	mpa	mycophenolate mofetil	false	false
therefore, do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of myfortic.	myfortic	cholestyramine	false	advise
therefore, do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of myfortic.	myfortic	activated charcoal	false	advise
therefore, do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of myfortic.	myfortic	myfortic	false	false
therefore, do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of myfortic.	cholestyramine	activated charcoal	false	false
therefore, do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of myfortic.	cholestyramine	myfortic	false	false
therefore, do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of myfortic.	activated charcoal	myfortic	false	false
oral contraceptives: given the different metabolism of myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected.	contraceptives	myfortic	false	false
oral contraceptives: given the different metabolism of myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected.	contraceptives	contraceptives	false	false
oral contraceptives: given the different metabolism of myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected.	myfortic	contraceptives	false	false
however, in a drug-drug interaction study, mean levonorgesterol auc was decreased by 15% when coadministered with mycophenolate mofetil.	levonorgesterol	mycophenolate mofetil	false	mechanism
therefore, it is recommended that oral contraceptives are co- administered with myfortic with caution and additional birth control methods be considered.	contraceptives	myfortic	false	advise
live vaccines: during treatment with myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.	live vaccines	myfortic	false	false
live vaccines: during treatment with myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.	live vaccines	live attenuated vaccines	false	false
live vaccines: during treatment with myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.	myfortic	live attenuated vaccines	false	advise
interference of mpag hydrolysis may lead to less mpa available for absorption.	mpag	mpa	false	false
because ondansetron is metabolized by hepatic cytochrome p-450 drug-metabolizing enzymes (cyp3a4, cyp2d6, cyp1a2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron.	ondansetron	ondansetron	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	carbamazepine	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	rifampicin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	phenytoin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	carbamazepine	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	rifampicin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	ondansetron	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	ondansetron	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	rifampicin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	phenytoin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	carbamazepine	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	rifampicin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	ondansetron	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	ondansetron	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	rifampicin	phenytoin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	rifampicin	carbamazepine	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	rifampicin	rifampicin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	rifampicin	ondansetron	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	rifampicin	ondansetron	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	carbamazepine	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	rifampicin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	ondansetron	false	mechanism
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	phenytoin	ondansetron	false	mechanism
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	rifampicin	false	false
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	ondansetron	false	mechanism
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	carbamazepine	ondansetron	false	mechanism
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	rifampicin	ondansetron	false	mechanism
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	rifampicin	ondansetron	false	mechanism
phenytoin, carbamazepine, and rifampicin: in patients treated with potent inducers of cyp3a4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	ondansetron	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	tramadol	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	tramadol	false	effect
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	ondansetron	ondansetron	false	false
however, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  tramadol: although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  chemotherapy: tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron.	tramadol	ondansetron	false	false
in humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.	carmustine	etoposide	false	false
in humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.	carmustine	cisplatin	false	false
in humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.	carmustine	ondansetron	false	false
in humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.	etoposide	cisplatin	false	false
in humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.	etoposide	ondansetron	false	false
in humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.	cisplatin	ondansetron	false	false
ondansetron did not increase blood levels of high-dose methotrexate.	ondansetron	methotrexate	false	false
other beta adrenergic aerosol bronchodilators should not be used concomitantly with alupent    (metaproterenol sulfate usp) because they may have additive effects.	beta adrenergic aerosol bronchodilators	alupent	false	advise
other beta adrenergic aerosol bronchodilators should not be used concomitantly with alupent    (metaproterenol sulfate usp) because they may have additive effects.	beta adrenergic aerosol bronchodilators	metaproterenol sulfate	false	advise
other beta adrenergic aerosol bronchodilators should not be used concomitantly with alupent    (metaproterenol sulfate usp) because they may have additive effects.	alupent	metaproterenol sulfate	false	false
beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	beta adrenergic agonists	monoamine oxidase inhibitors	false	advise
beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	beta adrenergic agonists	tricyclic antidepressants	false	advise
beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	beta adrenergic agonists	beta adrenergic agonists	false	false
beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	monoamine oxidase inhibitors	tricyclic antidepressants	false	false
beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	monoamine oxidase inhibitors	beta adrenergic agonists	false	false
beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	tricyclic antidepressants	beta adrenergic agonists	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	xenical	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	alcohol	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	alcohol	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	xenical	alcohol	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	xenical	alcohol	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	xenical	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	xenical	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	alcohol	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	alcohol	orlistat	false	false
alcohol: in a multiple-dose study in 30 normal weight subjects, coadministration of xenical and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	orlistat	orlistat	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	xenical	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	xenical	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	xenical	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	xenical	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	xenical	xenical	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	xenical	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	xenical	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	xenical	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	cyclosporine	cyclosporine	false	false
cyclosporine: preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine.	xenical	cyclosporine	false	mechanism
digoxin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the pharmacokinetics of a single dose of digoxin.	digoxin	xenical	false	false
digoxin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the pharmacokinetics of a single dose of digoxin.	digoxin	xenical	false	false
digoxin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the pharmacokinetics of a single dose of digoxin.	digoxin	digoxin	false	false
digoxin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the pharmacokinetics of a single dose of digoxin.	xenical	xenical	false	false
digoxin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the pharmacokinetics of a single dose of digoxin.	xenical	digoxin	false	false
digoxin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the pharmacokinetics of a single dose of digoxin.	xenical	digoxin	false	false
fat-soluble vitamin supplements and analogues: a pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with xenical.	fat-soluble vitamin supplements	beta-carotene	false	false
fat-soluble vitamin supplements and analogues: a pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with xenical.	fat-soluble vitamin supplements	xenical	false	false
fat-soluble vitamin supplements and analogues: a pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with xenical.	beta-carotene	xenical	false	mechanism
xenical inhibited absorption of a vitamin e acetate supplement by approximately 60%.	xenical	vitamin e acetate	false	mechanism
the effect of orlistat on the absorption of supplemental vitamin d, vitamin a, and nutritionally-derived vitamin k is not known at this time.	orlistat	vitamin d	false	false
the effect of orlistat on the absorption of supplemental vitamin d, vitamin a, and nutritionally-derived vitamin k is not known at this time.	orlistat	vitamin a	false	false
the effect of orlistat on the absorption of supplemental vitamin d, vitamin a, and nutritionally-derived vitamin k is not known at this time.	orlistat	vitamin k	false	false
the effect of orlistat on the absorption of supplemental vitamin d, vitamin a, and nutritionally-derived vitamin k is not known at this time.	vitamin d	vitamin a	false	false
the effect of orlistat on the absorption of supplemental vitamin d, vitamin a, and nutritionally-derived vitamin k is not known at this time.	vitamin d	vitamin k	false	false
the effect of orlistat on the absorption of supplemental vitamin d, vitamin a, and nutritionally-derived vitamin k is not known at this time.	vitamin a	vitamin k	false	false
glyburide: in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	glyburide	orlistat	false	false
glyburide: in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	glyburide	orlistat	false	false
glyburide: in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	glyburide	glyburide	false	false
glyburide: in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	orlistat	orlistat	false	false
glyburide: in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	orlistat	glyburide	false	false
glyburide: in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	orlistat	glyburide	false	false
nifedipine (extended-release tablets): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the bioavailability of nifedipine (extended-release tablets).	nifedipine	xenical	false	false
nifedipine (extended-release tablets): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the bioavailability of nifedipine (extended-release tablets).	nifedipine	xenical	false	false
nifedipine (extended-release tablets): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the bioavailability of nifedipine (extended-release tablets).	nifedipine	nifedipine	false	false
nifedipine (extended-release tablets): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the bioavailability of nifedipine (extended-release tablets).	xenical	xenical	false	false
nifedipine (extended-release tablets): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the bioavailability of nifedipine (extended-release tablets).	xenical	nifedipine	false	false
nifedipine (extended-release tablets): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days, xenical did not alter the bioavailability of nifedipine (extended-release tablets).	xenical	nifedipine	false	false
oral contraceptives: in 20 normal-weight female subjects, the treatment of xenical 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.	contraceptives	xenical	false	false
oral contraceptives: in 20 normal-weight female subjects, the treatment of xenical 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.	contraceptives	contraceptives	false	false
oral contraceptives: in 20 normal-weight female subjects, the treatment of xenical 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.	xenical	contraceptives	false	false
phenytoin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days, xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	phenytoin	xenical	false	false
phenytoin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days, xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	phenytoin	xenical	false	false
phenytoin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days, xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	phenytoin	phenytoin	false	false
phenytoin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days, xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	xenical	xenical	false	false
phenytoin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days, xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	xenical	phenytoin	false	false
phenytoin: in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days, xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	xenical	phenytoin	false	false
pravastatin: in a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days, xenical did not affect the pharmacokinetics of pravastatin.	pravastatin	xenical	false	false
pravastatin: in a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days, xenical did not affect the pharmacokinetics of pravastatin.	pravastatin	xenical	false	false
pravastatin: in a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days, xenical did not affect the pharmacokinetics of pravastatin.	pravastatin	pravastatin	false	false
pravastatin: in a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days, xenical did not affect the pharmacokinetics of pravastatin.	xenical	xenical	false	false
pravastatin: in a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days, xenical did not affect the pharmacokinetics of pravastatin.	xenical	pravastatin	false	false
pravastatin: in a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days, xenical did not affect the pharmacokinetics of pravastatin.	xenical	pravastatin	false	false
warfarin: in 12 normal-weight subjects, administration of xenical 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both r- and s-enantiomers) or pharmacodynamics (prothrombin time and serum factor vii).	warfarin	xenical	false	false
warfarin: in 12 normal-weight subjects, administration of xenical 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both r- and s-enantiomers) or pharmacodynamics (prothrombin time and serum factor vii).	warfarin	warfarin	false	false
warfarin: in 12 normal-weight subjects, administration of xenical 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both r- and s-enantiomers) or pharmacodynamics (prothrombin time and serum factor vii).	xenical	warfarin	false	false
although undercarboxylated osteocalcin, a marker of vitamin k nutritional status, was unaltered with xenical administration, vitamin k levels tended to decline in subjects taking xenical.	xenical	xenical	false	false
therefore, as vitamin k absorption may be decreased with xenical, patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters.	vitamin k	xenical	false	mechanism
therefore, as vitamin k absorption may be decreased with xenical, patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters.	vitamin k	warfarin	false	false
therefore, as vitamin k absorption may be decreased with xenical, patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters.	vitamin k	xenical	false	false
therefore, as vitamin k absorption may be decreased with xenical, patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters.	xenical	warfarin	false	false
therefore, as vitamin k absorption may be decreased with xenical, patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters.	xenical	xenical	false	false
therefore, as vitamin k absorption may be decreased with xenical, patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters.	warfarin	xenical	false	advise
tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	tetracycline	antibiotic	false	false
tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	tetracycline	penicillin	false	effect
tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	antibiotic	penicillin	false	false
no pharmacokinetic interaction between 85 mg/m2 eloxatin and infusional 5-fu has been observed in patients treated every 2 weeks.	eloxatin	5-fu	false	false
increases of 5-fu plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 eloxatin dosed every 3 weeks.	5-fu	eloxatin	false	mechanism
anticoagulants anabolic steroids may increase sensitivity to oral anticoagulants.	anticoagulants	anabolic steroids	false	false
anticoagulants anabolic steroids may increase sensitivity to oral anticoagulants.	anticoagulants	anticoagulants	false	false
anticoagulants anabolic steroids may increase sensitivity to oral anticoagulants.	anabolic steroids	anticoagulants	false	effect
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	warfarin	oxandrolone	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	warfarin	warfarin	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	warfarin	s-warfarin	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	warfarin	r-warfarin	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	oxandrolone	warfarin	false	mechanism
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	oxandrolone	s-warfarin	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	oxandrolone	r-warfarin	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	warfarin	s-warfarin	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	warfarin	r-warfarin	false	false
warfarin: a multidose study of oxandrolone, given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml: similar increases in r-warfarin half-life and auc were also detected.	s-warfarin	r-warfarin	false	false
a 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target inr of 1.5.	warfarin	warfarin	false	false
when oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the inr or prothrombin time (pt) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target inr or pt has been achieved.	oxandrolone	warfarin	false	advise
when oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the inr or prothrombin time (pt) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target inr or pt has been achieved.	oxandrolone	warfarin	false	false
when oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the inr or prothrombin time (pt) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target inr or pt has been achieved.	warfarin	warfarin	false	false
furthermore, in patients receiving both drugs, careful monitoring of the inr or pt, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued.	warfarin	oxandrolone	false	advise
oral hypoglycemic agents oxandrolone may inhibit the metabolism of oral hypoglycemic agents.	hypoglycemic agents	oxandrolone	false	false
oral hypoglycemic agents oxandrolone may inhibit the metabolism of oral hypoglycemic agents.	hypoglycemic agents	hypoglycemic agents	false	false
oral hypoglycemic agents oxandrolone may inhibit the metabolism of oral hypoglycemic agents.	oxandrolone	hypoglycemic agents	false	mechanism
adrenal steroids or acth in patients with edema, concomitant administration with adrenal cortical steroids or acth may increase the edema.	adrenal steroids	acth	false	false
adrenal steroids or acth in patients with edema, concomitant administration with adrenal cortical steroids or acth may increase the edema.	adrenal steroids	adrenal cortical steroids	false	false
adrenal steroids or acth in patients with edema, concomitant administration with adrenal cortical steroids or acth may increase the edema.	adrenal steroids	acth	false	false
adrenal steroids or acth in patients with edema, concomitant administration with adrenal cortical steroids or acth may increase the edema.	acth	adrenal cortical steroids	false	false
adrenal steroids or acth in patients with edema, concomitant administration with adrenal cortical steroids or acth may increase the edema.	acth	acth	false	false
adrenal steroids or acth in patients with edema, concomitant administration with adrenal cortical steroids or acth may increase the edema.	adrenal cortical steroids	acth	false	false
the concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.	oxybutynin	anticholinergic drugs	false	effect
mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when ditropan xl was administered with ketoconazole, a potent cyp3a4 inhibitor.	oxybutynin chloride	ditropan xl	false	false
mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when ditropan xl was administered with ketoconazole, a potent cyp3a4 inhibitor.	oxybutynin chloride	ketoconazole	false	false
mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when ditropan xl was administered with ketoconazole, a potent cyp3a4 inhibitor.	ditropan xl	ketoconazole	false	mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	antimycotic agents	itraconazole	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	antimycotic agents	miconazole	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	antimycotic agents	macrolide antibiotics	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	antimycotic agents	erythromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	antimycotic agents	clarithromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	antimycotic agents	oxybutynin	false	mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	itraconazole	miconazole	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	itraconazole	macrolide antibiotics	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	itraconazole	erythromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	itraconazole	clarithromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	itraconazole	oxybutynin	false	mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	miconazole	macrolide antibiotics	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	miconazole	erythromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	miconazole	clarithromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	miconazole	oxybutynin	false	mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	macrolide antibiotics	erythromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	macrolide antibiotics	clarithromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	macrolide antibiotics	oxybutynin	false	mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	erythromycin	clarithromycin	false	false
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	erythromycin	oxybutynin	false	mechanism
other inhibitors of the cytochrome p450 3a4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., cmax and auc).	clarithromycin	oxybutynin	false	mechanism
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	antacid	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	aluminum hydroxide	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	magnesium hydroxide	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	simethicone	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	oxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	desethyloxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	aluminum hydroxide	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	magnesium hydroxide	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	simethicone	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	oxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	antacid	desethyloxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	aluminum hydroxide	magnesium hydroxide	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	aluminum hydroxide	simethicone	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	aluminum hydroxide	oxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	aluminum hydroxide	desethyloxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	magnesium hydroxide	simethicone	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	magnesium hydroxide	oxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	magnesium hydroxide	desethyloxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	simethicone	oxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	simethicone	desethyloxybutynin	false	false
concurrent ingestion of antacid (20 ml of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	oxybutynin	desethyloxybutynin	false	false
the cns depressant effects of oxycodone hydrochloride may be additive with that of other cns depressants..	oxycodone hydrochloride	cns depressants	false	effect
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	sedatives	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	hypnotics	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	tranquilizers	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	anesthetics	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	phenothiazines	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	opioids	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	tricyclic antidepressants	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	cns depressants	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	hypnotics	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	tranquilizers	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	anesthetics	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	phenothiazines	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	opioids	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	tricyclic antidepressants	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	sedatives	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	hypnotics	tranquilizers	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	hypnotics	anesthetics	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	hypnotics	phenothiazines	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	hypnotics	opioids	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	hypnotics	tricyclic antidepressants	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	hypnotics	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	hypnotics	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tranquilizers	anesthetics	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tranquilizers	phenothiazines	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tranquilizers	opioids	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tranquilizers	tricyclic antidepressants	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tranquilizers	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tranquilizers	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	anesthetics	phenothiazines	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	anesthetics	opioids	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	anesthetics	tricyclic antidepressants	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	anesthetics	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	anesthetics	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	phenothiazines	opioids	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	phenothiazines	tricyclic antidepressants	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	phenothiazines	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	phenothiazines	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	opioids	tricyclic antidepressants	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	opioids	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	opioids	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tricyclic antidepressants	monoamine oxidase (mao) inhibitors	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	tricyclic antidepressants	alcohol	false	false
the concomitant use of other cns depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (mao) inhibitors, and alcohol may produce additive cns depressant effects.	monoamine oxidase (mao) inhibitors	alcohol	false	false
anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.	anticholinergics	opioid analgesics	false	effect
it has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia.	oxymorphone	propofol	false	effect
in addition, cns toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics;	cimetidine	opioid analgesics	false	effect
potential for invega    to affect other drugs paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome p450 isozymes.	invega	paliperidone	false	false
given the primary cns effects of paliperidone, invega    should be used with caution in combination with other centrally acting drugs and alcohol.	paliperidone	invega	false	false
given the primary cns effects of paliperidone, invega    should be used with caution in combination with other centrally acting drugs and alcohol.	paliperidone	centrally acting drugs	false	advise
given the primary cns effects of paliperidone, invega    should be used with caution in combination with other centrally acting drugs and alcohol.	paliperidone	alcohol	false	advise
given the primary cns effects of paliperidone, invega    should be used with caution in combination with other centrally acting drugs and alcohol.	invega	centrally acting drugs	false	advise
given the primary cns effects of paliperidone, invega    should be used with caution in combination with other centrally acting drugs and alcohol.	invega	alcohol	false	advise
given the primary cns effects of paliperidone, invega    should be used with caution in combination with other centrally acting drugs and alcohol.	centrally acting drugs	alcohol	false	false
paliperidone may antagonize the effect of levodopa and other dopamine agonists.	paliperidone	levodopa	false	effect
paliperidone may antagonize the effect of levodopa and other dopamine agonists.	paliperidone	dopamine agonists	false	effect
paliperidone may antagonize the effect of levodopa and other dopamine agonists.	levodopa	dopamine agonists	false	false
potential for other drugs to affect invega    paliperidone is not a substrate of cyp1a2, cyp2a6, cyp2c9, and cyp2c19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.	invega	paliperidone	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	theophylline	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	cisapride	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	antipyrine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	caffeine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	carbamazepine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	diazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	desmethyldiazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	pantoprazole	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	cisapride	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	antipyrine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	caffeine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	carbamazepine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	diazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	desmethyldiazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	theophylline	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	antipyrine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	caffeine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	carbamazepine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	diazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	desmethyldiazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	cisapride	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	caffeine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	carbamazepine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	diazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	desmethyldiazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	antipyrine	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	carbamazepine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	diazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	desmethyldiazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	caffeine	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	diazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	desmethyldiazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	carbamazepine	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	desmethyldiazepam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diazepam	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	diclofenac	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	desmethyldiazepam	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	naproxen	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	diclofenac	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	piroxicam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	naproxen	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	digoxin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	piroxicam	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	ethanol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	digoxin	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	glyburide	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethanol	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	contraceptive	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	glyburide	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	levonorgestrel	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	contraceptive	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	ethinyl estradiol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	levonorgestrel	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	metoprolol	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	ethinyl estradiol	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metoprolol	nifedipine	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metoprolol	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metoprolol	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metoprolol	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metoprolol	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metoprolol	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metoprolol	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	nifedipine	phenytoin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	nifedipine	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	nifedipine	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	nifedipine	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	nifedipine	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	nifedipine	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	phenytoin	warfarin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	phenytoin	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	phenytoin	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	phenytoin	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	phenytoin	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	warfarin	midazolam	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	warfarin	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	warfarin	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	warfarin	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	midazolam	clarithromycin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	midazolam	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	midazolam	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	clarithromycin	metronidazole	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	clarithromycin	amoxicillin	false	false
based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	metronidazole	amoxicillin	false	false
therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary.	pantoprazole	pantoprazole	false	false
there have been postmarketing reports of increased inr and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.	proton pump inhibitors	pantoprazole	false	false
there have been postmarketing reports of increased inr and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.	proton pump inhibitors	warfarin	false	effect
there have been postmarketing reports of increased inr and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.	pantoprazole	warfarin	false	effect
patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in inr and prothrombin time.	proton pump inhibitors	warfarin	false	advise
because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).	pantoprazole	ketoconazole	false	mechanism
because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).	pantoprazole	ampicillin	false	mechanism
because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).	pantoprazole	iron	false	mechanism
because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).	ketoconazole	ampicillin	false	false
because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).	ketoconazole	iron	false	false
because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).	ampicillin	iron	false	false
laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol (thc) in patients receiving most proton pump inhibitors, including pantoprazole.	tetrahydrocannabinol	thc	false	false
laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol (thc) in patients receiving most proton pump inhibitors, including pantoprazole.	tetrahydrocannabinol	proton pump inhibitors	false	false
laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol (thc) in patients receiving most proton pump inhibitors, including pantoprazole.	tetrahydrocannabinol	pantoprazole	false	false
laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol (thc) in patients receiving most proton pump inhibitors, including pantoprazole.	thc	proton pump inhibitors	false	false
laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol (thc) in patients receiving most proton pump inhibitors, including pantoprazole.	thc	pantoprazole	false	false
laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol (thc) in patients receiving most proton pump inhibitors, including pantoprazole.	proton pump inhibitors	pantoprazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	paricalcitol	false	mechanism
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	paricalcitol	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	ketoconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	paricalcitol	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	ketoconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	atazanavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	clarithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	indinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	paricalcitol	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ketoconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	paricalcitol	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ketoconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	atazanavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	clarithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	indinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ketoconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	paricalcitol	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ketoconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	atazanavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	clarithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	indinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	paricalcitol	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	ketoconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	atazanavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	clarithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	indinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ketoconazole	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	atazanavir	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	clarithromycin	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	indinavir	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	itraconazole	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	nefazodone	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	nelfinavir	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	ritonavir	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	saquinavir	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	telithromycin	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	paricalcitol	voriconazole	false	advise
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	atazanavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	clarithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	indinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ketoconazole	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	clarithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	indinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	atazanavir	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	indinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	clarithromycin	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	indinavir	itraconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	indinavir	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	indinavir	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	indinavir	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	indinavir	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	indinavir	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	indinavir	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	itraconazole	nefazodone	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	itraconazole	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	itraconazole	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	itraconazole	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	itraconazole	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	itraconazole	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nefazodone	nelfinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nefazodone	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nefazodone	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nefazodone	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nefazodone	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nelfinavir	ritonavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nelfinavir	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nelfinavir	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	nelfinavir	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ritonavir	saquinavir	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ritonavir	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	ritonavir	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	saquinavir	telithromycin	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	saquinavir	voriconazole	false	false
a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-   . since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	telithromycin	voriconazole	false	false
dose adjustment of zemplar capsules may be required, and ipth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor such as ketoconazole.	zemplar	ketoconazole	false	advise
drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of zemplar capsules.	fat-soluble vitamins	cholestyramine	false	mechanism
drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of zemplar capsules.	fat-soluble vitamins	zemplar	false	false
drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of zemplar capsules.	cholestyramine	zemplar	false	mechanism
patients receiving lithium and neulasta should have more frequent monitoring of neutrophil counts.	lithium	neulasta	false	advise
in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving methadone, treatment with peg-intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone auc;	methadone	peg-intron	false	mechanism
in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving methadone, treatment with peg-intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone auc;	methadone	methadone	false	false
in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving methadone, treatment with peg-intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone auc;	peg-intron	methadone	false	false
acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with somavert.	insulin	hypoglycemic	false	false
acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with somavert.	insulin	somavert	false	advise
acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with somavert.	hypoglycemic	somavert	false	advise
in clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate igf-i suppression compared with patients not receiving opioids.	opioids	pegvisomant	false	mechanism
in clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate igf-i suppression compared with patients not receiving opioids.	opioids	opioids	false	false
in clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate igf-i suppression compared with patients not receiving opioids.	pegvisomant	opioids	false	false
concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of alimta.	probenecid	alimta	false	mechanism
although ibuprofen (400 mg qid) can be administered with alimta in patients with normal renal function (creatinine clearance    80 ml/min), caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min).	ibuprofen	alimta	false	false
although ibuprofen (400 mg qid) can be administered with alimta in patients with normal renal function (creatinine clearance    80 ml/min), caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min).	ibuprofen	ibuprofen	false	false
although ibuprofen (400 mg qid) can be administered with alimta in patients with normal renal function (creatinine clearance    80 ml/min), caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min).	ibuprofen	alimta	false	false
although ibuprofen (400 mg qid) can be administered with alimta in patients with normal renal function (creatinine clearance    80 ml/min), caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min).	alimta	ibuprofen	false	false
although ibuprofen (400 mg qid) can be administered with alimta in patients with normal renal function (creatinine clearance    80 ml/min), caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min).	alimta	alimta	false	false
although ibuprofen (400 mg qid) can be administered with alimta in patients with normal renal function (creatinine clearance    80 ml/min), caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min).	ibuprofen	alimta	false	advise
patients with mild to moderate renal insufficiency should avoid taking nsaids with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of alimta.	nsaids	alimta	false	advise
in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives, all patients taking these nsaids should interrupt dosing for at least 5 days before, the day of, and 2 days following alimta administration.	alimta	nsaids	false	false
in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives, all patients taking these nsaids should interrupt dosing for at least 5 days before, the day of, and 2 days following alimta administration.	alimta	nsaids	false	false
in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives, all patients taking these nsaids should interrupt dosing for at least 5 days before, the day of, and 2 days following alimta administration.	alimta	alimta	false	false
in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives, all patients taking these nsaids should interrupt dosing for at least 5 days before, the day of, and 2 days following alimta administration.	nsaids	nsaids	false	false
in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives, all patients taking these nsaids should interrupt dosing for at least 5 days before, the day of, and 2 days following alimta administration.	nsaids	alimta	false	false
in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives, all patients taking these nsaids should interrupt dosing for at least 5 days before, the day of, and 2 days following alimta administration.	nsaids	alimta	false	advise
the interaction of cylert (pemoline) with other drugs has not been studied in humans.	cylert	pemoline	false	false
decreased seizure threshold has been reported in patients receiving cylert concomitantly with antiepileptic medications.	cylert	antiepileptic medications	false	effect
concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	bacteriostatic antibiotics	erythromycin	false	false
concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	bacteriostatic antibiotics	tetracycline	false	false
concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	bacteriostatic antibiotics	penicillins	false	effect
concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	erythromycin	tetracycline	false	false
concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	erythromycin	penicillins	false	effect
concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	tetracycline	penicillins	false	effect
penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.	penicillin	probenecid	false	mechanism
penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.	penicillin	penicillins	false	false
penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.	probenecid	penicillins	false	false
displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum.	penicillin	penicillin	false	false
usage with alcohol: due to the potential for increased cns depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.	alcohol	alcohol	false	false
usage with alcohol: due to the potential for increased cns depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.	alcohol	pentazocine	false	false
usage with alcohol: due to the potential for increased cns depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.	alcohol	pentazocine	false	advise
although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with trental with and without anticoagulants or platelet aggregation inhibitors.	trental	anticoagulants	false	effect
although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with trental with and without anticoagulants or platelet aggregation inhibitors.	trental	platelet aggregation inhibitors	false	effect
although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with trental with and without anticoagulants or platelet aggregation inhibitors.	anticoagulants	platelet aggregation inhibitors	false	false
concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	trental	theophylline	false	mechanism
concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	trental	theophylline	false	false
concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	trental	theophylline	false	false
concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	theophylline	theophylline	false	false
concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	theophylline	theophylline	false	false
concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	theophylline	theophylline	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	trental	antihypertensive drugs	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	trental	beta blockers	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	trental	digitalis	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	trental	diuretics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	trental	antidiabetic agents	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	trental	antiarrhythmics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	antihypertensive drugs	beta blockers	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	antihypertensive drugs	digitalis	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	antihypertensive drugs	diuretics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	antihypertensive drugs	antidiabetic agents	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	antihypertensive drugs	antiarrhythmics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	beta blockers	digitalis	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	beta blockers	diuretics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	beta blockers	antidiabetic agents	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	beta blockers	antiarrhythmics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	digitalis	diuretics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	digitalis	antidiabetic agents	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	digitalis	antiarrhythmics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	diuretics	antidiabetic agents	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	diuretics	antiarrhythmics	false	false
trental has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	antidiabetic agents	antiarrhythmics	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	dopamine antagonists	neuroleptics	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	dopamine antagonists	phenothiazines	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	dopamine antagonists	butyrophenones	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	dopamine antagonists	thioxanthines	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	dopamine antagonists	metoclopramide	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	dopamine antagonists	permax	false	advise
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	dopamine antagonists	dopamine agonist	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	neuroleptics	phenothiazines	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	neuroleptics	butyrophenones	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	neuroleptics	thioxanthines	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	neuroleptics	metoclopramide	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	neuroleptics	permax	false	advise
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	neuroleptics	dopamine agonist	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	phenothiazines	butyrophenones	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	phenothiazines	thioxanthines	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	phenothiazines	metoclopramide	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	phenothiazines	permax	false	advise
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	phenothiazines	dopamine agonist	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	butyrophenones	thioxanthines	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	butyrophenones	metoclopramide	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	butyrophenones	permax	false	advise
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	butyrophenones	dopamine agonist	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	thioxanthines	metoclopramide	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	thioxanthines	permax	false	advise
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	thioxanthines	dopamine agonist	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	metoclopramide	permax	false	advise
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	metoclopramide	dopamine agonist	false	false
dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with permax (a dopamine agonist);	permax	dopamine agonist	false	false
because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.	pergolide mesylate	pergolide mesylate	false	false
diuretics: patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of aceon    tablets therapy.	diuretics	diuretics	false	false
diuretics: patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of aceon    tablets therapy.	diuretics	aceon	false	false
diuretics: patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of aceon    tablets therapy.	diuretics	aceon	false	effect
the possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.	diuretic	perindopril	false	effect
if diuretics cannot be interrupted, close medical supervision should be provided with the first dose of aceon    tablets, for at least two hours and until blood pressure has stabilized for another hour.	diuretics	aceon	false	advise
the rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics.	perindopril	diuretics	false	false
the bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ace inhibition.	perindoprilat	diuretics	false	false
potassium supplements and potassium-sparing diuretics: aceon    tablets may increase serum potassium because of its potential to decrease aldosterone production.	potassium	potassium-sparing diuretics	false	false
potassium supplements and potassium-sparing diuretics: aceon    tablets may increase serum potassium because of its potential to decrease aldosterone production.	potassium	aceon	false	false
potassium supplements and potassium-sparing diuretics: aceon    tablets may increase serum potassium because of its potential to decrease aldosterone production.	potassium-sparing diuretics	aceon	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium-sparing diuretics	spironolactone	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium-sparing diuretics	amiloride	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium-sparing diuretics	triamterene	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium-sparing diuretics	potassium	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium-sparing diuretics	indomethacin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium-sparing diuretics	heparin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium-sparing diuretics	cyclosporine	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	spironolactone	amiloride	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	spironolactone	triamterene	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	spironolactone	potassium	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	spironolactone	indomethacin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	spironolactone	heparin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	spironolactone	cyclosporine	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	amiloride	triamterene	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	amiloride	potassium	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	amiloride	indomethacin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	amiloride	heparin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	amiloride	cyclosporine	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	triamterene	potassium	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	triamterene	indomethacin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	triamterene	heparin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	triamterene	cyclosporine	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium	indomethacin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium	heparin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	potassium	cyclosporine	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	indomethacin	heparin	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	indomethacin	cyclosporine	false	false
use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	heparin	cyclosporine	false	false
lithium: increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy.	lithium	lithium	false	false
lithium: increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy.	lithium	lithium	false	false
lithium: increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy.	lithium	lithium	false	false
lithium: increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy.	lithium	lithium	false	false
lithium: increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy.	lithium	lithium	false	false
lithium: increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy.	lithium	lithium	false	false
use of a diuretic may further increase the risk of lithium toxicity.	diuretic	lithium	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	digoxin	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	aceon	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	digoxin	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	perindopril	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	perindoprilat	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	aceon	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	digoxin	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	perindopril	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	perindoprilat	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	aceon	digoxin	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	aceon	perindopril	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	aceon	perindoprilat	false	false
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	perindopril	false	mechanism
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	digoxin	perindoprilat	false	mechanism
digoxin: a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon    tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	perindopril	perindoprilat	false	false
gentamicin: animal data have suggested the possibility of interaction between perindopril and gentamicin.	gentamicin	perindopril	false	false
gentamicin: animal data have suggested the possibility of interaction between perindopril and gentamicin.	gentamicin	gentamicin	false	false
gentamicin: animal data have suggested the possibility of interaction between perindopril and gentamicin.	perindopril	gentamicin	false	int
food interaction: oral administration of aceon    tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state.	aceon	perindopril	false	false
however, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ace inhibition curve of approximately 20%, probably clinically insignificant.	perindopril	perindoprilat	false	false
concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.	alcohol	phentermine hydrochloride	false	int
vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	vasopressors	metaraminol	false	false
vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	vasopressors	halothane	false	effect
vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	metaraminol	halothane	false	effect
mao inhibitors: the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	mao inhibitors	sympathomimetic pressor amines	false	false
mao inhibitors: the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	mao inhibitors	monoamine oxidase inhibitors	false	false
mao inhibitors: the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	mao inhibitors	maoi	false	false
mao inhibitors: the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	sympathomimetic pressor amines	monoamine oxidase inhibitors	false	effect
mao inhibitors: the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	sympathomimetic pressor amines	maoi	false	effect
mao inhibitors: the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	monoamine oxidase inhibitors	maoi	false	false
the pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.	adrenergic agents	tricyclic antidepressants	false	effect
vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	vasopressors	metaraminol	false	false
vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	vasopressors	halothane	false	effect
vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	metaraminol	halothane	false	effect
mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	mao inhibitors	sympathomimetic pressor amines	false	false
mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	mao inhibitors	monoamine oxidase inhibitors	false	false
mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	mao inhibitors	maoi	false	false
mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	sympathomimetic pressor amines	monoamine oxidase inhibitors	false	effect
mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	sympathomimetic pressor amines	maoi	false	effect
mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (maoi).	monoamine oxidase inhibitors	maoi	false	false
the pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.	adrenergic agents	tricyclic antidepressants	false	effect
pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.	pilocarpine	beta adrenergic antagonists	false	advise
these effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium).	atropine	ipratropium	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	calcium	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	conjugated estrogens	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	hydroxychloroquine sulfate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	ibuprofen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	levothyroxine sodium	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	medroxyprogesterone acetate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	methotrexate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	acetylsalicylic acid	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	conjugated estrogens	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	hydroxychloroquine sulfate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	ibuprofen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	levothyroxine sodium	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	medroxyprogesterone acetate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	methotrexate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	calcium	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	hydroxychloroquine sulfate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	ibuprofen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	levothyroxine sodium	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	medroxyprogesterone acetate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	methotrexate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	conjugated estrogens	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	ibuprofen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	levothyroxine sodium	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	medroxyprogesterone acetate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	methotrexate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	hydroxychloroquine sulfate	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	levothyroxine sodium	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	medroxyprogesterone acetate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	methotrexate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	ibuprofen	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	medroxyprogesterone acetate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	methotrexate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	levothyroxine sodium	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	methotrexate	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	medroxyprogesterone acetate	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	multivitamins	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	methotrexate	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	naproxen	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	multivitamins	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	naproxen	omeprazole	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	naproxen	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	naproxen	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	omeprazole	paracetamol	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	omeprazole	prednisone	false	false
while no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	paracetamol	prednisone	false	false
catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.	reserpine	beta-blocking agents	false	effect
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	pindolol	antihypertensive agents	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	pindolol	hydrochlorothiazide	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	pindolol	hydralazine	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	pindolol	guanethidine	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	antihypertensive agents	hydrochlorothiazide	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	antihypertensive agents	hydralazine	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	antihypertensive agents	guanethidine	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	hydrochlorothiazide	hydralazine	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	hydrochlorothiazide	guanethidine	false	false
pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	hydralazine	guanethidine	false	false
pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered.	pindolol	thioridazine	false	mechanism
other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with maxair autohaler because they may have additive effects.	short-acting beta adrenergic aerosol bronchodilators	maxair autohaler	false	advise
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	coumarin-type anticoagulants	coumarin-type anticoagulants	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	coumarin-type anticoagulants	feldene	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	coumarin-type anticoagulants	feldene	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	coumarin-type anticoagulants	coumarin-type anticoagulants	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	coumarin-type anticoagulants	feldene	false	int
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	coumarin-type anticoagulants	feldene	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	coumarin-type anticoagulants	coumarin-type anticoagulants	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	feldene	feldene	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	feldene	coumarin-type anticoagulants	false	false
although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with feldene since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	feldene	coumarin-type anticoagulants	false	advise
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	feldene	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	aspirin	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	antacids	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	piroxicam	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	nonsteroidal anti-inflammatory agents	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	feldene	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	lithium	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	feldene	aspirin	false	mechanism
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	feldene	antacids	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	feldene	piroxicam	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	feldene	nonsteroidal anti-inflammatory agents	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	feldene	feldene	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	feldene	lithium	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	aspirin	antacids	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	aspirin	piroxicam	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	aspirin	nonsteroidal anti-inflammatory agents	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	aspirin	feldene	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	aspirin	lithium	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	antacids	piroxicam	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	antacids	nonsteroidal anti-inflammatory agents	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	antacids	feldene	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	antacids	lithium	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	nonsteroidal anti-inflammatory agents	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	feldene	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	piroxicam	lithium	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	nonsteroidal anti-inflammatory agents	feldene	false	false
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	nonsteroidal anti-inflammatory agents	lithium	false	mechanism
plasma levels of piroxicam are depressed to approximately 80% of their normal values when feldene is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . nonsteroidal anti-inflammatory agents, including feldene, have been reported to increase steady state plasma lithium levels.	feldene	lithium	false	mechanism
it is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing feldene.	lithium	feldene	false	advise
when atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.	atropine	pralidoxime	false	effect
when atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.	atropine	atropine	false	false
when atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.	pralidoxime	atropine	false	false
this is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed.	atropine	pralidoxime	false	false
2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;	pralidoxime	barbiturates	false	false
2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;	pralidoxime	anticholinesterases	false	false
2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;	barbiturates	anticholinesterases	false	effect
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	theophylline	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	aminophylline	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	succinylcholine	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	reserpine	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	morphine	phenothiazine-type tranquilizers	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	aminophylline	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	succinylcholine	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	reserpine	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	theophylline	phenothiazine-type tranquilizers	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	aminophylline	succinylcholine	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	aminophylline	reserpine	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	aminophylline	phenothiazine-type tranquilizers	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	succinylcholine	reserpine	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	succinylcholine	phenothiazine-type tranquilizers	false	false
morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	reserpine	phenothiazine-type tranquilizers	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	carbidopa	levodopa	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	carbidopa	carbidopa	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	carbidopa	levodopa	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	carbidopa	pramipexole	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	levodopa	carbidopa	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	levodopa	levodopa	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	levodopa	pramipexole	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	carbidopa	levodopa	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	carbidopa	pramipexole	false	false
carbidopa/levodopa: carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (n= 10).	levodopa	pramipexole	false	false
selegiline: in healthy volunteers (n= 11), selegiline did not influence the pharmacokinetics of pramipexole.	selegiline	selegiline	false	false
selegiline: in healthy volunteers (n= 11), selegiline did not influence the pharmacokinetics of pramipexole.	selegiline	pramipexole	false	false
selegiline: in healthy volunteers (n= 11), selegiline did not influence the pharmacokinetics of pramipexole.	selegiline	pramipexole	false	false
amantadine: population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (n= 54).	amantadine	amantadine	false	false
amantadine: population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (n= 54).	amantadine	pramipexole	false	false
amantadine: population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (n= 54).	amantadine	pramipexole	false	false
cimetidine: cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole auc and a 40% increase in half-life (n= 12).	cimetidine	cimetidine	false	false
cimetidine: cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole auc and a 40% increase in half-life (n= 12).	cimetidine	pramipexole	false	false
cimetidine: cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole auc and a 40% increase in half-life (n= 12).	cimetidine	pramipexole	false	mechanism
probenecid: probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (n= 12).	probenecid	probenecid	false	false
probenecid: probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (n= 12).	probenecid	pramipexole	false	false
probenecid: probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (n= 12).	probenecid	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	ranitidine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	diltiazem	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	triamterene	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	verapamil	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	quinidine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	quinine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cimetidine	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	diltiazem	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	triamterene	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	verapamil	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	quinidine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	quinine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	ranitidine	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	triamterene	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	verapamil	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	quinidine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	quinine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	diltiazem	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	verapamil	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	quinidine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	quinine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	triamterene	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	quinidine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	quinine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	verapamil	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	quinine	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinidine	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinine	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinine	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinine	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinine	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinine	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinine	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	quinine	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	pramipexole	cephalosporins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	pramipexole	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	pramipexole	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	pramipexole	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	pramipexole	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	pramipexole	pramipexole	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cephalosporins	penicillins	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cephalosporins	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cephalosporins	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cephalosporins	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	cephalosporins	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	penicillins	indomethacin	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	penicillins	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	penicillins	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	penicillins	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	indomethacin	hydrochlorothiazide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	indomethacin	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	indomethacin	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	hydrochlorothiazide	chlorpropamide	false	false
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	hydrochlorothiazide	pramipexole	false	mechanism
other drugs eliminated via renal secretion: population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	chlorpropamide	pramipexole	false	mechanism
cyp interactions: inhibitors of cytochrome p450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro.	pramipexole	pramipexole	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	pramipexole	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	dopamine agonist	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	dopamine antagonists	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	neuroleptics	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	phenothiazines	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	butyrophenones	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	thioxanthenes	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	mirapex	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	dopamine agonist	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	dopamine antagonists	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	neuroleptics	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	phenothiazines	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	butyrophenones	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	thioxanthenes	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	pramipexole	mirapex	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine agonist	dopamine antagonists	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine agonist	neuroleptics	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine agonist	phenothiazines	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine agonist	butyrophenones	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine agonist	thioxanthenes	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine agonist	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine agonist	mirapex	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	neuroleptics	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	phenothiazines	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	butyrophenones	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	thioxanthenes	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	dopamine antagonists	mirapex	false	effect
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	neuroleptics	phenothiazines	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	neuroleptics	butyrophenones	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	neuroleptics	thioxanthenes	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	neuroleptics	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	neuroleptics	mirapex	false	effect
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	phenothiazines	butyrophenones	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	phenothiazines	thioxanthenes	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	phenothiazines	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	phenothiazines	mirapex	false	effect
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	butyrophenones	thioxanthenes	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	butyrophenones	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	butyrophenones	mirapex	false	effect
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	thioxanthenes	metoclopramide	false	false
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	thioxanthenes	mirapex	false	effect
dopamine antagonists: since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of mirapex.	metoclopramide	mirapex	false	effect
due to its effects on gastric emptying, symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	symlin	anticholinergic agents	false	advise
due to its effects on gastric emptying, symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	symlin	atropine	false	advise
due to its effects on gastric emptying, symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	symlin	alpha glucosidase inhibitors	false	advise
due to its effects on gastric emptying, symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	anticholinergic agents	atropine	false	false
due to its effects on gastric emptying, symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	anticholinergic agents	alpha glucosidase inhibitors	false	false
due to its effects on gastric emptying, symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	atropine	alpha glucosidase inhibitors	false	false
when the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after symlin injection.	analgesics	symlin	false	advise
in clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of symlin.	sulfonylureas	biguanides	false	false
in clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of symlin.	sulfonylureas	symlin	false	false
in clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of symlin.	biguanides	symlin	false	false
no formal interaction studies have been performed to assess the effect of symlin on the kinetics of oral antidiabetic agents.	symlin	antidiabetic agents	false	false
mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular, nph, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	symlin	insulin	false	false
mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular, nph, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	symlin	symlin	false	false
mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular, nph, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	symlin	human insulin	false	false
mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular, nph, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	insulin	symlin	false	false
mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular, nph, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	insulin	human insulin	false	false
mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular, nph, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	symlin	human insulin	false	mechanism
thus, symlin and insulin should not be mixed and must be administered separately.	symlin	insulin	false	false
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	phenobarbital	phenytoin	false	false
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	phenobarbital	rifampin	false	false
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	phenobarbital	corticosteroids	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	phenobarbital	corticosteroid	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	phenytoin	rifampin	false	false
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	phenytoin	corticosteroids	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	phenytoin	corticosteroid	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	rifampin	corticosteroids	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	rifampin	corticosteroid	false	mechanism
drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	corticosteroids	corticosteroid	false	false
drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.	troleandomycin	ketoconazole	false	false
drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.	troleandomycin	corticosteroids	false	mechanism
drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.	ketoconazole	corticosteroids	false	mechanism
corticosteroids may increase the clearance of chronic high dose aspirin.	corticosteroids	aspirin	false	mechanism
this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.	salicylate	salicylate	false	false
this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.	salicylate	corticosteroid	false	false
this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.	salicylate	corticosteroid	false	effect
aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.	aspirin	corticosteroids	false	advise
the effect of corticosteroids on oral anticoagulants is variable.	corticosteroids	anticoagulants	false	effect
there are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.	anticoagulants	corticosteroids	false	effect
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	anticholinesterases	procaine hydrochloride	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	anticholinesterases	anticholinesterase agents	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	anticholinesterases	anticholinesterases	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	anticholinesterases	procaine hydrochloride	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	procaine hydrochloride	anticholinesterase agents	false	effect
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	procaine hydrochloride	anticholinesterases	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	procaine hydrochloride	procaine hydrochloride	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	anticholinesterase agents	anticholinesterases	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	anticholinesterase agents	procaine hydrochloride	false	false
anticholinesterases: concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	anticholinesterases	procaine hydrochloride	false	mechanism
cns depressant medications: concurrent use of procaine hydrochloride and cns depressant medications may result in additive depressant effects.	cns depressant	procaine hydrochloride	false	false
cns depressant medications: concurrent use of procaine hydrochloride and cns depressant medications may result in additive depressant effects.	cns depressant	cns depressant medications	false	false
cns depressant medications: concurrent use of procaine hydrochloride and cns depressant medications may result in additive depressant effects.	procaine hydrochloride	cns depressant medications	false	effect
hyaluronidase: hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.	hyaluronidase	hyaluronidase	false	false
hyaluronidase: hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.	hyaluronidase	procaine hydrochloride	false	false
hyaluronidase: hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.	hyaluronidase	procaine hydrochloride	false	mechanism
neuromuscular blocking agents (such as suxamethonium chloride): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	neuromuscular blocking agents	suxamethonium chloride	false	false
neuromuscular blocking agents (such as suxamethonium chloride): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	neuromuscular blocking agents	procaine hydrochloride	false	false
neuromuscular blocking agents (such as suxamethonium chloride): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	neuromuscular blocking agents	neuromuscular blocking agents	false	false
neuromuscular blocking agents (such as suxamethonium chloride): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	suxamethonium chloride	procaine hydrochloride	false	false
neuromuscular blocking agents (such as suxamethonium chloride): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	suxamethonium chloride	neuromuscular blocking agents	false	false
neuromuscular blocking agents (such as suxamethonium chloride): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	procaine hydrochloride	neuromuscular blocking agents	false	effect
sulfonamides: concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	sulfonamides	procaine hydrochloride	false	false
sulfonamides: concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	sulfonamides	sulfonamides	false	false
sulfonamides: concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	sulfonamides	sulfonamide	false	false
sulfonamides: concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	procaine hydrochloride	sulfonamides	false	effect
sulfonamides: concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	procaine hydrochloride	sulfonamide	false	false
sulfonamides: concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	sulfonamides	sulfonamide	false	false
acetazolamide: concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	acetazolamide	acetazolamide	false	false
acetazolamide: concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	acetazolamide	procaine hydrochloride	false	false
acetazolamide: concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	acetazolamide	procaine	false	false
acetazolamide: concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	acetazolamide	procaine hydrochloride	false	mechanism
acetazolamide: concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	acetazolamide	procaine	false	false
acetazolamide: concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.	procaine hydrochloride	procaine	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	barbiturates	antihistamines	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	barbiturates	narcotics	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	barbiturates	hypotensive agents	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	barbiturates	phenothiazines	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	antihistamines	narcotics	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	antihistamines	hypotensive agents	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	antihistamines	phenothiazines	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	narcotics	hypotensive agents	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	narcotics	phenothiazines	false	false
to minimize cns depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.	hypotensive agents	phenothiazines	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	matulane	sympathomimetic drugs	false	advise
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	matulane	tricyclic antidepressant	false	advise
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	matulane	amitriptyline hcl	false	advise
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	matulane	imipramine hcl	false	advise
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	matulane	tyramine	false	advise
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	sympathomimetic drugs	tricyclic antidepressant	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	sympathomimetic drugs	amitriptyline hcl	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	sympathomimetic drugs	imipramine hcl	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	sympathomimetic drugs	tyramine	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	tricyclic antidepressant	amitriptyline hcl	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	tricyclic antidepressant	imipramine hcl	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	tricyclic antidepressant	tyramine	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	amitriptyline hcl	imipramine hcl	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	amitriptyline hcl	tyramine	false	false
because matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline hcl, imipramine hcl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	imipramine hcl	tyramine	false	false
no cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.	chemotherapeutic agents	steroids	false	false
thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.	thiazide diuretics	phenothiazines	false	effect
antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.	guanethidine	phenothiazines	false	effect
concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.	propranolol	phenothiazines	false	mechanism
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	diprivan	narcotics	false	effect
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	diprivan	morphine	false	effect
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	diprivan	meperidine	false	effect
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	diprivan	fentanyl	false	effect
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	narcotics	morphine	false	false
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	narcotics	meperidine	false	false
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	narcotics	fentanyl	false	false
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	morphine	meperidine	false	false
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	morphine	fentanyl	false	false
the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)	meperidine	fentanyl	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	opioids	sedatives	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	opioids	benzodiazepines	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	opioids	barbiturates	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	opioids	chloral hydrate	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	opioids	droperidol	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	sedatives	benzodiazepines	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	sedatives	barbiturates	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	sedatives	chloral hydrate	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	sedatives	droperidol	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	benzodiazepines	barbiturates	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	benzodiazepines	chloral hydrate	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	benzodiazepines	droperidol	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	barbiturates	chloral hydrate	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	barbiturates	droperidol	false	false
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	chloral hydrate	droperidol	false	false
during maintenance of anesthesia or sedation, the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).	diprivan	analgesic agents	false	advise
during maintenance of anesthesia or sedation, the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).	diprivan	nitrous oxide	false	advise
during maintenance of anesthesia or sedation, the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).	diprivan	opioids	false	advise
during maintenance of anesthesia or sedation, the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).	analgesic agents	nitrous oxide	false	false
during maintenance of anesthesia or sedation, the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).	analgesic agents	opioids	false	false
during maintenance of anesthesia or sedation, the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).	nitrous oxide	opioids	false	false
the concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with diprivan injectable emulsion has not been extensively evaluated.	isoflurane	enflurane	false	false
the concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with diprivan injectable emulsion has not been extensively evaluated.	isoflurane	halothane	false	false
the concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with diprivan injectable emulsion has not been extensively evaluated.	isoflurane	diprivan	false	false
the concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with diprivan injectable emulsion has not been extensively evaluated.	enflurane	halothane	false	false
the concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with diprivan injectable emulsion has not been extensively evaluated.	enflurane	diprivan	false	false
the concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with diprivan injectable emulsion has not been extensively evaluated.	halothane	diprivan	false	false
diprivan injectable emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).	diprivan	neuromuscular blocking agents	false	false
diprivan injectable emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).	diprivan	succinylcholine	false	false
diprivan injectable emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).	diprivan	nondepolarizing muscle relaxants	false	false
diprivan injectable emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).	neuromuscular blocking agents	succinylcholine	false	false
diprivan injectable emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).	neuromuscular blocking agents	nondepolarizing muscle relaxants	false	false
diprivan injectable emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).	succinylcholine	nondepolarizing muscle relaxants	false	false
no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.	muscle relaxants	analgesic agents	false	false
no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.	muscle relaxants	anesthetic agents	false	false
no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.	analgesic agents	anesthetic agents	false	false
the cns-depressant effect of propoxyphene is additive with that of other cns depressants, including alcohol.	propoxyphene	cns depressants	false	effect
the cns-depressant effect of propoxyphene is additive with that of other cns depressants, including alcohol.	propoxyphene	alcohol	false	effect
the cns-depressant effect of propoxyphene is additive with that of other cns depressants, including alcohol.	cns depressants	alcohol	false	false
such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.	propoxyphene	antidepressants	false	false
such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.	propoxyphene	anticonvulsants	false	false
such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.	propoxyphene	warfarin	false	false
such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.	antidepressants	anticonvulsants	false	false
such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.	antidepressants	warfarin	false	false
such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.	anticonvulsants	warfarin	false	false
mao inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.	mao inhibitors	beta adrenergic blockers	false	false
mao inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.	mao inhibitors	pseudoephedrine	false	effect
mao inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.	beta adrenergic blockers	pseudoephedrine	false	effect
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	sympathomimetics	methyldopa	false	effect
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	sympathomimetics	mecamylamine	false	effect
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	sympathomimetics	reserpine	false	effect
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	sympathomimetics	veratrum alkaloids	false	effect
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	methyldopa	mecamylamine	false	false
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	methyldopa	reserpine	false	false
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	methyldopa	veratrum alkaloids	false	false
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	mecamylamine	reserpine	false	false
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	mecamylamine	veratrum alkaloids	false	false
sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.	reserpine	veratrum alkaloids	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	pyrimethamine	sulfonamides	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	pyrimethamine	quinine	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	pyrimethamine	antimalarials	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	pyrimethamine	antibiotics	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	sulfonamides	quinine	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	sulfonamides	antimalarials	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	sulfonamides	antibiotics	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	quinine	antimalarials	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	quinine	antibiotics	false	false
pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.	antimalarials	antibiotics	false	false
folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.	folinic acid	leucovorin	false	false
mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.	lorazepam	pyrimethamine	false	effect
cholestyramine: cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista.	cholestyramine	cholestyramine	false	false
cholestyramine: cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista.	cholestyramine	raloxifene	false	false
cholestyramine: cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista.	cholestyramine	evista	false	false
cholestyramine: cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista.	cholestyramine	raloxifene	false	mechanism
cholestyramine: cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista.	cholestyramine	evista	false	advise
cholestyramine: cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista.	raloxifene	evista	false	false
warfarin: the coadministration of evista and warfarin has not been assessed under chronic conditions.	warfarin	evista	false	false
warfarin: the coadministration of evista and warfarin has not been assessed under chronic conditions.	warfarin	warfarin	false	false
warfarin: the coadministration of evista and warfarin has not been assessed under chronic conditions.	evista	warfarin	false	false
if evista is given concurrently with warfarin, prothrombin time should be monitored.	evista	warfarin	false	advise
in vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.	raloxifene	warfarin	false	false
in vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.	raloxifene	phenytoin	false	false
in vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.	raloxifene	tamoxifen	false	false
in vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.	warfarin	phenytoin	false	false
in vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.	warfarin	tamoxifen	false	false
in vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.	phenytoin	tamoxifen	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	evista	clofibrate	false	advise
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	evista	indomethacin	false	advise
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	evista	naproxen	false	advise
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	evista	ibuprofen	false	advise
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	evista	diazepam	false	advise
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	evista	diazoxide	false	advise
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	clofibrate	indomethacin	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	clofibrate	naproxen	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	clofibrate	ibuprofen	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	clofibrate	diazepam	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	clofibrate	diazoxide	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	indomethacin	naproxen	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	indomethacin	ibuprofen	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	indomethacin	diazepam	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	indomethacin	diazoxide	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	naproxen	ibuprofen	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	naproxen	diazepam	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	naproxen	diazoxide	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	ibuprofen	diazepam	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	ibuprofen	diazoxide	false	false
caution should be used when evista is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	diazepam	diazoxide	false	false
coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	tritec	clarithromycin	false	mechanism
coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	tritec	ranitidine	false	false
coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	tritec	14- hydroxy- clarithromycin	false	false
coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	clarithromycin	ranitidine	false	false
coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	clarithromycin	14- hydroxy- clarithromycin	false	false
coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	ranitidine	14- hydroxy- clarithromycin	false	false
coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant.	aspirin	salicylate	false	false
coadministration with a high dose of antacid (170 meq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from tritec.	antacid	ranitidine	false	mechanism
coadministration with a high dose of antacid (170 meq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from tritec.	antacid	tritec	false	mechanism
coadministration with a high dose of antacid (170 meq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from tritec.	ranitidine	tritec	false	false
for information on drug interactions associated with ranitidine, refer to the zantac     package insert.	ranitidine	zantac	false	false
co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean auc(0-24) and cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.	ketoconazole	retapamulin	false	false
co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean auc(0-24) and cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.	ketoconazole	retapamulin	false	mechanism
co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean auc(0-24) and cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.	retapamulin	retapamulin	false	false
due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with cyp3a4 inhibitors, such as ketoconazole.	retapamulin	retapamulin	false	false
due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with cyp3a4 inhibitors, such as ketoconazole.	retapamulin	ketoconazole	false	false
due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with cyp3a4 inhibitors, such as ketoconazole.	retapamulin	ketoconazole	false	false
based on in vitro p450 inhibition studies and the low systemic exposure observed following topical application of altabax, retapamulin is unlikely to affect the metabolism of other p450 substrates.	altabax	retapamulin	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	heparin	vitamin k antagonists	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	heparin	aspirin	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	heparin	dipyridamole	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	heparin	abciximab	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	heparin	retavase	false	effect
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	vitamin k antagonists	aspirin	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	vitamin k antagonists	dipyridamole	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	vitamin k antagonists	abciximab	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	vitamin k antagonists	retavase	false	effect
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	aspirin	dipyridamole	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	aspirin	abciximab	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	aspirin	retavase	false	effect
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	dipyridamole	abciximab	false	false
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	dipyridamole	retavase	false	effect
in addition to bleeding associated with heparin and vitamin k antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after retavase    therapy.	abciximab	retavase	false	effect
interactions for vitamin b2 (riboflavin):  alcohol - impairs the intestinal absorption of riboflavin	vitamin b2	riboflavin	false	false
interactions for vitamin b2 (riboflavin):  alcohol - impairs the intestinal absorption of riboflavin	vitamin b2	alcohol	false	false
interactions for vitamin b2 (riboflavin):  alcohol - impairs the intestinal absorption of riboflavin	vitamin b2	riboflavin	false	false
interactions for vitamin b2 (riboflavin):  alcohol - impairs the intestinal absorption of riboflavin	riboflavin	alcohol	false	false
interactions for vitamin b2 (riboflavin):  alcohol - impairs the intestinal absorption of riboflavin	riboflavin	riboflavin	false	false
interactions for vitamin b2 (riboflavin):  alcohol - impairs the intestinal absorption of riboflavin	alcohol	riboflavin	false	mechanism
probenecid - concurrent use decreases gastrointestinal absorption of riboflavin;	probenecid	riboflavin	false	mechanism
requirements for riboflavin may be increased in patients receiving probenecid.	riboflavin	probenecid	false	effect
cimetidine: the effects of chronic cimetidine use on the metabolism of rimantadine are not known.	cimetidine	cimetidine	false	false
cimetidine: the effects of chronic cimetidine use on the metabolism of rimantadine are not known.	cimetidine	rimantadine	false	false
cimetidine: the effects of chronic cimetidine use on the metabolism of rimantadine are not known.	cimetidine	rimantadine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	rimantadine hcl	cimetidine	false	mechanism
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	rimantadine hcl	rimantadine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	rimantadine hcl	rimantadine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	rimantadine hcl	cimetidine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	cimetidine	rimantadine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	cimetidine	rimantadine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	cimetidine	cimetidine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	rimantadine	rimantadine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	rimantadine	cimetidine	false	false
when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	rimantadine	cimetidine	false	false
acetaminophen: rimantadine hcl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers.	acetaminophen	rimantadine hcl	false	false
coadministration with acetaminophen reduced the peak concentration and auc values for rimantadine by approximately 11%.	acetaminophen	rimantadine	false	mechanism
aspirin: rimantadine hcl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.	aspirin	rimantadine hcl	false	false
peak plasma concentrations and auc of rimantadine were reduced approximately 10% in the presence of aspirin.	rimantadine	aspirin	false	mechanism
drug-drug interactions effect of exelon    (rivastigmine tartrate) on the metabolism of other drugs: rivastigmine is primarily metabolized through hydrolysis by esterases.	exelon	rivastigmine tartrate	false	false
drug-drug interactions effect of exelon    (rivastigmine tartrate) on the metabolism of other drugs: rivastigmine is primarily metabolized through hydrolysis by esterases.	exelon	rivastigmine	false	false
drug-drug interactions effect of exelon    (rivastigmine tartrate) on the metabolism of other drugs: rivastigmine is primarily metabolized through hydrolysis by esterases.	rivastigmine tartrate	rivastigmine	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	rivastigmine	digoxin	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	rivastigmine	warfarin	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	rivastigmine	diazepam	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	rivastigmine	fluoxetine	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	digoxin	warfarin	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	digoxin	diazepam	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	digoxin	fluoxetine	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	warfarin	diazepam	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	warfarin	fluoxetine	false	false
no pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	diazepam	fluoxetine	false	false
the elevation of prothrombin time induced by warfarin is not affected by administration of exelon.	warfarin	exelon	false	false
effect of other drugs on the metabolism of exelon: drugs that induce or inhibit cyp450 metabolism are not expected to alter the metabolism of rivastigmine.	exelon	rivastigmine	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	rivastigmine	digoxin	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	rivastigmine	warfarin	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	rivastigmine	diazepam	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	rivastigmine	fluoxetine	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	digoxin	warfarin	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	digoxin	diazepam	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	digoxin	fluoxetine	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	warfarin	diazepam	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	warfarin	fluoxetine	false	false
single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.	diazepam	fluoxetine	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	antacids	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	antihypertensives	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	calcium channel blockers	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	antidiabetics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	nonsteroidal anti-inflammatory drugs	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	estrogens	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	salicylate analgesics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	rivastigmine	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	antihypertensives	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	calcium channel blockers	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	antidiabetics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	nonsteroidal anti-inflammatory drugs	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	estrogens	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	salicylate analgesics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antacids	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antihypertensives	calcium channel blockers	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antihypertensives	antidiabetics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antihypertensives	nonsteroidal anti-inflammatory drugs	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antihypertensives	estrogens	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antihypertensives	salicylate analgesics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antihypertensives	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antihypertensives	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	calcium channel blockers	antidiabetics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	calcium channel blockers	nonsteroidal anti-inflammatory drugs	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	calcium channel blockers	estrogens	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	calcium channel blockers	salicylate analgesics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	calcium channel blockers	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	calcium channel blockers	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antidiabetics	nonsteroidal anti-inflammatory drugs	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antidiabetics	estrogens	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antidiabetics	salicylate analgesics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antidiabetics	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antidiabetics	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	nonsteroidal anti-inflammatory drugs	estrogens	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	nonsteroidal anti-inflammatory drugs	salicylate analgesics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	nonsteroidal anti-inflammatory drugs	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	nonsteroidal anti-inflammatory drugs	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	estrogens	salicylate analgesics	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	estrogens	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	estrogens	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	salicylate analgesics	antianginals	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	salicylate analgesics	antihistamines	false	false
population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	antianginals	antihistamines	false	false
use with anticholinergics: because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.	anticholinergics	cholinesterase inhibitors	false	false
use with anticholinergics: because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.	anticholinergics	anticholinergic medications	false	false
use with anticholinergics: because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.	cholinesterase inhibitors	anticholinergic medications	false	int
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinomimetics	cholinesterase inhibitors	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinomimetics	cholinesterase inhibitors	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinomimetics	succinylcholine	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinomimetics	neuromuscular blocking agents	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinomimetics	cholinergic agonists	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinomimetics	bethanechol	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	cholinesterase inhibitors	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	succinylcholine	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	neuromuscular blocking agents	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	cholinergic agonists	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	bethanechol	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	succinylcholine	false	effect
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	neuromuscular blocking agents	false	effect
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	cholinergic agonists	false	effect
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinesterase inhibitors	bethanechol	false	effect
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	succinylcholine	neuromuscular blocking agents	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	succinylcholine	cholinergic agonists	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	succinylcholine	bethanechol	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	neuromuscular blocking agents	cholinergic agonists	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	neuromuscular blocking agents	bethanechol	false	false
use with cholinomimetics and other cholinesterase inhibitors: a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	cholinergic agonists	bethanechol	false	false
drug interactions: the use of zemuron    (rocuronium bromide) injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	zemuron	rocuronium bromide	false	false
drug interactions: the use of zemuron    (rocuronium bromide) injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	zemuron	succinylcholine	false	false
drug interactions: the use of zemuron    (rocuronium bromide) injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	zemuron	succinylcholine	false	false
drug interactions: the use of zemuron    (rocuronium bromide) injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	rocuronium bromide	succinylcholine	false	false
drug interactions: the use of zemuron    (rocuronium bromide) injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	rocuronium bromide	succinylcholine	false	false
drug interactions: the use of zemuron    (rocuronium bromide) injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	succinylcholine	succinylcholine	false	false
if zemuron    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.	zemuron	succinylcholine	false	advise
if zemuron    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.	zemuron	succinylcholine	false	false
if zemuron    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.	succinylcholine	succinylcholine	false	false
the median duration of action of zemuron    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when t 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.	zemuron	succinylcholine	false	false
there are no controlled studies documenting the use of zemuron    before or after other nondepolarizing muscle relaxants.	zemuron	nondepolarizing muscle relaxants	false	false
ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.	ropivacaine	anesthetics	false	advise
ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.	ropivacaine	amide-type local anesthetics	false	false
ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.	anesthetics	amide-type local anesthetics	false	false
in vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent cyp1a2 inhibitor.	ropivacaine	fluvoxamine	false	mechanism
thus strong inhibitors of cytochrome p4501a2, such as fluvoxamine, given concomitantly during administration of ropivacaine, can interact with ropivacaine leading to increased ropivacaine plasma levels.	fluvoxamine	ropivacaine	false	int
thus strong inhibitors of cytochrome p4501a2, such as fluvoxamine, given concomitantly during administration of ropivacaine, can interact with ropivacaine leading to increased ropivacaine plasma levels.	fluvoxamine	ropivacaine	false	false
thus strong inhibitors of cytochrome p4501a2, such as fluvoxamine, given concomitantly during administration of ropivacaine, can interact with ropivacaine leading to increased ropivacaine plasma levels.	fluvoxamine	ropivacaine	false	false
thus strong inhibitors of cytochrome p4501a2, such as fluvoxamine, given concomitantly during administration of ropivacaine, can interact with ropivacaine leading to increased ropivacaine plasma levels.	ropivacaine	ropivacaine	false	false
thus strong inhibitors of cytochrome p4501a2, such as fluvoxamine, given concomitantly during administration of ropivacaine, can interact with ropivacaine leading to increased ropivacaine plasma levels.	ropivacaine	ropivacaine	false	false
thus strong inhibitors of cytochrome p4501a2, such as fluvoxamine, given concomitantly during administration of ropivacaine, can interact with ropivacaine leading to increased ropivacaine plasma levels.	ropivacaine	ropivacaine	false	false
possible interactions with drugs known to be metabolized by cyp1a2 via competitive inhibition such as theophylline and imipramine may also occur.	theophylline	imipramine	false	false
coadministration of a selective and potent inhibitor of cyp3a4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ropivacaine	false	false
coadministration of a selective and potent inhibitor of cyp3a4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ketoconazole	false	false
coadministration of a selective and potent inhibitor of cyp3a4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ropivacaine	false	mechanism
coadministration of a selective and potent inhibitor of cyp3a4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ropivacaine	ketoconazole	false	false
coadministration of a selective and potent inhibitor of cyp3a4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ropivacaine	ropivacaine	false	false
coadministration of a selective and potent inhibitor of cyp3a4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	ketoconazole	ropivacaine	false	false
an inhibitor of cyp2c8 (such as gemfibrozil) may increase the auc of rosiglitazone and an inducer of cyp2c8 (such as rifampin) may decrease the auc of rosiglitazone.	gemfibrozil	rosiglitazone	false	mechanism
an inhibitor of cyp2c8 (such as gemfibrozil) may increase the auc of rosiglitazone and an inducer of cyp2c8 (such as rifampin) may decrease the auc of rosiglitazone.	gemfibrozil	rifampin	false	false
an inhibitor of cyp2c8 (such as gemfibrozil) may increase the auc of rosiglitazone and an inducer of cyp2c8 (such as rifampin) may decrease the auc of rosiglitazone.	gemfibrozil	rosiglitazone	false	false
an inhibitor of cyp2c8 (such as gemfibrozil) may increase the auc of rosiglitazone and an inducer of cyp2c8 (such as rifampin) may decrease the auc of rosiglitazone.	rosiglitazone	rifampin	false	false
an inhibitor of cyp2c8 (such as gemfibrozil) may increase the auc of rosiglitazone and an inducer of cyp2c8 (such as rifampin) may decrease the auc of rosiglitazone.	rosiglitazone	rosiglitazone	false	false
an inhibitor of cyp2c8 (such as gemfibrozil) may increase the auc of rosiglitazone and an inducer of cyp2c8 (such as rifampin) may decrease the auc of rosiglitazone.	rifampin	rosiglitazone	false	mechanism
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	terfenadine	astemizole	false	false
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	terfenadine	macrolides	false	false
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	terfenadine	terfenadine	false	false
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	terfenadine	astemizole	false	false
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	astemizole	macrolides	false	false
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	astemizole	terfenadine	false	false
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	astemizole	astemizole	false	false
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	macrolides	terfenadine	false	int
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	macrolides	astemizole	false	int
concomitant administrations not recommended:  - terfenadine and astemizole: certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	terfenadine	astemizole	false	false
although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.	roxithromycin	roxithromycin	false	false
although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.	roxithromycin	terfenadine	false	false
although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.	roxithromycin	astemizole	false	false
although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.	roxithromycin	terfenadine	false	advise
although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.	roxithromycin	astemizole	false	advise
although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.	terfenadine	astemizole	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	cisapride	pimozide	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	cisapride	cisapride	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	cisapride	pimozide	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	cisapride	macrolide antibacterials	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	pimozide	cisapride	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	pimozide	pimozide	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	pimozide	macrolide antibacterials	false	mechanism
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	cisapride	pimozide	false	false
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	cisapride	macrolide antibacterials	false	mechanism
- cisapride, pimozide: other drugs such as cisapride or pimozide, which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	pimozide	macrolide antibacterials	false	false
although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.	roxithromycin	roxithromycin	false	false
however, in patients with paget's disease prior diphosphonate use appears to reduce the anti-resorptive response to calcitonin (salmon) nasal spray.	diphosphonate	calcitonin (salmon)	false	effect
aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels.	aspirin	salicylate drugs	false	false
aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels.	aspirin	disalcid	false	effect
aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels.	aspirin	salicylic acid	false	false
aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels.	salicylate drugs	disalcid	false	effect
aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels.	salicylate drugs	salicylic acid	false	false
aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels.	disalcid	salicylic acid	false	false
salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding.	salicylates	anticoagulant drugs	false	effect
salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.	salicylates	antidiabetic drugs	false	effect
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	penicillin	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	thiopental	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	thyroxine	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	triiodothyronine	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	phenytoin	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	sulfinpyrazone	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	naproxen	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	warfarin	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	methotrexate	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	salicylate	corticosteroids	false	mechanism
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	thiopental	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	thyroxine	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	triiodothyronine	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	phenytoin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	sulfinpyrazone	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	naproxen	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	warfarin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	penicillin	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	thyroxine	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	triiodothyronine	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	phenytoin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	sulfinpyrazone	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	naproxen	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	warfarin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thiopental	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thyroxine	triiodothyronine	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thyroxine	phenytoin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thyroxine	sulfinpyrazone	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thyroxine	naproxen	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thyroxine	warfarin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thyroxine	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	thyroxine	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	triiodothyronine	phenytoin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	triiodothyronine	sulfinpyrazone	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	triiodothyronine	naproxen	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	triiodothyronine	warfarin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	triiodothyronine	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	triiodothyronine	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	phenytoin	sulfinpyrazone	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	phenytoin	naproxen	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	phenytoin	warfarin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	phenytoin	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	phenytoin	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	sulfinpyrazone	naproxen	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	sulfinpyrazone	warfarin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	sulfinpyrazone	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	sulfinpyrazone	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	naproxen	warfarin	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	naproxen	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	naproxen	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	warfarin	methotrexate	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	warfarin	corticosteroids	false	false
salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	methotrexate	corticosteroids	false	false
drugs which may potentiate the myeloproliferative effects of leukine, such as lithium and corticosteroids, should be used with caution.	leukine	lithium	false	effect
drugs which may potentiate the myeloproliferative effects of leukine, such as lithium and corticosteroids, should be used with caution.	leukine	corticosteroids	false	effect
drugs which may potentiate the myeloproliferative effects of leukine, such as lithium and corticosteroids, should be used with caution.	lithium	corticosteroids	false	false
scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives, tranquilizers, or alcohol.	scopolamine	sedatives	false	advise
scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives, tranquilizers, or alcohol.	scopolamine	tranquilizers	false	advise
scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives, tranquilizers, or alcohol.	scopolamine	alcohol	false	advise
scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives, tranquilizers, or alcohol.	sedatives	tranquilizers	false	false
scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives, tranquilizers, or alcohol.	sedatives	alcohol	false	false
scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives, tranquilizers, or alcohol.	tranquilizers	alcohol	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	belladonna alkaloids	antihistamines	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	belladonna alkaloids	meclizine	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	belladonna alkaloids	tricyclic antidepressants	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	belladonna alkaloids	muscle relaxants	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	antihistamines	meclizine	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	antihistamines	tricyclic antidepressants	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	antihistamines	muscle relaxants	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	meclizine	tricyclic antidepressants	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	meclizine	muscle relaxants	false	false
e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.	tricyclic antidepressants	muscle relaxants	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	barbiturates	contraceptives	false	int
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	barbiturates	antibiotics	false	int
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	barbiturates	quinidine	false	int
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	barbiturates	theophylline	false	int
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	barbiturates	corticosteroids	false	int
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	barbiturates	anticoagulants	false	int
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	barbiturates	beta blockers	false	int
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	antibiotics	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	quinidine	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	theophylline	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	corticosteroids	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	anticoagulants	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	contraceptives	beta blockers	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	quinidine	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	theophylline	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	corticosteroids	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	anticoagulants	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	antibiotics	beta blockers	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	theophylline	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	corticosteroids	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	anticoagulants	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	quinidine	beta blockers	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	theophylline	corticosteroids	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	theophylline	anticoagulants	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	theophylline	beta blockers	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	corticosteroids	anticoagulants	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	corticosteroids	beta blockers	false	false
barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	anticoagulants	beta blockers	false	false
the occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine.	selegiline	meperidine	false	effect
this is typical of the interaction of meperidine and maois.	meperidine	maois	false	int
severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl.	tricyclic antidepressants	eldepryl	false	effect
severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl.	tricyclic antidepressants	selective serotonin reuptake inhibitors	false	false
severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl.	tricyclic antidepressants	eldepryl	false	false
severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl.	eldepryl	selective serotonin reuptake inhibitors	false	false
severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl.	eldepryl	eldepryl	false	false
severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl.	selective serotonin reuptake inhibitors	eldepryl	false	effect
one case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).	selegiline	sympathomimetic medication	false	effect
one case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).	selegiline	ephedrine	false	effect
one case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).	sympathomimetic medication	ephedrine	false	false
digoxin: there was a slight increase in the area under the curve (auc, 11%) and mean peak drug concentration (cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.	digoxin	digoxin	false	false
digoxin: there was a slight increase in the area under the curve (auc, 11%) and mean peak drug concentration (cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.	digoxin	sitagliptin	false	false
digoxin: there was a slight increase in the area under the curve (auc, 11%) and mean peak drug concentration (cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.	digoxin	sitagliptin	false	mechanism
no dosage adjustment of digoxin or januvia is recommended.	digoxin	januvia	false	false
norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.	norepinephrine	dobutamine	false	false
norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.	norepinephrine	sodium bicarbonate	false	int
norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.	dobutamine	sodium bicarbonate	false	int
the addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established.	sodium bicarbonate	calcium	false	false
do not exceed a 5 mg daily dose of vesicare when administered with therapeutic doses of ketoconazole or other potent cyp3a4 inhibitors.	vesicare	ketoconazole	false	advise
patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women, the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	solifenacin	solifenacin	false	false
patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women, the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	solifenacin	solifenacin	false	false
patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women, the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	solifenacin	moxifloxacin	false	false
patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women, the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	solifenacin	solifenacin	false	false
patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women, the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	solifenacin	moxifloxacin	false	false
patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women, the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.	solifenacin	moxifloxacin	false	false
if glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted.	glucocorticoid	glucocorticoid	false	false
limited published data indicate that gh treatment increases cytochrome p450 (cp450) mediated antipyrine clearance in man.	gh	antipyrine	false	mechanism
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	gh	corticosteroids	false	mechanism
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	gh	sex steroids	false	mechanism
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	gh	anticonvulsants	false	mechanism
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	gh	cyclosporin	false	mechanism
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	corticosteroids	sex steroids	false	false
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	corticosteroids	anticonvulsants	false	false
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	corticosteroids	cyclosporin	false	false
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	sex steroids	anticonvulsants	false	false
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	sex steroids	cyclosporin	false	false
these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).	anticonvulsants	cyclosporin	false	false
caution is recommended when administering nexavar with compounds that are metabolized/eliminated predominantly by the ugt1a1 pathway (e.g. irinotecan).	nexavar	irinotecan	false	advise
concomitant treatment with nexavar resulted in a 21% increase in the auc of doxorubicin.	nexavar	doxorubicin	false	mechanism
caution is recommended when administering doxorubicin with nexavar.	doxorubicin	nexavar	false	advise
zidovudine competitively inhibits the intracellular phosphorylation of stavudine.	zidovudine	stavudine	false	effect
therefore, use of zidovudine in combination with zerit should be avoided.	zidovudine	zerit	false	advise
in vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.	stavudine	doxorubicin	false	effect
in vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.	stavudine	ribavirin	false	effect
in vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.	doxorubicin	ribavirin	false	false
the interaction of streptase, streptokinase, with other drugs has not been well studied.	streptase	streptokinase	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	anticoagulants	antiplatelet agents	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	anticoagulants	streptase	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	anticoagulants	streptokinase	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	anticoagulants	antiplatelet agents	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	anticoagulants	anticoagulants	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	antiplatelet agents	streptase	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	antiplatelet agents	streptokinase	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	antiplatelet agents	antiplatelet agents	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	antiplatelet agents	anticoagulants	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	streptase	streptokinase	false	false
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	streptase	antiplatelet agents	false	effect
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	streptase	anticoagulants	false	effect
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	streptokinase	antiplatelet agents	false	effect
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	streptokinase	anticoagulants	false	effect
use of anticoagulants and antiplatelet agents -- streptase, streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	antiplatelet agents	anticoagulants	false	false
in the treatment of acute mi, aspirin, when not otherwise contraindicated, should be administered with streptokinase ( see below ).	aspirin	streptokinase	false	false
anticoagulation and antiplatelets after treatment for myocardial infarction -- in the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke.	antiplatelets	aspirin	false	false
the addition of aspirin to streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see	aspirin	streptokinase	false	effect
streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression;	streptozocin	doxorubicin	false	mechanism
a reduction of the doxorubicin dosage should be considered in patients receiving zanosar concurrently.	doxorubicin	zanosar	false	advise
the concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.	streptozocin	phenytoin	false	effect
the concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.	streptozocin	streptozocin	false	false
the concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.	phenytoin	streptozocin	false	false
chemet is not known to interact with other drugs including iron supplements;	chemet	iron	false	false
concomitant administration of chemet with other chelation therapy, such as cana 2 edta is not recommended.	chemet	cana 2 edta	false	advise
sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.	sulfamethizole	barbiturates	false	effect
sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.	sulfamethizole	tolbutamide	false	effect
sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.	sulfamethizole	uricosurics	false	effect
sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.	barbiturates	tolbutamide	false	false
sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.	barbiturates	uricosurics	false	false
sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.	tolbutamide	uricosurics	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	cyclosporine	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	sulfonylurea agents	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	warfarin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	sulfonylurea agents	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	warfarin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	warfarin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	phenytoin	phenytoin	false	false
in elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported.	diuretics	thiazides	false	false
it has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.	sulfamethoxazole	anticoagulant	false	false
it has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.	sulfamethoxazole	warfarin	false	effect
it has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.	anticoagulant	warfarin	false	false
sulfamethoxazole may inhibit the hepatic metabolism of phenytoin.	sulfamethoxazole	phenytoin	false	mechanism
at a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate.	sulfamethoxazole	phenytoin	false	mechanism
sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.	sulfonamides	methotrexate	false	mechanism
sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.	sulfonamides	methotrexate	false	false
sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.	methotrexate	methotrexate	false	false
reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.	folic acid	digoxin	false	false
reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.	folic acid	sulfasalazine	false	mechanism
reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.	digoxin	sulfasalazine	false	mechanism
when daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.	sulfasalazine	methotrexate	false	false
daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.	sulfasalazine	methotrexate	false	false
sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.	sulfoxone	barbiturates	false	effect
sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.	sulfoxone	tolbutamide	false	effect
sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.	sulfoxone	uricosurics	false	effect
sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.	barbiturates	tolbutamide	false	false
sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.	barbiturates	uricosurics	false	false
sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.	tolbutamide	uricosurics	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	cyclosporine	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	sulfonylurea agents	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	warfarin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	thiazides	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	sulfonylurea agents	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	warfarin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	cyclosporine	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	warfarin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	sulfonylurea agents	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	warfarin	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	methotrexate	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	methotrexate	phenytoin	false	false
it may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	phenytoin	phenytoin	false	false
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	ergotamine	ergot-type medications	false	false
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	ergotamine	dihydroergotamine	false	false
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	ergotamine	methysergide	false	false
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	ergotamine	sumatriptan	false	advise
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	ergot-type medications	dihydroergotamine	false	false
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	ergot-type medications	methysergide	false	false
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	ergot-type medications	sumatriptan	false	advise
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	dihydroergotamine	methysergide	false	false
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	dihydroergotamine	sumatriptan	false	advise
because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	methysergide	sumatriptan	false	advise
mao-a inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.	mao-a inhibitors	sumatriptan	false	mechanism
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	mao-a inhibitors	false	advise
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	selective serotonin reuptake inhibitors	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	ssris	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	fluoxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	fluvoxamine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	paroxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	sertraline	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sumatriptan succinate	sumatriptan	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	mao-a inhibitors	selective serotonin reuptake inhibitors	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	mao-a inhibitors	ssris	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	mao-a inhibitors	fluoxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	mao-a inhibitors	fluvoxamine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	mao-a inhibitors	paroxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	mao-a inhibitors	sertraline	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	mao-a inhibitors	sumatriptan	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	selective serotonin reuptake inhibitors	ssris	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	selective serotonin reuptake inhibitors	fluoxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	selective serotonin reuptake inhibitors	fluvoxamine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	selective serotonin reuptake inhibitors	paroxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	selective serotonin reuptake inhibitors	sertraline	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	selective serotonin reuptake inhibitors	sumatriptan	false	effect
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	ssris	fluoxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	ssris	fluvoxamine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	ssris	paroxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	ssris	sertraline	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	ssris	sumatriptan	false	effect
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	fluoxetine	fluvoxamine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	fluoxetine	paroxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	fluoxetine	sertraline	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	fluoxetine	sumatriptan	false	effect
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	fluvoxamine	paroxetine	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	fluvoxamine	sertraline	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	fluvoxamine	sumatriptan	false	effect
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	paroxetine	sertraline	false	false
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	paroxetine	sumatriptan	false	effect
therefore, the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated . selective serotonin reuptake inhibitors (ssris) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	sertraline	sumatriptan	false	effect
if concomitant treatment with sumatriptan and an ssri is clinically warranted, appropriate observation of the patient is advised.	sumatriptan	ssri	false	advise
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	ketoconazole	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	itraconazole	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	clarithromycin	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	atazanavir	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	indinavir	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	nefazodone	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	nelfinavir	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	ritonavir	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	saquinavir	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	telithromycin	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	voriconizole	false	mechanism
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	sutent	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	itraconazole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	clarithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	atazanavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	indinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	nefazodone	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	nelfinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	ritonavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ketoconazole	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	clarithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	atazanavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	indinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	nefazodone	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	nelfinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	ritonavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	itraconazole	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	atazanavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	indinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	nefazodone	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	nelfinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	ritonavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	clarithromycin	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	indinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	nefazodone	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	nelfinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	ritonavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	atazanavir	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	indinavir	nefazodone	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	indinavir	nelfinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	indinavir	ritonavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	indinavir	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	indinavir	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	indinavir	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	indinavir	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nefazodone	nelfinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nefazodone	ritonavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nefazodone	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nefazodone	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nefazodone	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nefazodone	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nelfinavir	ritonavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nelfinavir	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nelfinavir	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nelfinavir	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	nelfinavir	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ritonavir	saquinavir	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ritonavir	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ritonavir	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	ritonavir	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	saquinavir	telithromycin	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	saquinavir	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	saquinavir	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	telithromycin	voriconizole	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	telithromycin	sunitinib	false	false
co-administration of sutent with strong inhibitors of the cyp3a4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	voriconizole	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	dexamethasone	false	mechanism
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	phenytoin	false	mechanism
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	carbamazepine	false	mechanism
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	rifampin	false	mechanism
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	rifabutin	false	mechanism
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	rifapentin	false	mechanism
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	phenobarbital	false	mechanism
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	sutent	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	dexamethasone	phenytoin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	dexamethasone	carbamazepine	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	dexamethasone	rifampin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	dexamethasone	rifabutin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	dexamethasone	rifapentin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	dexamethasone	phenobarbital	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	dexamethasone	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	phenytoin	carbamazepine	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	phenytoin	rifampin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	phenytoin	rifabutin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	phenytoin	rifapentin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	phenytoin	phenobarbital	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	phenytoin	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	carbamazepine	rifampin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	carbamazepine	rifabutin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	carbamazepine	rifapentin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	carbamazepine	phenobarbital	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	carbamazepine	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifampin	rifabutin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifampin	rifapentin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifampin	phenobarbital	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifampin	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifabutin	rifapentin	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifabutin	phenobarbital	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifabutin	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifapentin	phenobarbital	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	rifapentin	sunitinib	false	false
co-administration of sutent with inducers of the cyp3a4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, st. johns wort) may decrease sunitinib concentrations.	phenobarbital	sunitinib	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	miochol	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	carbachol	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	carboptic	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	isopto carbachol	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	acetylcholine chloride	suprofen	false	effect
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	miochol	carbachol	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	miochol	carboptic	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	miochol	isopto carbachol	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	miochol	suprofen	false	effect
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	carbachol	carboptic	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	carbachol	isopto carbachol	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	carbachol	suprofen	false	effect
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	carboptic	isopto carbachol	false	false
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	carboptic	suprofen	false	effect
other eye drops or medications such as acetylcholine chloride (miochol) and carbachol (carboptic, isopto carbachol) may decrease the effects of suprofen ophthalmic.	isopto carbachol	suprofen	false	effect
drug-drug interactions: the pharmacokinetic and pharmacodynamic interactions between flomax capsules and other alpha-adrenergic blocking agents have not been determined.	flomax	alpha-adrenergic blocking agents	false	false
however, interactions may be expected and flomax capsules should not be used in combination with other alpha-adrenergic blocking agents.	flomax	alpha-adrenergic blocking agents	false	advise
the pharmacokinetic interaction between cimetidine and flomax capsules was investigated.	cimetidine	flomax	false	false
therefore, flomax capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.	flomax	cimetidine	false	advise
results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin hci and warfarin are inconclusive.	tamsulosin hci	warfarin	false	false
therefore, caution should be exercised with concomitant administration of warfarin and flomax capsules.	warfarin	flomax	false	advise
administration of valproic acid decreases oral clearance of temozolomide by about 5%.	valproic acid	temozolomide	false	mechanism
patients studied in clinical trials of tnkase were routinely treated with heparin and aspirin.	tnkase	heparin	false	false
patients studied in clinical trials of tnkase were routinely treated with heparin and aspirin.	tnkase	aspirin	false	false
patients studied in clinical trials of tnkase were routinely treated with heparin and aspirin.	heparin	aspirin	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	anticoagulants	heparin	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	anticoagulants	vitamin k antagonists	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	anticoagulants	acetylsalicylic acid	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	anticoagulants	dipyridamole	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	anticoagulants	tnkase	false	effect
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	heparin	vitamin k antagonists	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	heparin	acetylsalicylic acid	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	heparin	dipyridamole	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	heparin	tnkase	false	effect
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	vitamin k antagonists	acetylsalicylic acid	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	vitamin k antagonists	dipyridamole	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	vitamin k antagonists	tnkase	false	effect
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	acetylsalicylic acid	dipyridamole	false	false
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	acetylsalicylic acid	tnkase	false	effect
anticoagulants (such as heparin and vitamin k antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and gp iib/iiia inhibitors) may increase the risk of bleeding if administered prior to, during, or after tnkase therapy.	dipyridamole	tnkase	false	effect
in a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	tolbutamide	sodium salicylate	false	false
in a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	tolbutamide	sulfamethizole	false	false
in a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	tolbutamide	teniposide	false	mechanism
in a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	sodium salicylate	sulfamethizole	false	false
in a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	sodium salicylate	teniposide	false	mechanism
in a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	sulfamethizole	teniposide	false	mechanism
therefore, caution should be used in administering vumon (teniposide injection) to patients receiving these other agents.	vumon	teniposide	false	false
there was no change in the plasma kinetics of teniposide when coadministered with methotrexate.	teniposide	methotrexate	false	false
an increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.	methotrexate	teniposide	false	mechanism
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	terbinafine	tolbutamide	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	terbinafine	ethinylestradiol	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	terbinafine	ethoxycoumarin	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	terbinafine	cyclosporine	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	tolbutamide	ethinylestradiol	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	tolbutamide	ethoxycoumarin	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	tolbutamide	cyclosporine	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	ethinylestradiol	ethoxycoumarin	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	ethinylestradiol	cyclosporine	false	false
in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.	ethoxycoumarin	cyclosporine	false	false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (ssris), and monoamine oxidase inhibitors (mao-is) type b, if they have a narrow therapeutic window.	tricyclic antidepressants	selective serotonin reuptake inhibitors	false	false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (ssris), and monoamine oxidase inhibitors (mao-is) type b, if they have a narrow therapeutic window.	tricyclic antidepressants	ssris	false	false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (ssris), and monoamine oxidase inhibitors (mao-is) type b, if they have a narrow therapeutic window.	tricyclic antidepressants	monoamine oxidase inhibitors (mao-is) type b	false	false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (ssris), and monoamine oxidase inhibitors (mao-is) type b, if they have a narrow therapeutic window.	selective serotonin reuptake inhibitors	ssris	false	false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (ssris), and monoamine oxidase inhibitors (mao-is) type b, if they have a narrow therapeutic window.	selective serotonin reuptake inhibitors	monoamine oxidase inhibitors (mao-is) type b	false	false
this may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (ssris), and monoamine oxidase inhibitors (mao-is) type b, if they have a narrow therapeutic window.	ssris	monoamine oxidase inhibitors (mao-is) type b	false	false
in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin.	terbinafine	antipyrine	false	false
in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin.	terbinafine	digoxin	false	false
in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin.	antipyrine	digoxin	false	false
terbinafine decreases the clearance of caffeine by 19%.	terbinafine	caffeine	false	mechanism
terbinafine increases the clearance of cyclosporine by 15%.	terbinafine	cyclosporine	false	mechanism
there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between lamisil    tablets and these changes has not been established.	terbinafine	warfarin	false	effect
there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between lamisil    tablets and these changes has not been established.	terbinafine	lamisil	false	false
there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between lamisil    tablets and these changes has not been established.	warfarin	lamisil	false	false
terbinafine clearance is increased 100% by rifampin, a cyp450 enzyme inducer, and decreased 33% by cimetidine, a cyp450 enzyme inhibitor.	terbinafine	rifampin	false	mechanism
terbinafine clearance is increased 100% by rifampin, a cyp450 enzyme inducer, and decreased 33% by cimetidine, a cyp450 enzyme inhibitor.	terbinafine	cimetidine	false	mechanism
terbinafine clearance is increased 100% by rifampin, a cyp450 enzyme inducer, and decreased 33% by cimetidine, a cyp450 enzyme inhibitor.	rifampin	cimetidine	false	false
terbinafine clearance is unaffected by cyclosporine.	terbinafine	cyclosporine	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	hypoglycemics	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	theophyllines	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	phenytoins	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	thiazide diuretics	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	beta blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	contraceptives	calcium channel blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	theophyllines	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	phenytoins	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	thiazide diuretics	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	beta blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	hypoglycemics	calcium channel blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	phenytoins	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	thiazide diuretics	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	beta blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	theophyllines	calcium channel blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	phenytoins	thiazide diuretics	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	phenytoins	beta blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	phenytoins	calcium channel blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	thiazide diuretics	beta blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	thiazide diuretics	calcium channel blockers	false	false
there is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	beta blockers	calcium channel blockers	false	false
ketoconazole: spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate qt interval prolongation and rare serious cardiac events, e.g.	ketoconazole	ketoconazole	false	false
ketoconazole: spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate qt interval prolongation and rare serious cardiac events, e.g.	ketoconazole	terfenadine	false	false
ketoconazole: spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate qt interval prolongation and rare serious cardiac events, e.g.	ketoconazole	terfenadine	false	effect
pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.	ketoconazole	terfenadine	false	mechanism
pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.	ketoconazole	terfenadine	false	false
pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.	terfenadine	terfenadine	false	false
concomitant administration of ketoconazole and terfenadine is contraindicated.	ketoconazole	terfenadine	false	advise
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	itraconazole	terfenadine	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	itraconazole	terfenadine	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	itraconazole	itraconazole	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	itraconazole	itraconazole	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	terfenadine	terfenadine	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	terfenadine	itraconazole	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	terfenadine	itraconazole	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	terfenadine	itraconazole	false	mechanism
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	terfenadine	itraconazole	false	false
itraconazole: torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	itraconazole	itraconazole	false	false
concomitant administration of itraconazole and terfenadine is contraindicated.	itraconazole	terfenadine	false	advise
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	azole-type antifungal agents	fluconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	azole-type antifungal agents	metronidazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	azole-type antifungal agents	miconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	azole-type antifungal agents	ketoconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	azole-type antifungal agents	itraconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	azole-type antifungal agents	terfenadine	false	advise
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	fluconazole	metronidazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	fluconazole	miconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	fluconazole	ketoconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	fluconazole	itraconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	fluconazole	terfenadine	false	advise
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	metronidazole	miconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	metronidazole	ketoconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	metronidazole	itraconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	metronidazole	terfenadine	false	advise
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	miconazole	ketoconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	miconazole	itraconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	miconazole	terfenadine	false	advise
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	ketoconazole	itraconazole	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	ketoconazole	terfenadine	false	false
due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	itraconazole	terfenadine	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	macrolides	erythromycin	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	macrolides	clarithromycin	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	macrolides	terfenadine	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	macrolides	ketoconazole	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	erythromycin	clarithromycin	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	erythromycin	terfenadine	false	mechanism
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	erythromycin	ketoconazole	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	clarithromycin	terfenadine	false	mechanism
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	clarithromycin	ketoconazole	false	false
macrolides: clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	terfenadine	ketoconazole	false	false
a few spontaneous accounts of qt interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin.	erythromycin	troleandomycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	clarithromycin	false	advise
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	erythromycin	false	advise
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	troleandomycin	false	advise
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	terfenadine	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	macrolide antibiotics	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	azithromycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	clarithromycin	erythromycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	clarithromycin	troleandomycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	clarithromycin	terfenadine	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	clarithromycin	macrolide antibiotics	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	clarithromycin	azithromycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	erythromycin	troleandomycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	erythromycin	terfenadine	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	erythromycin	macrolide antibiotics	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	erythromycin	azithromycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	troleandomycin	terfenadine	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	troleandomycin	macrolide antibiotics	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	troleandomycin	azithromycin	false	false
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	macrolide antibiotics	false	advise
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	terfenadine	azithromycin	false	advise
concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	macrolide antibiotics	azithromycin	false	false
studies to evaluate potential interactions of terfenadine with azithromycin are in progress.	terfenadine	azithromycin	false	false
when administered concurrently, testolactone may increase the effects of oral anticoagulants;	testolactone	anticoagulants	false	effect
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	thalidomide	barbiturates	false	effect
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	thalidomide	alcohol	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	thalidomide	chlorpromazine	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	thalidomide	reserpine	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	barbiturates	alcohol	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	barbiturates	chlorpromazine	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	barbiturates	reserpine	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	alcohol	chlorpromazine	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	alcohol	reserpine	false	false
thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.	chlorpromazine	reserpine	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	contraceptives	norethindrone	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	contraceptives	ethinyl estradiol	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	contraceptives	norethindrone acetate	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	contraceptives	ethinyl estradiol	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	norethindrone	ethinyl estradiol	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	norethindrone	norethindrone acetate	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	norethindrone	ethinyl estradiol	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	ethinyl estradiol	norethindrone acetate	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	ethinyl estradiol	ethinyl estradiol	false	false
oral contraceptives: in 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.	norethindrone acetate	ethinyl estradiol	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	hormonal contraceptives	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	hiv-protease inhibitors	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	griseofulvin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	modafinil	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	penicillins	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	rifampin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	rifabutin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	thalidomide	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	hiv-protease inhibitors	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	griseofulvin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	modafinil	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	penicillins	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	rifampin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	rifabutin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hormonal contraceptives	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hiv-protease inhibitors	griseofulvin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hiv-protease inhibitors	modafinil	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hiv-protease inhibitors	penicillins	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hiv-protease inhibitors	rifampin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hiv-protease inhibitors	rifabutin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hiv-protease inhibitors	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	hiv-protease inhibitors	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	griseofulvin	modafinil	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	griseofulvin	penicillins	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	griseofulvin	rifampin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	griseofulvin	rifabutin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	griseofulvin	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	griseofulvin	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	modafinil	penicillins	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	modafinil	rifampin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	modafinil	rifabutin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	modafinil	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	modafinil	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	penicillins	rifampin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	penicillins	rifabutin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	penicillins	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	penicillins	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	rifampin	rifabutin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	rifampin	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	rifampin	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	rifabutin	phenytoin	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	rifabutin	carbamazepine	false	false
important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives: concomitant use of hiv-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as st.	phenytoin	carbamazepine	false	false
john's wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.	john's wort	hormonal contraceptive agents	false	effect
thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.	thiabendazole	theophylline	false	mechanism
therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.	thiabendazole	xanthine derivatives	false	advise
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	vitamin b1	thiamine	false	false
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	vitamin b1	loop diuretics	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	vitamin b1	contraceptives	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	vitamin b1	stavudine	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	vitamin b1	tricyclic antidepressants	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	thiamine	loop diuretics	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	thiamine	contraceptives	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	thiamine	stavudine	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	thiamine	tricyclic antidepressants	false	int
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	loop diuretics	contraceptives	false	false
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	loop diuretics	stavudine	false	false
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	loop diuretics	tricyclic antidepressants	false	false
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	contraceptives	stavudine	false	false
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	contraceptives	tricyclic antidepressants	false	false
interactions for vitamin b1 (thiamine):  loop diuretics, oral contraceptives, stavudine, tricyclic antidepressants	stavudine	tricyclic antidepressants	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	phenothiazines	cns depressants	advise	effect
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	phenothiazines	barbiturates	false	effect
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	phenothiazines	anesthetics	false	effect
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	phenothiazines	opiates	false	effect
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	phenothiazines	alcohol	false	effect
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	cns depressants	barbiturates	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	cns depressants	anesthetics	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	cns depressants	opiates	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	cns depressants	alcohol	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	barbiturates	anesthetics	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	barbiturates	opiates	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	barbiturates	alcohol	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	anesthetics	opiates	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	anesthetics	alcohol	false	false
phenothiazines are capable of potentiating cns depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	opiates	alcohol	false	false
as well as atropine and phosphorous insecticides.	atropine	phosphorous insecticides	false	false
there is usually complete cross-resistance between purinethol (mercaptopurine) and tabloid brand thioguanine.	purinethol	mercaptopurine	false	false
there is usually complete cross-resistance between purinethol (mercaptopurine) and tabloid brand thioguanine.	purinethol	tabloid	false	effect
there is usually complete cross-resistance between purinethol (mercaptopurine) and tabloid brand thioguanine.	purinethol	thioguanine	false	effect
there is usually complete cross-resistance between purinethol (mercaptopurine) and tabloid brand thioguanine.	mercaptopurine	tabloid	false	effect
there is usually complete cross-resistance between purinethol (mercaptopurine) and tabloid brand thioguanine.	mercaptopurine	thioguanine	false	effect
there is usually complete cross-resistance between purinethol (mercaptopurine) and tabloid brand thioguanine.	tabloid	thioguanine	false	false
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	aminosalicylate derivatives	olsalazine	false	false
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	aminosalicylate derivatives	mesalazine	false	false
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	aminosalicylate derivatives	sulphasalazine	false	false
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	aminosalicylate derivatives	thioguanine	false	mechanism
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	olsalazine	mesalazine	false	false
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	olsalazine	sulphasalazine	false	false
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	olsalazine	thioguanine	false	mechanism
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	mesalazine	sulphasalazine	false	false
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	mesalazine	thioguanine	false	mechanism
as there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the tpmt enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	sulphasalazine	thioguanine	false	mechanism
caution should be exercised when administering zadaxin therapy in combination with other immunomodulating drugs.	zadaxin	immunomodulating drugs	false	advise
prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.	tigecycline	warfarin	false	advise
concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.	antibacterial drugs	contraceptives	false	effect
concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.	antibacterial drugs	contraceptives	false	false
concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.	contraceptives	contraceptives	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	calcium	false	mechanism
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	calcium	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	skelid	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	aluminum	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	magnesium	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	antacids	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	skelid	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	calcium	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	skelid	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	aluminum	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	magnesium	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	antacids	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	skelid	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	skelid	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	aluminum	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	magnesium	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	antacids	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	calcium	skelid	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	aluminum	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	magnesium	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	antacids	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	skelid	skelid	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	aluminum	magnesium	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	aluminum	antacids	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	aluminum	skelid	false	mechanism
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	magnesium	antacids	false	false
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	magnesium	skelid	false	mechanism
the bioavailability of skelid is decreased 80% by calcium, when calcium and skelid are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before skelid.	antacids	skelid	false	false
aspirin may decrease bioavailability of skelid by up to 50% when taken 2 hours after skelid.	aspirin	skelid	false	mechanism
aspirin may decrease bioavailability of skelid by up to 50% when taken 2 hours after skelid.	aspirin	skelid	false	false
aspirin may decrease bioavailability of skelid by up to 50% when taken 2 hours after skelid.	skelid	skelid	false	false
the bioavailability of skelid is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.	skelid	indomethacin	false	mechanism
the bioavailability of skelid is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.	skelid	diclofenac	false	false
the bioavailability of skelid is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.	indomethacin	diclofenac	false	false
the pharmacokinetic parameters of digoxin are not significantly modified by skelid coadministration.	digoxin	skelid	false	false
in vitro studies show that tiludronate does not displace warfarin from its binding site on protein.	tiludronate	warfarin	false	false
these include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.	sympathomimetic bronchodilators	methylxanthines	false	false
these include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.	sympathomimetic bronchodilators	steroids	false	false
these include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.	methylxanthines	steroids	false	false
however, the co   administration of spiriva with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	spiriva	anticholinergic	false	advise
however, the co   administration of spiriva with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	spiriva	ipratropium	false	advise
however, the co   administration of spiriva with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	anticholinergic	ipratropium	false	false
aggrastat has been studied on a background of aspirin and heparin.	aggrastat	aspirin	false	false
aggrastat has been studied on a background of aspirin and heparin.	aggrastat	heparin	false	false
aggrastat has been studied on a background of aspirin and heparin.	aspirin	heparin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aggrastat	heparin	false	effect
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aggrastat	aspirin	false	effect
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aggrastat	heparin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aggrastat	aspirin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	aspirin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	heparin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	aspirin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aspirin	heparin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	aspirin	aspirin	false	false
the use of aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	heparin	aspirin	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	tobi	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	dornase alfa	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	pulmozyme	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	(beta)-agonists	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	corticosteroids	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	anti-pseudomonal antibiotics	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	aminoglycosides	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	dornase alfa	false	effect
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	pulmozyme	false	effect
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	(beta)-agonists	false	effect
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	corticosteroids	false	effect
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	anti-pseudomonal antibiotics	false	effect
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	tobi	aminoglycosides	false	effect
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	dornase alfa	pulmozyme	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	dornase alfa	(beta)-agonists	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	dornase alfa	corticosteroids	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	dornase alfa	anti-pseudomonal antibiotics	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	dornase alfa	aminoglycosides	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	pulmozyme	(beta)-agonists	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	pulmozyme	corticosteroids	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	pulmozyme	anti-pseudomonal antibiotics	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	pulmozyme	aminoglycosides	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	(beta)-agonists	corticosteroids	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	(beta)-agonists	anti-pseudomonal antibiotics	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	(beta)-agonists	aminoglycosides	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	corticosteroids	anti-pseudomonal antibiotics	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	corticosteroids	aminoglycosides	false	false
in clinical studies of tobi, patients taking tobi concomitantly with dornase alfa (pulmozyme   , genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	anti-pseudomonal antibiotics	aminoglycosides	false	false
some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.	diuretics	aminoglycoside	false	effect
some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.	diuretics	antibiotic	false	false
some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.	aminoglycoside	antibiotic	false	false
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	tobi	ethacrynic acid	advise	advise
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	tobi	furosemide	advise	advise
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	tobi	urea	advise	advise
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	tobi	mannitol	advise	advise
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	ethacrynic acid	furosemide	false	false
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	ethacrynic acid	urea	false	false
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	ethacrynic acid	mannitol	false	false
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	furosemide	urea	false	false
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	furosemide	mannitol	false	false
tobi should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.	urea	mannitol	false	false
the in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers.	warfarin	tolmetin	false	false
the in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers.	warfarin	tolmetin	false	false
the in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers.	tolmetin	tolmetin	false	false
however, increased prothrombin time and bleeding have been reported in patients on concomitant tolectin and warfarin therapy.	tolectin	warfarin	false	effect
therefore, caution should be exercised when administering tolectin to patients on anticoagulants.	tolectin	anticoagulants	false	advise
in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents.	sulfonylureas	insulin	false	false
in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents.	sulfonylureas	tolectin	false	false
in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents.	sulfonylureas	hypoglycemic agents	false	false
in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents.	insulin	tolectin	false	false
in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents.	insulin	hypoglycemic agents	false	false
in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents.	tolectin	hypoglycemic agents	false	false
caution should be used if tolectin is administered concomitantly with methotrexate.	tolectin	methotrexate	false	advise
tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	tolectin	nonsteroidal anti-inflammatory drugs	false	false
tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	tolectin	methotrexate	false	mechanism
tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	tolectin	methotrexate	false	false
tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	nonsteroidal anti-inflammatory drugs	methotrexate	false	mechanism
tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	nonsteroidal anti-inflammatory drugs	methotrexate	false	false
tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	methotrexate	methotrexate	false	false
cyp3a4 inhibitors: ketoconazole, an inhibitor of the drug metabolizing enzyme cyp3a4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see clinical pharmacology, variability in metabolism and drug-drug interactions).	ketoconazole	tolterodine	false	mechanism
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	azole antifungals	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	itraconazole	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	miconazole	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	macrolide antibiotics	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	erythromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	clarithromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	cyclosporine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	ketoconazole	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	itraconazole	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	miconazole	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	macrolide antibiotics	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	erythromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	clarithromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	cyclosporine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	azole antifungals	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	itraconazole	miconazole	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	itraconazole	macrolide antibiotics	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	itraconazole	erythromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	itraconazole	clarithromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	itraconazole	cyclosporine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	itraconazole	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	itraconazole	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	miconazole	macrolide antibiotics	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	miconazole	erythromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	miconazole	clarithromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	miconazole	cyclosporine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	miconazole	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	miconazole	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	macrolide antibiotics	erythromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	macrolide antibiotics	clarithromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	macrolide antibiotics	cyclosporine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	macrolide antibiotics	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	macrolide antibiotics	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	erythromycin	clarithromycin	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	erythromycin	cyclosporine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	erythromycin	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	erythromycin	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	clarithromycin	cyclosporine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	clarithromycin	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	clarithromycin	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	cyclosporine	vinblastine	false	false
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	cyclosporine	detrol la	false	advise
for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of detrol la is 2 mg daily.	vinblastine	detrol la	false	advise
administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies.	paclitaxel	herceptin	false	mechanism
administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies.	paclitaxel	herceptin	false	false
administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies.	paclitaxel	herceptin	false	false
administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies.	herceptin	herceptin	false	false
administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies.	herceptin	herceptin	false	false
administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies.	herceptin	herceptin	false	false
trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).	trilostane	aminoglutethimide	false	int
trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).	trilostane	mitotane	false	int
trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).	aminoglutethimide	mitotane	false	false
trimethoprim may inhibit the hepatic metabolism of phenytoin.	trimethoprim	phenytoin	false	mechanism
trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.	trimethoprim	phenytoin	false	mechanism
trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.	trimethoprim	phenytoin	mechanism	mechanism
trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.	phenytoin	phenytoin	false	false
since trimetrexate is metabolized by a p450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations.	trimetrexate	trimetrexate	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	trimetrexate	erythromycin	false	effect
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	trimetrexate	rifampin	false	effect
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	trimetrexate	rifabutin	false	effect
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	trimetrexate	ketoconazole	false	effect
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	trimetrexate	fluconazole	false	effect
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	erythromycin	rifampin	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	erythromycin	rifabutin	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	erythromycin	ketoconazole	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	erythromycin	fluconazole	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	rifampin	rifabutin	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	rifampin	ketoconazole	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	rifampin	fluconazole	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	rifabutin	ketoconazole	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	rifabutin	fluconazole	false	false
agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.	ketoconazole	fluconazole	false	false
in vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	cimetidine	trimetrexate	false	mechanism
in vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	cimetidine	acetaminophen	false	false
in vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	trimetrexate	acetaminophen	false	false
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	imidazole drugs	clotrimazole	false	false
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	imidazole drugs	ketoconazole	false	false
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	imidazole drugs	miconazole	false	false
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	imidazole drugs	trimetrexate	false	mechanism
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	clotrimazole	ketoconazole	false	false
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	clotrimazole	miconazole	false	false
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	clotrimazole	trimetrexate	false	mechanism
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	ketoconazole	miconazole	false	false
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	ketoconazole	trimetrexate	false	mechanism
based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	miconazole	trimetrexate	false	mechanism
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	triprolidine	central nervous system depressants	false	effect
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	triprolidine	alcohol	false	effect
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	triprolidine	barbiturates	false	effect
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	triprolidine	hypnotics	false	effect
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	triprolidine	narcotic analgesics	false	effect
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	triprolidine	sedatives	false	effect
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	triprolidine	tranquillisers	false	effect
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	central nervous system depressants	alcohol	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	central nervous system depressants	barbiturates	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	central nervous system depressants	hypnotics	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	central nervous system depressants	narcotic analgesics	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	central nervous system depressants	sedatives	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	central nervous system depressants	tranquillisers	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	alcohol	barbiturates	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	alcohol	hypnotics	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	alcohol	narcotic analgesics	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	alcohol	sedatives	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	alcohol	tranquillisers	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	barbiturates	hypnotics	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	barbiturates	narcotic analgesics	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	barbiturates	sedatives	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	barbiturates	tranquillisers	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	hypnotics	narcotic analgesics	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	hypnotics	sedatives	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	hypnotics	tranquillisers	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	narcotic analgesics	sedatives	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	narcotic analgesics	tranquillisers	false	false
triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	sedatives	tranquillisers	false	false
the effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	anticholinergic drugs	atropine	false	false
the effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	anticholinergic drugs	tricyclic antidepressants	false	false
the effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	anticholinergic drugs	triprolidine	false	effect
the effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	atropine	tricyclic antidepressants	false	false
the effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	atropine	triprolidine	false	effect
the effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	tricyclic antidepressants	triprolidine	false	effect
the concomitant use of sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.	sanctura	anticholinergic agents	false	effect
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	sanctura	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	digoxin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	procainamide	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	pancuronium	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	morphine	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	vancomycin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	metformin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	tenofovir	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	digoxin	false	mechanism
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	procainamide	false	mechanism
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	pancuronium	false	mechanism
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	morphine	false	mechanism
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	vancomycin	false	mechanism
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	metformin	false	mechanism
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	sanctura	tenofovir	false	mechanism
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	digoxin	procainamide	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	digoxin	pancuronium	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	digoxin	morphine	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	digoxin	vancomycin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	digoxin	metformin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	digoxin	tenofovir	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	procainamide	pancuronium	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	procainamide	morphine	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	procainamide	vancomycin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	procainamide	metformin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	procainamide	tenofovir	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	pancuronium	morphine	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	pancuronium	vancomycin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	pancuronium	metformin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	pancuronium	tenofovir	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	morphine	vancomycin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	morphine	metformin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	morphine	tenofovir	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	vancomycin	metformin	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	vancomycin	tenofovir	false	false
drugs eliminated by active tubular secretion: although studies to assess drug-drug interactions with sanctura have not been conducted, sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	metformin	tenofovir	false	false
coadministration of sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of sanctura and/or the coadministered drug due to competition for this elimination pathway.	sanctura	sanctura	false	false
concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions.	vancomycin	anesthetic agents	false	effect
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin b	aminoglycosides	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin b	bacitracin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin b	polymyxin b	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin b	colistin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin b	viomycin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	amphotericin b	cisplatin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	bacitracin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	polymyxin b	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	colistin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	viomycin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	aminoglycosides	cisplatin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	polymyxin b	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	colistin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	viomycin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	bacitracin	cisplatin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	polymyxin b	colistin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	polymyxin b	viomycin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	polymyxin b	cisplatin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	colistin	viomycin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	colistin	cisplatin	false	false
concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin b, aminoglycosides, bacitracin, polymyxin b, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	viomycin	cisplatin	false	false
a study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine.	vigabatrin	carbamazepine	false	mechanism
in 1984, drs rimmer and richens at the university of wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.	vigabatrin	phenytoin	false	mechanism
in 1984, drs rimmer and richens at the university of wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.	vigabatrin	phenytoin	false	false
in 1984, drs rimmer and richens at the university of wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.	phenytoin	phenytoin	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vindesine	phenytoin	false	int
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vindesine	live virus vaccines	false	int
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vindesine	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vindesine	mitomycin-c	false	int
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vindesine	killed virus vaccines	false	int
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vindesine	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	phenytoin	live virus vaccines	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	phenytoin	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	phenytoin	mitomycin-c	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	phenytoin	killed virus vaccines	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	phenytoin	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	live virus vaccines	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	live virus vaccines	mitomycin-c	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	live virus vaccines	killed virus vaccines	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	live virus vaccines	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vaccine	mitomycin-c	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vaccine	killed virus vaccines	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	vaccine	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	mitomycin-c	killed virus vaccines	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	mitomycin-c	vaccine	false	false
vindesine can interact with the drugs of the following categories:  - blood dyscrasia: can cause unpredictable myelotoxicity - bone marrow depressants: can cause a predictable dose-related myelotoxicity - radiation therapy: may cause marrow depression - neurotoxic medications: can cause neurologic toxicity - phenytoin: can increase seizure activity - live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - mitomycin-c: may cause shortness of breath and bronchospasm - killed virus vaccines: may decrease patient's response to the vaccine	killed virus vaccines	vaccine	false	false
drug interactions: women on oral contraceptives have shown a significant increase in plasma vitamin a levels.	contraceptives	vitamin a	false	mechanism
limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.	ascorbic acid	bishydroxycoumarin	false	mechanism
coumarin-derivative anticoagulants: prolongation of prothrombin time (pt) and international normalized ratio (inr) were observed in patients receiving zolinza concomitantly with coumarin-derivative anticoagulants.	coumarin-derivative anticoagulants	zolinza	false	false
coumarin-derivative anticoagulants: prolongation of prothrombin time (pt) and international normalized ratio (inr) were observed in patients receiving zolinza concomitantly with coumarin-derivative anticoagulants.	coumarin-derivative anticoagulants	coumarin-derivative anticoagulants	false	false
coumarin-derivative anticoagulants: prolongation of prothrombin time (pt) and international normalized ratio (inr) were observed in patients receiving zolinza concomitantly with coumarin-derivative anticoagulants.	zolinza	coumarin-derivative anticoagulants	false	effect
physicians should carefully monitor pt and inr in patients concurrently administered zolinza and coumarin derivatives.	zolinza	coumarin derivatives	false	advise
other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors (e.g., valproic acid).	hdac inhibitors	zolinza	false	false
other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors (e.g., valproic acid).	hdac inhibitors	hdac inhibitors	false	false
other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors (e.g., valproic acid).	hdac inhibitors	valproic acid	false	false
other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors (e.g., valproic acid).	zolinza	hdac inhibitors	false	effect
other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors (e.g., valproic acid).	zolinza	valproic acid	false	effect
other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors (e.g., valproic acid).	hdac inhibitors	valproic acid	false	false
